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ENGLISH SUMMARY 
In recent decades, there has been a shift in disease patterns towards chronic disease. 
Along with an ageing population, people live longer with chronic disease, including 
an often decreased health-related quality of life (HRQoL). The rising burdens of 
chronic conditions put economic pressures on the health-care system. For example, 
the increasing costs of medicine have resulted in layoffs for hospital staff. Several 
experts have forecasted that the rising budget burdens are not sustainable unless 
action is taken. Thus, there is a need for prioritization and health economic 
evaluation if existing universal health-care systems are to be sustained. However, 
there is a shortage of comparative data providing an overview of the burdens of 
chronic conditions in terms of both size and severity, and standardized data that can 
be used within health economic evaluation and other research, although reliable 
estimates and data are crucial for decision-makers making solid and lasting choices 
for future health care.  
The current dissertation aims to support future health economic evaluation, 
decision-makers but also other health-care related research. This is done by 
providing a framework for identifying 199 chronic conditions within health 
registers (objective 1), which can be used for different outcomes and research areas. 
Moreover, the thesis provides prevalence estimates of chronic conditions (objective 
2) in order to give estimates of the size of a problem. However, as size may not give 
any indication of the severity of a condition, estimates of HRQoL are crucial too. 
Thus, HRQoL based on EQ-5D 3L preference scores – which is the burden measure 
preferred within health economic evaluation – are calculated (objective 3) based on 
new, complex regression methods. Finally, a case example of HRQoL analytics of a 
survey-based chronic condition in contrast to register-based definitions is presented 
(objective 4). 
Paper 1 contains a register-based catalogue of definitions for 199 chronic conditions 
and subgroups of conditions by medical assessment comprising if not all, then most 
chronic conditions (objective 1). To ensure inclusion of all conditions treated within 
the health-care system, ICD-10-based hospital discharge codes as well as 
medication ATC codes, services of general practitioners (GPs) and other variables 
were included.  
A catalogue of 199 chronic condition prevalence rates is provided in paper 2 
(objective 2) based on a point estimate from 2013. This provides the basic 
epidemiology of the burden, basically answering the questions: what’s the size of 
the potential disease problems, and what are the different conditions like in 
comparison?  
VI 
A catalogue of ICD-10-based EQ-5D 3L preference scores of 199 chronic 
conditions is provided in paper 3, including both unadjusted mean estimates and 
adjusted regression estimates (objective 3). This catalogue shed light on the 
severity, essentially answering the questions: which conditions have it worst, how 
bad is it, and what are the potential health gains? The regression estimates were 
provided in four models to accommodate different needs of health economic 
evaluation modelling including a fourth model with health risk, BMI, stress and 
social network. This especially enables health-care analysts to identify disparities 
and potential health gains within health inequalities. A technical guide on how to 
use the EQ-5D estimates and the four regression models is provided.  
Finally, paper 4 shows the limitations of register-based approaches as not all 
conditions are reported or treated within the health-care system.  
The results are expected to have several implications within priority settings. 
Overall, the estimates could help in setting priorities for resource allocation within 
health services, prevention and research in mainly two ways. First, the estimates of 
size and severity themselves may provide information that is useable in policy 
setting generating an awareness and overview of potential issues. Secondly, the 
estimates can be used in health economic evaluation to assist decision-makers in 
concrete resource allocation and prioritization. In regard to the first point, the 
results derived from estimates could potentially generate new policy dilemmas and 
priorities. For example, some cancers and heart conditions have comparatively high 
prevalence and mortality, but also relatively good HRQoL, while the conditions at 
the same time have high priority and high financing. On the other hand, several 
musculoskeletal- and psychiatric conditions have both relatively high prevalence 
and low HRQoL while they do not have the same priority and financing. Similar 
priority dilemmas can be found within the estimates. Moreover, the framework can 
be used for monitoring trends in population health as well as monitoring policies 
such as, for example, compulsory regional and local health agreements. However, 
in regard to the second point, the estimates themselves do not provide information 
about competitive alternatives or interventions and recommendations for decision-
makers. Thus, using the estimates within cost-effectiveness analysis (CEA) is 
crucial, as described.  
In summary, the dissertation delivers a register-based framework for identifying 
chronic conditions and complementing estimates of quantity/size (by prevalence) 
and severity (by EQ-5D HRQoL) for use in health economic evaluation and other 
research. Thus, the aim is not to provide any specific recommendations for 
decision-makers, but simply to provide the means for others to do so. 
 
VII 
DANSK RESUME  
I de seneste årtier er der sket et skifte i sygdomsmønstre således, at flere lever med 
en eller flere kroniske sygdomme. En aldrende befolkning, der lever længere med 
kronisk sygdom og for en stor dels vedkommende med nedsat helbredsrelateret 
livskvalitet (HRQoL). Den øgede kroniske sygdomsbyrde presser sundhedsvæsenet 
såvel i Danmark som internationalt. Flere eksperter understreger, at de stigende 
udgifter er ikke økonomisk bæredygtige med mindre de adresseres og håndteres. 
Således er der et behov for sundhedsøkonomisk evaluering og prioritering, hvis 
vestelige landes nuværende fri og skattebetalte sundhedssystem skal bestå. 
Samtidigt er der mangel på sammenlignelige data, som kan give overblik over 
kroniske lidelser og byrder, og som kan bruges i sundhedsøkonomisk evaluering, 
både hvad angår omfang (prævalens) og sværhedsgrad (HRQoL). Dette er tilfældet 
til trods for, pålidelige data er afgørende for, at beslutningstagere kan vurdere og 
lave solidt funderede prioriteringer.  
 
Nærværende afhandling har bl.a. til formål at understøtte fremtidig 
sundhedsøkonomisk evaluering og beslutningstagere. Dette søges imødekommet 
ved at skabe et register baseret katalog af definitioner (framework), der identificerer 
199 kroniske sygdomme (formål 1), som desuden kan kombineres med forskellige 
sundhedsbyrdemål. Endvidere estimeres prævalens af kroniske sygdomme (formål 
2) for at give et estimat over omfanget af byrden. Ydermere, og da prævalens ikke 
giver en indikation af sværhedsgraden, målt som den oplevede helbredsrelaterede 
livskvalitet, af en kronisk sygdom, er HRQoL byrdemål også centralt. Formål 3 er 
således at give estimater af HRQoL baseret på EQ-5D 3L præference scores - som 
er det mest anvendte byrdemål inden for sundhedsøkonomisk evaluering - for de 
199 kroniske sygdomme. Estimaterne er baseret på nye, komplekse regressions 
metoder. Endelig gives et case-eksempel på HRQoL analyse af en survey baseret 
kronisk sygdom i kontrast til register baserede definitioner (formål 4). 
 
Artikel 1 præsenterer et katalog over register baserede definitioner for 199 kroniske 
tilstande og undergrupper baseret på medicinske vurderinger af, hvis ikke alle, så 
flest mulige kroniske sygdomme (formål 1). For at sikre, at alle sygdomme 
inkluderes, er både ICD-10 baserede hospitals koder samt medicin ATC-koder og 
tjenester af praktiserende læger (GP) med mere, medtaget. 
 
Artikel 2 præsenterer et katalog over prævalens af 199 kroniske sygdomme (formål 
2) baseret på et punkt estimat fra 2013. Dette grundlæggende epidemiologiske 
byrdemål besvarer essentielt: hvad er størrelsen af de potentielle 
sygdomsproblemer, og hvordan er de er i sammenligning?  
 
Artikel 3 præsenterer et katalog over ICD-10 baserede EQ-5D 3L præferencer 
scores for 199 kroniske sygdomme, herunder både ujusterede gennemsnits estimater 
VIII 
og justerede regression gennemsnits estimater (formål 3). Dette kaster lys over 
sværhedsgraden af sygdomme og besvarer grundlæggende: hvilke sygdomme har 
det ”værst”, hvor slemt er det, og hvad er de potentielle sundhedsmæssige gevinster 
for de 199 sygdomme? De regression baserede estimater præsenteres i fire 
regressionsmodeller for at imødekomme forskellige behov for modellering i 
sundhedsøkonomisk evaluering, herunder særligt en fjerde model med følgende 
risikofaktorer, BMI, stress og socialt netværk. Dette giver mulighed for 
sundhedsøkonomer og forskere at identificere forskelle, sociale uligheder, 
potentielle sundhedsmæssige gevinster. Der er lavet en særskilt teknisk vejledning 
af, hvordan EQ-5D estimaterne og de fire regressionsmodeller kan bruges i 
sundhedsøkonomisk evaluering.  
 
Artikel 4 illustrerer begrænsninger af at bruge registerdata til at identificere 
kroniske sygdomme, da ikke alle sygdomme er rapporteret i sundhedsvæsenet. 
 
Resultaterne kan have flere anvendelser og implikationer indenfor sundhedsvæsnet. 
Samlet set kunne katalogerne assistere prioritering inden for sundhedsvæsenet, 
forebyggelse og forskning på primært to måder. Først og fremmest kan estimaterne 
over omfang og sværhedsgrad i sig selv generere bevidsthed og overblik over 
potentielle problemer til brug i prioritering. For det andet kan estimater anvendes i 
sundhedsøkonomisk evaluering og hjælpe beslutningstagere i ressource allokering 
og prioritering. I forhold til den første pointe, kan forhold afledt fra estimaterne 
potentielt set generere nye politiske dilemmaer og prioriteringer. For eksempel har 
flere kræftformer og hjerte sygdomme en forholdsvis høje forekomst og 
dødelighed, men også relativt fint / høj HRQoL, mens de på samme tid har høj 
prioritet og høj finansiering. På den anden side har flere muskel-skelet sygdomme- 
og psykiatriske sygdomme både relativ høj forekomst og lav HRQoL, mens de ikke 
har samme prioritet og finansiering. Lignende prioriterings dilemmaer kunne findes 
i kataloget blandt andre sygdomme. Derudover kan de register baserede definitioner 
bruges til at monitere tendenser i befolkningens sundhed og monitering af politikker 
som for eksempel obligatoriske regionale og lokale sundhedsaftaler. Imidlertid, jf. 
den anden pointe, giver estimaterne ikke i sig selv oplysninger om konkurrerende 
alternativer, interventioner og anbefalinger til beslutningstagere. Derfor er det 
centralt at bruge estimaterne indenfor cost-effektivitetsanalyse (CEA), som 
anbefalet. 
 
Sammenfattende leverer afhandlingen en ramme for at identificere kroniske 
sygdomme via registrer; og den giver komplementerende estimater af disse 
kroniske sygdommes omfang (ved prævalens) og den sætter værdi på 
sværhedsgraden målt som HRQoL (ved EQ-5D) til brug i sundhedsøkonomisk 
evaluering og anden forskning. Således er formålet ikke at give nogen konkrete 
anbefalinger til beslutningstagere, men blot at levere redskaber for at andre kan 
komme med fremtidige anbefalinger. 
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1 
CHAPTER 1. INTRODUCTION  
1.1. THE RISING BURDENS OF CHRONIC CONDITIONS  
The burden of chronic conditions has been an important issue worldwide for years, 
for citizens, health-care providers, researchers and governments. The burden is 
considered a “rising” problem of “epidemic proportions” by the World Health 
Organization (WHO) that should and can be significantly reduced [1]. Studies show 
a global shift from communicable diseases to chronic diseases [2, 3] as well as 
varying burdens by chronic condition and country [1, 4–9]. These studies all depict 
major challenges for not only personal health but also societal development:  
“Noncommunicable diseases (NCDs1) are one of the major health and 
development challenges of the 21st century, in terms of both the human 
suffering they cause and the harm they inflict on the socioeconomic 
fabric of countries, particularly low- and middle-income countries. No 
government can afford to ignore the rising burden of NCDs. In the 
absence of evidence-based actions, the human, social and economic 
costs of NCDs will continue to grow and overwhelm the capacity of 
countries to address them…. The human, social and economic 
consequences of NCDs are felt by all countries but are particularly 
devastating in poor and vulnerable populations. Reducing the global 
burden of NCDs is an overriding priority and a necessary condition for 
sustainable development. As the leading cause of death globally, NCDs 
were responsible for 38 million (68%) of the world’s 56 million deaths 
in 2012. More than 40% of them (16 million) were premature deaths 
under age 70 years….” WHO 2014 [5]. 
Although the WHO states that the burdens of chronic conditions in particular strike 
low- and middle-income countries, high-income countries like Denmark also have 
similar health-care issues on the horizon pressuring the health-care system [10]. 
Consequently, the Danish universal health-care model is also under pressure. For 
instance, in 2011, several Danish experts concluded that there were three major 
interrelated challenges in the health-care system: 1. the demographic development: 
ageing and more chronic patients; 2. a declining workforce; and 3. the fiscal 
sustainability of the universal health-care system [11]. Also, the demographic issues 
projected in the report are supported by the Danish Rational Economic Agents 
Model (DREAM). Projections from 2011 to 2100 show a 20 per cent increase in the 
                                                          
1 “Noncommunicable – or chronic – diseases are diseases of long duration and generally 
slow progression.” See: http://www.who.int/features/factfiles/noncommunicable_diseases/en/  
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total size of the future Danish population and a relative decrease in the workforce 
[12]. Moreover, the number of citizens over 65 and 80 years will double by 2035. 
Similar conclusions were drawn earlier by Eurostat for other high-income European 
countries, and for several countries even more explicitly [10]. This demographic 
tendency is particularly troubling because empirical studies have shown that the 
average public spending per citizen is considerably higher for these age groups 
[13]. Currently, around two persons support one person outside the legal 
occupationally active age2. However, by 2035 this number will increase to roughly 
four persons supporting three persons [11].  
Obviously, there must be a balance between tax income and expenditures in order 
to maintain a sustainable health-care system. From 2000 to 2012, the Danish annual 
health-care spending of GDP increased from 8.7 to 11 per cent of GDP [4]. Yet, 
estimates are still debated due to different economic settlement methods, but in 
absolute numbers, the estimates varied from around 110 to 165 billion Danish 
crowns in 2012 [14, 15], including an approximately 50 per cent increase in 
hospital medical spending from 2009 to 2012 [16]. Of the total costs, the National 
Board of Health and others cite that chronic conditions possibly account for up to 
80 per cent of all health-care expenditures [17, 18]. Another recent study from 2015 
estimates total costs for approximately 20 selected conditions of 25.6 billion DK kr. 
annually in 2010–2012, though the inclusion of costs has several limitations [19]. 
And as this study does not include all chronic conditions, the numbers are without 
doubt much higher.  
Adding the issues of demographic projections, increased life expectancy, healthy 
ageing, prices, wages and health-care productivity, several scenarios published by 
the Danish Economic Council show that the health-care expenditures are not 
sustainable unless some action is taken [20]. The Council’s projected scenarios 
estimated an increase in expenditures ranging from 20 to 60 per cent up to 2050. 
Notably, a more recent publication found that an important contribution to 
increasing numbers was partly found to be the rise in chronic conditions [11].  
In summary, the above issues highlight the need for prioritization within health care 
in order to ensure a sustainable health-care system, and the ability to handle an 
increasing number of chronic conditions with a smaller workforce to address the 
rising expenditures. For this, reliable methods and estimates for monitoring and 
evaluating chronic disease burden are crucial for health-care research and 
prioritization. It is within this context that this PhD thesis has been composed.  
                                                          
2 The problem is further complicated due to potential future shortages of physicians and 
nurses [211], which in the Danish context is forecasted to be as high as 15–16 per cent of 
health-care personnel in 2020 [11], although other international estimates are more 
conservative [212]. 
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1.2. HEALTH ECONOMIC EVALUATION AND PRIORITIZATION 
PER SE  
Disease prevalence rates and cost of illness (COI) analysis have been the commonly 
used methods to illustrate the burden of disease, but also to some extent decision-
making [21–23]. However, although informative, these methods are descriptive and 
do not provide an evaluation of interventions and alternatives, or any explicit 
recommendations; therefore, they are of little use for decision-making and 
prioritization of new technologies and resource allocation [21, 22]. For this, cost-
effectiveness analysis (CEA) and cost-utility analysis (CUA) are the better-suited 
and preferred methods within health economic evaluation as they relate health to 
costs and compare alternatives with recommendations [24, 25]. This is done using 
the incremental cost-effectiveness ratio (ICER), which measures effect against costs 
for different disease interventions [21]. The ratio is then compared to a predefined, 
normative willingness-to-pay threshold to decide whether the new intervention is 
cost-effective. This and CEA/CUA are described in more detail in chapter 2.  
Several countries have institutions for health economic evaluation and prioritization 
of new technologies including new medications. One of the leading international 
institutions often mentioned is the National Institute of Clinical Excellence (NICE) 
in England. NICE is a decision unit that is independent of politicians, and that 
operates within a comprehensive framework of methods and requirements including 
the use of CEA/CUA and effect measures based on Quality-Adjusted Life Years 
(QALY) [26–28]. In 2006, 14 countries had different institutions and requirements 
for implementing new medications and technologies, including Denmark, Norway, 
Australia, Canada and England [29]. In 2016, 41 countries had pharmacoeconomic 
guidelines around the world, including South Africa, Egypt, Brazil, Cuba, Thailand, 
Israel, Taiwan, South Korea, Malaysia, China Mainland and several countries in 
Europe, among others [30]. 
The majority of new CEA are done in relation to new medications; hence, 
medication is particularly important within health economic evaluation/institutions 
– which is why NICE, for example, has comprehensive guidelines for evaluation 
[31, 32], although guidelines for all kinds of health technologies exist [28]. 
Moreover, rising costs of medicine in particular have been heavily debated 
worldwide in regard to how to handle this, whether the prices are set fair by the 
pharmaceutical companies, whether we should implement all new medicine even if 
the cost-effectiveness is low, and how to handle layoffs in hospitals in a Danish 
context due to rising medicine costs [16, 33–38]. A recent Health Technology 
Assessment (HTA) summarized several related issues also illustrating the public 
and political pressures on institutions as follows: 
“Organisations across diverse health care systems making decisions 
about the funding of new medical technologies face extensive 
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stakeholder and political pressures. As a consequence, there is quite 
understandable pressure to take account of other attributes of benefit and 
to fund technologies, even when the opportunity costs are likely to 
exceed the benefits they offer. Recent evidence suggests that NICE 
technology appraisal is already approving drugs where more health is 
likely to be lost than gained. Also, NICE recently proposed increasing 
the upper bound of the cost-effectiveness threshold to reflect other 
attributes of benefit but without a proper assessment of the types of 
benefits that are expected to be displaced. It appears that NICE has taken 
a direction of travel, which means that more harm than good is being, 
and will continue to be, done, but it is unidentified NHS patients who 
bear the real opportunity costs.” Claxton, 2015 [38] 
Denmark has recently responded to these issues by making it compulsory to 
conduct CEA when new medicine is implemented in the future, even though the 
specific requirements are currently unclear and under development [39, 40]. Thus, 
authorities are increasingly resolving to carry out health economic evaluation, 
including the previously mentioned international accumulation of new guidelines in 
an attempt to meet the increasing need for prioritization and the rising burdens of 
health-care spending, and hence to regulate the monopoly and maximum costs of 
new medicine.  
Where CEA can use different effect measures, CUA is based on one standardized 
effect measure, the Quality-Adjusted Life Years, which combines life years with 
health-related quality of life (HRQoL) most commonly based on the generic EQ-5D 
five-dimension health questionnaire (see chapter 2 for further details). This enables 
comparisons across different interventions and diseases. Notably, numerous effect 
and disease burden measures exist as well as other methods for health economic 
evaluation (again see chapter 2 for further details). What is important here is that 
CUA together with the QALY/EQ-5D is the preferred and most commonly used 
method within health economic evaluation, and is not dependent on a monetary 
evaluation of health from patients [24, 25]. Equally important in regard to the 
present thesis, the increasingly wide use of health economic evaluation and QALY 
founds a need for local EQ-5D preference scores of chronic diseases for use in 
CUA when modelling health scenarios. 
 
5 
1.3. STANDARDIZING HRQOL PREFERENCE SCORES FOR 
CHRONIC CONDITIONS – AND LIMITATIONS OF EXISTING 
RESEARCH 
Even though CUA already uses a standardized effect measure (the EQ-5D), 
different EQ-5D-based studies of the same condition often give different HRQoL 
results; thus, comparisons of HRQoL estimates can still be difficult [41, 42]. 
Agreed, this is not surprising as different studies cannot be expected, for example, 
to use exactly the same sampling methods, regression or other methods, or to have 
exactly the same patient population etc. Nevertheless, when the industry or others 
provide documentation and CUA of new medicine, or treatments use estimates from 
existing literature, different studies and effect measures still enable selection of the 
effect results risking picking results that put the evaluated treatment into the best 
light – or publishing non-reliable results unintentionally. 
Consequently, US and UK authorities have already called for standardized methods 
within CUA including an “‘off-the-shelf’ catalogue of nationally representative, 
community-based preference scores for health states, illnesses, and conditions” [41, 
42]. In response, a local American catalogue of EQ-5D scores had already been 
published in 2005 based on approximately 140 chronic conditions within a single 
study and survey sample from 2000 to 2002, and later with UK EQ-5D preference 
values based on the same sample [43]. Notably, a few other single studies have also 
provided other local national EQ-5D preference catalogues, although for a much 
more limited number of chronic conditions [44–47].  
Basing estimates on uniform methods/data was one of the key issues and reasons 
for recommending the catalogue in order to increase comparability and reduce the 
variability of existing estimates derived from different studies and methods; but 
also providing estimates that can be used without the burden of collecting primary 
data retrospectively when, for example, no other data exist [41, 42]. Thus, a 
standardized catalogue calculated based on a uniform methodology/data for all 
conditions enables impartial comparisons of severity (essentially revealing who has 
it worst) across conditions (although, naturally, with the limitations of the 
methodology and measures, but equal for all conditions). Moreover, the estimates 
enable the prevention and cure potentials of interventions within CUA to be 
modelled (see further description in chapter 5) [48, 49]. 
However, besides being based on older surveys from 2000 to 2002, the existing 
catalogues have several shortcomings. First, the regression methods are median 
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based, although health economists mostly use and prefer3 means [24, 25]. Secondly, 
the regression method used might not be appropriate for handling the complex 
statistical distribution of the EQ-5D. Thirdly, the conditions are self-reported and 
based on the outdated International Classification of Disease Version 9 [50]. 
Fourthly, the studies could be improved by estimates of health risk factors, BMI, 
stress, social network and other variables of relevance for health economic 
evaluation and other research – and more conditions. This could further improve 
future analytics and shed light on unequal health characteristics, socio-economic 
determinants, associations and their strengths, not done before within a single study 
comprising if not all, then most chronic conditions. Finally, no catalogue of uniform 
Danish EQ-5D preference-based estimates exists of chronic conditions for use in 
health economic evaluation. Thus, there is room for further improvement and 
standardization of methods and estimates. 
 
1.4. THE NEED FOR A STANDARDIZED FRAMEWORK FOR 
IDENTIFYING CHRONIC CONDITIONS 
A “methodological framework” is defined in the present thesis as “appropriate data 
and transparent definitions or algorithms for identifying chronic conditions within 
these data”.  
Specific attention to the framework and methodology for identifying chronic 
conditions is critical. For example, the interpretation of burden estimates can be 
vastly “misleading without transparent information about all the input data that 
informed the calculations” [51]. Burden of disease measures often have a black box 
reputation because the reported results do not always include evidence about all the 
                                                          
3 Notably, some health economists do also use medians, which statistically can be justified as 
the EQ-5D distribution is skewed [72], which is why the median might provide a statistically 
more accurate measure of the central tendency if needed. However, leading health 
economists argue that the mean is the “theoretically correct way to aggregate individual 
values, irrespective of the nature of distribution”… as “the mean reflects the people’s 
intensity of preferences and follows conventional welfare concerns by addressing whether 
the total benefits to those who gain are greater than the sum of the benefits to those who lose 
from a policy change” [25]. Furthermore, studies have shown that median-based studies 
produce higher values for less severe conditions and lower values for more severe conditions 
compared to mean-based studies [213]. (However, the opposite association was found in 
paper 4, although this confirms that the mean and median produce different estimates [204].) 
As mean and median are different measures, and no absolute gold standard for choosing 
exists, the recommendations are to choose the measure based on a “prior philosophical 
position on how preferences should be aggregated” rather than intuition [25, 213]. 
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epidemiological data – as well as assumptions about social value choices [51–53]. 
Invalid methods can result in biased results regarding the population’s health status 
and, in the worst cases, lead to biased decisions and priorities [51]. Despite the 
importance, a relatively recent systematic review of general burden of disease 
studies showed a lack of methodological uniformity in the basic framework and 
data across studies:  
“However, large differences in used methodology exist between general 
burden of disease studies. Because of the methodological variation 
between studies it is difficult to assess whether differences in DALY 
estimates between the studies are due to actual differences in population 
health or whether these are the result of methodological choices. 
Overcoming this methodological rigor between burden of disease 
studies using the DALY approach is a critical priority for advancing 
burden of disease studies. Harmonization of the methodology used and 
high-quality data can enlarge the detection of true variation in DALY 
outcomes between populations or over time.” Polinder et al. 2012 [53]  
Thus, a new uniform framework for identifying conditions could potentially be used 
across different research fields and different measures of disease burdens.  
In the US, a government report a few years back also called for more work 
allocating burden to specific diseases to avoid double counting etc., especially in 
regard to costs, but also deaths, utilization and other outcomes, and thus to enhance 
the accuracy of burden estimates for multiple diseases [54]. A new framework 
should naturally take this into account, including choosing appropriate data. Other 
COI studies have also recommended focusing on data and how to identify 
conditions as important issues [54–56]. 
In Denmark, the “calls” for using health-care data for monitoring chronic 
conditions, including using hospital discharge diagnosis, have been partly answered 
by Statens Serum Institute in regard to ongoing work on developing register-based 
definitions (framework) for a few selected conditions including diabetes, heart 
conditions, COPD, asthma, arthritis, osteoporosis, schizophrenia and dementia [57, 
58]. However, this still does not include a comprehensive number of chronic 
conditions, or HRQoL burden measures. Likewise, various studies have tried 
applying big data based on registers to assess the burden of chronic disease [59–
66]; nevertheless, the studies have typically only covered a few designated chronic 
conditions, thereby not using the full potential of existing data. To the best of the 
author’s knowledge, no current register-based studies have explicitly aimed to 
present a uniform framework and methodology of register-based definitions on all 
chronic conditions in pursuit of comprising if not all, then most chronic conditions 
systemically. Notably, new problems arise in terms of when to include conditions 
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once comprising all and different register-based chronic conditions as they have 
diverse levels of chronicity as described later. This, for example, requires explicit 
judgment of how long a time each condition is included back in time from a time of 
interest (for example the survey time). To the best of the author’s knowledge, this is 
not explicitly addressed or standardized within existing frameworks and research. 
Nevertheless, some studies have attempted to comprise numerous chronic 
conditions in relation to different HRQoL measures such as, for example, the WHO 
Global Burden of Disease Studies (GBD) [2, 3, 6, 8, 67] (DALY) or Sullivan et al. 
[41, 42, 49] (the EQ-5D). Nevertheless, while the WHO studies are based on ICD-
10 codes, unspecified data sources often vary across countries, why their use of data 
sources is at best unclear in the opinion of this author and naturally not uniform due 
to the different resources of the different countries. For example, studies have 
criticized and recommended methodological improvements [51, 53, 68, 69], and the 
authors of the GBD studies have recommended future use of hospital discharge and 
outpatient data [8]. But more importantly, the GBD studies lack a solution for how 
to include a substantial proportion of patients treated outside hospitals based on 
registers, and they do not provide a solution for how to treat the differences in 
chronicity across conditions and thus different inclusion times using register data. 
These issues need to be addressed transparently, which the current author intends to 
do within the present thesis.  
Finally, the most comprehensive study in terms of number of included conditions 
actually using the EQ-5D is based on self-reported ICD-9 conditions (survey 
based), not the ICD-10 or doctor-reported register-based chronic conditions. For 
this, Danish national health registers containing diagnoses, medications and more 
can add the precision of ICD-10 doctor-reported diagnoses to the EQ-5D scores and 
other outcomes rarely seen, by combining survey data comprising the EQ-5D with 
national health registers from both private and public hospitals, and both primary 
and secondary sectors. Scandinavian national health registers have a long tradition 
of reporting different conditions and matters at the micro level. Although other 
countries have registers, the scope, comprehensiveness and population 
completeness are unique to Scandinavian countries:  
 “The Nordic countries are world-famous within the research community 
for their ability to conduct register-based health- and welfare-oriented 
population studies. Legislation in most countries in the Nordic region 
allows researchers to carry out studies linking various registers by 
means of the individual personal identification number allocated to each 
person. This provides a unique source of data, which is invaluable for 
the public health community.” Kamper-Jørgensen, 2008 [70]  
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Consequently, the use of several registers enables the incorporation of all types of 
nationwide-reported chronic conditions into a framework, with enhanced medical 
diagnostic precision, and without self-reported bias.  
 
1.5. THE OBJECTIVES OF THE THESIS AND READING 
INFORMATION 
The aims of the present thesis are to provide national standardized EQ-5D 3L 
health-related quality of life preference scores and prevalence rates of 199 chronic 
conditions, and to provide a transparent framework and method for identifying 
chronic conditions within public health registers. Altogether, the overall aim is to 
provide essential disease burden estimates and a new method for generating these 
estimates. This is done in order to support health economic evaluation, and 
epidemiological and other research. Thus, the aim is not to provide any specific 
recommendations for decision-making, merely the means for others to do so.  
Initially, the main aim was to provide a catalogue of health-related quality of life 
(burden) estimates for health economic evaluation; yet this required register-based 
definitions (framework) of chronic conditions, which is also of epidemiological 
interest, which is why one of the first and most substantial parts of the thesis was to 
develop these in cooperation with medical and other specialists. Furthermore, 
health-care analysts, epidemiological and other researchers can benefit from 
prevalence (burden) estimates of chronic conditions, thus the thesis also provides 
estimates thereof. Therefore the thesis delivers estimates of both quantity 
(prevalence) and severity (HRQoL), which complement each other for use in health 
economic evaluation and other research.  
Accordingly, the objectives of the PhD thesis are: 
 Objective 1: To establish and present standardized register-based 
definitions of 199 medically reviewed chronic conditions.  
 Objective 2: To estimate the population-based prevalence rates of the 199 
chronic conditions. 
 Objective 3: To establish and present a catalogue of Danish EQ-5D 
preference scores for 199 nationally representative chronic conditions.  
 Objective 4: To present a case example of HRQoL analytics of a survey-
based chronic condition and a case example of limitations of register-based 
definitions. 
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Background and reading information about objectives 
As the basic methodological framework identifying all chronic conditions using 
register data was insufficient, one of the first and most important parts of the PhD 
study was to create reliable methodological, uniform definitions embracing all – or 
as many as possible – chronic conditions by clinical assessment (objective 1and 
paper 1). Thus, the methodological issues are thoroughly discussed. This is the 
foundation for the two catalogues of the selected burden estimates, but could also 
be used by other researchers and health-care professionals for other outcomes of 
interest, such as, for example, DALYs, mortality, incidence and life expectancy, 
among others [3].  
A catalogue of prevalence estimates of chronic conditions (objective 2 and paper 2) 
provides the basic epidemiology of the burden, essentially answering the questions: 
how many are affected by the different conditions comparatively speaking, and how 
big (size) are the (potential) disease problems? Moreover, it provides new insights 
into the burden of chronic conditions based on data within an entire country not 
seen before. Furthermore, the prevalence study can be used for COI, and the 
framework can be used for monitoring disease prevalence by using the definitions 
in paper 1. However, prevalence data do not capture the burden of disease 
experienced by citizens in terms of lost health or differences in severity of the 
conditions [67]; hence, they are merely a measure of a potential problem. Neither 
do they provide useable information for health economic evaluation. Consequently, 
a second catalogue with severity outcomes is essential. 
In this respect, the US and UK authorities have for a long time called for uniform 
measures for health economic evaluation and prioritization, including “off-the-
shelf” catalogues of preference scores for health states [42]. The EQ-5D preference 
catalogue (objective 3 and paper 3) will shed light on which conditions have it 
worst based on the EQ-5D, and how bad it is, and thus what the potential health 
gains are. The discussion section will provide more details on the potential and 
practical use. Furthermore, the catalogue will be an improved version of existing 
research on several areas: improved regression modelling, more regression models, 
and the use of ICD-10-based conditions including health risk, BMI and social 
network, thereby constituting different methodological contributions to the field. 
Moreover, the estimates are intended for modelling within health economic 
evaluation as described elsewhere [41, 42, 49, 50]. Furthermore, the UK authorities 
require the EQ-5D to be used within all public health economic evaluation as the 
preferred measure [27] and it is the preferred measure among researchers within the 
field [24]. Thus, a catalogue of EQ-5D preference scores for 199 chronic conditions 
will meet several authorities’ and researchers’ needs and benefit future research, 
health economic evaluation and future prioritization. Also, we expect an EQ-5D 
preference catalogue to be of increasing importance in a Danish context, as, in 
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spring 2016, the Danish authorities decided that health economics evaluation is also 
required within prioritization of hospital medicine due to growing costs [39, 40]. 
Finally, the HRQoL case example of a survey-based chronic condition has two 
purposes (objective 4 and paper 4): first, to show a case example of how each 
condition could be analysed and presented; and secondly, it is also intended as a 
case example of the limitations of register-based definitions, as the condition is not 
representatively identified in registers even though it is a worldwide common 
condition. The case example is Myalgic Encephalomyelitis / Chronic Fatigue 
Syndrome (ME/CFS).  
The results and stages are described in more detail in chapter 3, while methods and 
process are described in detail in chapter 2.  
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CHAPTER 2. THEORY, 
METHODOLOGIES AND DEFINITIONS  
2.1. THE BASICS, HISTORY, STRENGTH AND LIMITATIONS OF 
COST-OF-ILLNESS ANALYSIS AND HEALTH ECONOMIC 
EVALUATION  
As the framework and estimates may be used for future cost-of-illness (COI) 
analysis and health economic evaluation, these methods are briefly introduced in 
the following. However, it is beyond the scope of this thesis to further address this 
comprehensive field in details as well as counteract the many theoretical limitations 
and discussions; therefore, the following is solely a limited introduction to the field 
that naturally can be explored further in references. 
Cost-of-illness analysis 
One of the first health evaluation methods, cost-of-illness (COI) analysis, appeared 
well before the mid-1960s and was the first method used within health-care 
assessment; COI measures the economic burden of illnesses for society and has 
been commonly provided by several countries as well as the US National Institute 
of Public Health, the World Bank and WHO, and researchers, although COI is 
debated [22]. The underlining assumption was that the economic costs of illness 
signified the potential economic benefits of a given health-care intervention if it 
eliminated the illness [22]. What COI does not do is provide an evaluation of the 
best alternatives to choose from as it does not provide information on the health-
related burden or whether a condition can actually be cured or reduced by an 
intervention; thus critics say that it is little help to those taking decisions and 
ranking priorities [22]. As a consequence, COI is not considered a health economic 
evaluation by all [21], including by the definition below. Other so-called welfare 
economists criticize the lack of a theoretical foundation, while the human capital 
approach makes the criticism that costs of morbidity and mortality lack “the value 
people attach to their lives”, e.i. lack of focus on potential growth, for example, 
based on personal earnings in relation to health [22]. 
Nevertheless, COI is a descriptive study and one type of burden measure among 
others that can provide information and input to decision-makers at different levels, 
yet is still used and recommended for use [23]. For example, COI may provide 
information on the highest expenditures and biggest potential gains for use within 
research priorities besides generating obvious awareness of the economic burden as 
costs matter [21]. Several methods and guidelines exist for providing COI and these 
are provided elsewhere [21, 22]. Although it is beyond the scope of the current 
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thesis to provide a comprehensive description and evaluation thereof, as well as 
other technical methods, COI can be estimated based on prevalence/incidence, top-
down/bottom-up, retrospective versus prospective [22]. However, no real 
agreement exists: for example, Tarricone recommends a bottom-up approach, while 
Pedersen describes and uses a combined prevalence approach as the most common 
method [21, 22]. Nevertheless, what is important to mention in relation to this thesis 
is that it is possible to use prevalence studies for estimating COI.  
Health economic evaluation methods 
In line with the earlier described sparse societal resources, there is a need for 
assessing and choosing the best solution within health care, i.e. prioritization. In 
essence, this is what health economic evaluation is about: assessing the health-care 
inputs and outputs, costs and consequences, of activities [24]. Drummond et al. 
define health economic evaluation as: 
“The comparative analysis of alternative courses of action in terms of 
both their costs and consequences.” Drummond et al. (2015) [24]. 
Two main types of health economic evaluation is often described in the literature: 
cost-benefit analysis (CBA) and cost-effectiveness analysis (CEA) [21]. Although 
not specified as CBA/CEA, some of the first CBAs and CEAs were done in the late 
1960s [24]. From the 1970s, several new tools for health economic evaluation 
emerged, including the so-called Rosser Scale4, and from the 1990s, the EQ-5D, as 
described later [25]. In contrast to COI, CBA and CEA evaluate different 
alternatives of interventions and provide a recommendation to decision-makers in 
order to get most value for money [21].  
Cost-benefit analysis (CBA) 
CBA measures all benefits in monetary terms. Monetary terms also include valuing, 
for instance, survival or health using money as the numéraire [25], for example the 
willingness to pay (WTP) different amounts for a pregnancy screening [21]. One 
advantage of CBA is its economic theoretical foundation and attempt to quantify 
the willingness to pay for health-care goods and services for society. On the other 
hand, there are practical difficulties to providing reliable estimates thereof as it can 
                                                          
4 Rosser disability/distress scale: this was originally a measure of hospital output, which in 
the 1980s became the most widely used tool for deriving QALYs in the UK, but fell into 
disuse following the introduction of the EQ-5D and others. Basically, the survey measure has 
two dimensions, disability and distress, with a total of 29 health states. Originally, the 
measure was conducted by a clinical assessment, but it was also performed as a self-reported 
measure [25].  
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be difficult to monetize the value of health and life; moreover, valuing health in 
monetary terms clashes with the acceptance and norms within health-care. 
Additionally, market failure due to the complexity and asymmetric information 
about health and treatments within health-care systems makes such estimates 
difficult to obtain and should be used with caution [21].  
The theoretical school behind CBA is closely related to welfare economics, often 
called welfarists.  What matters to welfarists is measuring the social welfare, health 
or well-being assessed by the individuals themselves, as done in WTP, and less 
emphasis is laid on the problems of a non-functioning health-care market 
(asymmetric information and uncertainty of future health) and equity. Thus, 
welfarist benefits or social welfare are the sum of individual utility [25]. 
Cost-effectiveness analysis (CEA) 
Since CBA (and COI) have met some criticisms and have practical issues regarding 
use within health economic evaluation, for instance equity issues of health-services 
and a nonfunctioning market, CEA is the most commonly used method. Within 
CEA, the benefits (effects) of an intervention are measured in natural units in 
comparison with the costs. Natural units may be life-years saved, mortality, 
morbidity, pain, “health”, treatments avoided, illnesses avoided, high blood 
pressures avoided and others. Moreover, CEA measures the effect using the 
incremental cost effectiveness ratio (ICER) of two – or more – interventions as 
follows:  
𝐼𝐶𝐸𝑅 =
𝐸𝑓𝑓𝑒𝑐𝑡 𝑛𝑒𝑤 𝑖𝑛𝑡𝑒𝑟𝑣𝑒𝑛𝑡𝑖𝑜𝑛 − 𝑒𝑓𝑓𝑒𝑐𝑡 𝑜𝑙𝑑 𝑖𝑛𝑡𝑒𝑟𝑣𝑒𝑛𝑡𝑖𝑜𝑛
𝐶𝑜𝑠𝑡𝑠 𝑛𝑒𝑤 𝑖𝑛𝑡𝑒𝑟𝑣𝑒𝑛𝑡𝑖𝑜𝑛 − 𝑐𝑜𝑠𝑡𝑠 𝑜𝑙𝑑 𝑖𝑛𝑡𝑒𝑟𝑣𝑒𝑛𝑡𝑖𝑜𝑛
 
Because the many different effect measures make diverse ICERs and comparisons 
difficult, and since interpretation of the ICER5 is crucial for the recommendation of 
alternatives, standardized generic health effect measures based on the QALY/EQ-
5D have been developed for comparisons across conditions and treatments – the 
cost utility analysis (CUA) as a subgroup of CEA [25]. In essence, the QALY 
combines life-years, the HRQoL based on the EQ-5D and its five predefined health 
dimensions and the time into single value. The EQ-5D/QALY is described in more 
detail in a later section. Besides enabling comparisons, this also decreases the 
industry and others’ chance of choosing the method – for example effect measure – 
that puts the treatment of evaluation in the best light or similar problems described 
                                                          
5 Furthermore, new interventions are often more expensive, but with better effect. Thus, a 
crucial issue is where to set the threshold of how much society is willing to pay pr. increased 
effect (QALY). In the UK, the threshold is set at £20–30,000 pr. QALY, while other 
countries, including Denmark, do not have a threshold yet. 
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elsewhere [71]. For example, a treatment of diabetes may show a significant 
decrease in low blood sugars measurements and the number of injections needed, 
but not enough to generate a significant impact on the HRQoL based on generic 
measures. Yet, some disease-specific measures might show an impact, tempting 
medical companies to solely choose measures showing the impact at its best. 
Respectively, there may be technical reasons as the measure is not sensitive to the 
disease or effect, but it may also be that the effect is actually small on the HRQoL. 
CUA decreases this issue. 
The theoretical foundation behind CEA and QALY is often mentioned as extra- 
welfarism. Extra welfarists challenge the welfarists’ assumption that individuals 
necessarily are the best valuators of their own welfare, and benefits should be 
measured as the sum of individual utility; moreover non-health benefits can be left 
out as the objective of publicly funded health care is to improve population health 
[25]. Thus, within the extra welfarist perspective, benefits can be measured based 
on population preferences of different health states from a proxy (i.e. not directly 
patient valued) representative survey sample. Hence, “…the QALY is not a 
representation of individual utility, but a measure of health as a social desideratum” 
[25]. Notably, Brazier stresses that a welfarist interpretation of CEA would be to 
see the QALY as (substitute) representation of individual utility although not 
directly valued by patients themselves. Finally, an extra welfarist key issue is equity 
and is as such a response to the absence of a functioning market and to the welfare 
state’s actual political and normative organization and distribution of health care 
without the concern of people’s ability to pay for services. 
The current thesis is implicit placed within the tradition of CUA and thus the extra 
welfarrist perspective as it aims to improve methods for future CUA. It is not the 
argument that CEA/CUA are without limitations as thoroughly described in the 
literature [21, 24, 25, 72], but the view of NICE and others is that CUA is probably 
the best alternative at this time for health economic evaluation and prioritization 
[21, 26, 27, 73]. 
 
2.2. THE BASICS OF QALY, EQ-5D, STRENGTHS AND 
LIMITATIONS  
The concept of the QALY was initially introduced in 1968 in relation to a study of 
chronic renal failure; although the study did not use the phrase “QALY”, the 
concept was the same [24]. The basic idea of the QALY, as previously mentioned, 
is that it combines both life-years and the HRQoL into a single measure. Therefore, 
it is not surprising that the concept was born in relation to chronic renal patients as 
they experience marked change in both HRQoL and life-years with and without 
treatment (see also Figure 2-1 for an example of QALY estimation with and 
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without treatment). Moreover, the increasing number of chronic conditions 
characterized by people who do not die immediately but live for several years 
within different health states has made the classic use of years of survival as the one 
single health measure outdated [21]. The QALY can be notated as follows, where H 
is the quality of health and Y is the years lived in the health state:  
QALY = H * Y 
  
 
 
 
 
 
Figure 2-1. The QALY and interventions. 
To estimate QALYs, it is necessary to represent the quality of health on a scale 
where full health and death are allocated values of 1 and 0, respectively, where 1 
equals one year in perfect health and 0 death [25]. The most commonly used 
measured for this in health economic evaluation is the EQ-5D [21, 24, 25, 74] – a 
generic self-reported questionnaire transforming different dimensions of HRQoL 
into a single index score: the QALY weight or utility score (H). However, other 
measures can be used (see later description of QoL measures). The EQ-5D 
measures five dimensions of HRQoL: 1) mobility, 2) self-care, 3) usual activities, 
4) pain/discomfort, and 5) anxiety/depression. Each dimension has three (3L) or 
five (5L) levels of possible answers [75–77]. The answers of the three-level version 
– used in the present thesis – range from no problem to some problems and extreme 
problems [74, 76]. The five dimensions and corresponding three levels of the EQ-
5D-3L have a total of 243 unique health states. These combinations of health states 
are transformed into a linear scale ranging from 0.624 to 1.000 based on the DK 
value set. The negative values represent health states worse than death. However, 
the way the index score is calculated is not trivial. First of all, the EQ-5D is 
preference based, i.e. the utility of the population. For Denmark, US and UK and 
other countries, the preferences are obtained based on national representative 
samples, not individual willingness to pay, for approximately 40–50 of the 243 
health states of the EQ-5D using the so-called time trade-off method (TTO) [21, 
78–80]. Naturally, only 40–50 health states are assessed as it is not practically 
possible to present all 243 health states to the respondents. Thus, the remaining 
health states are estimated based on advanced econometrics and regression 
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modelling. In essence, different health states, for example those with the answers 
“no problems” to mobility, self-care and anxiety/depression and “some problems” 
to the usual activates and pain dimension (1:1:2:2:1), are compared to a state of full 
health (1:1:1:1:1). The TTO exercise then assesses how much time spent in each of 
the health states makes the compared health states equally preferable [21]. 
Basically, it is the same choice that, for example, a cancer patient needs to make: 
how much extra survival time taking medication with side effects and reduced 
HRQoL is preferable to a shorter life in better health without side effects. The 
“choice” and preference of health states is the key and link to economic theory [21]. 
Other methods of valuing can be used, for example Standard Gamble (SG) or 
Person Trade-off, however it is beyond the scope of the present thesis to discuss 
this. Further reading and thorough descriptions of all valuation techniques can be 
found in references [21, 24, 25]. 
The construct validity, reliability and responsiveness of the EQ-5D have been 
investigated comprehensively [41]. Thus, some limitations related to the present 
thesis are well known: for example, the ceiling effects – as a large proportion 
indicates no problems at all (i.e. health state 11111) even though they have 
problems in other instruments [25] – and a lack of sensitivity of mild disease states 
in the 3L version in both general and disease-specific populations [27, 41, 81–83]. 
Consequently, the EQ-5D-3L might underestimate less severe conditions, but also 
to some extent overestimate more severe conditions. A newer systematic review 
regarding the responsiveness of the EQ-5D-3L, comprising 145 clinical studies and 
different conditions, found that 21 (45 per cent) of the examined conditions were 
responsive and could detect meaningful change in health. Another 27 conditions, or 
48 per cent, had varied evidence. Finally, four conditions, or 7 per cent, were not 
found to be responsive to the EQ-5D-3L [81]. In addition, NICE has also identified 
trouble with the construct validity for the EQ-5D and a “weak” relationship with 
HRQoL for some forms of visual impairment, hearing loss and schizophrenia [27]. 
Paper 3 also discusses some of the well-known issues regarding the EQ-5D.  
Notably, the 5L version of the EQ-5D was constructed in order to address ceiling 
effects [24, 84], although the current literature about whether this has succeeded is 
sparse, yet implications exist for eight chosen conditions for some ceiling 
improvement from 20 to 16 per cent on average [46]. Moreover, both the 3L and 5L 
have complex, multimodal distributions including gaps needing complex mixed 
regression modelling as most common regression models cannot handle these 
issues.  
Finally, the EQ-5D is used in many countries and is, for example, required within 
health economic evaluation in the UK by the National Institute of Clinical 
Excellence (NICE) when making decisions about the use of new drugs, devices and 
prevention, among other things [24, 27, 41, 42]. In general, the QALY and the EQ-
5D are the preferred HRQoL measures within health economic evaluation [24, 27]. 
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In 2006, QALYs were also recommended as the preferred CEA measure in the US 
by the “Institute of Medicine (IOM) Committee to Evaluate Measures of Health 
Benefits for Environmental, Health, and Safety Regulation” – largely because of its 
ease of calculation and widespread use [85], but also as the QALY is considered 
useful for decision-making because the instrument reflects trade-offs (that people 
are willing to make) between quality of life and survival [54, 85]. 
In the Danish context, new principles for prioritization of hospital medication are 
under construct allowing for economic evaluation of new drugs in pursuit of 
ensuring “more value for money” [39, 40]. Although the details are still unknown, it 
is a possible first step towards a more systematic QALY-based health-care 
prioritization that has been debated for years. 
 
2.3. DISEASE BURDEN MEASURES ACROSS TIME AND 
RESEARCH AREAS  
Measuring disease burden is crucial for understanding chronic illness and the extent 
of issues, as well as prioritizing interventions; consequently, many measures have 
been developed over time [51]. This section describes the different disease burden 
measures in order to provide the reader with an overview of the history, uses, 
relationships and the state of the art across different research areas – and 
limitations. This will help the reader to put the used burden measures of the current 
thesis into the context of existing research and use. If the reader is already familiar 
with existing burden measures and limitations, this section can be skipped.  
Naturally, there is no unambiguous definition of disease burden in the literature, 
and it is often defined broadly and comprises several different dimensions and 
measures [86]. Thus, within the present thesis, “disease burden” is likewise broadly 
defined as “the impact of a health problem measured using different indicators or 
disease burden measures”.  
One way of grouping disease burden measures is into three broad categories: 
Epidemiological Burden, Economic Burden and Quality of Life Burden [54]. 
Although not distinctly differentiated, this categorization is useful for illustrating 
the dependence and historical succession and development. For example, the 
Epidemiological Burden measures, such as prevalence, incidence, mortality, 
morbidity and life expectancy, can be seen to provide the building blocks and value 
of Economic Burden and Quality of Life Burden measures [54]. Furthermore, 
economic burden measures such as COI are based on epidemiological estimates 
such as prevalence and mortality, and Quality of Life measures such as QALY and 
disability-adjusted life-years (DALY) combine information about non-fatal health 
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outcomes and mortality describing population health. In what follows, the three 
groups of burden measures will be described.  
Epidemiological burden  
Epidemiology is defined as: 
“The study of the occurrence and distribution of health-related events, 
states, and processes in specified populations, including the study of the 
determinants influencing such processes, and the application of this 
knowledge to control relevant health problems” [87].  
Epidemiology has roots that go far back to the Greek physician Hippocrates (c. 460 
– c. 370 BC), who was the first person known to have investigated the relationships 
between environmental influences and occurrence of disease [88]. In the late 19
th
 
and early 20
th
 century, comparing subgroup population disease rates became 
common practice initially in order to control communicable disease, but later 
proved useful in linking environmental conditions to specific diseases [89]. Yet, 
modern quantitative methods studying population diseases, informing prevention 
and controlling efforts, are a relatively new discipline. For example, the Richard 
Doll and Andrew study of tobacco use and lung cancer in the early 1950s was one 
of the first to use long-term cohort studies, and established an association between 
smoking and lung cancer [89]. 
Epidemiologists distinguish between descriptive, analytical, theoretical and clinical 
branches of epidemiology [90]. Common descriptive epidemiological disease 
burden measures in the 21st century include prevalence, incidence, mortality, 
morbidity and life expectancy as mentioned, but also the Charlson Comorbidity 
Index, which combines mortality and comorbidity [91–93]. The initial use of 
population-based morbidity and mortality estimates gained momentum in the 1960s 
[94]. While prevalence measures the occurrence of a disease at a specific point in 
time, incidence measures new cases arising in a chosen period of time. Together, 
these two measures form the foundation for measuring disease occurrence and the 
overall scale of a health problem as well as the short-term population trends [54]. 
Mortality or mortality rate is often measured as the number of deaths by population 
or disease, per unit of time and scaled to the population. Life expectancy is defined 
as “the average number of years an individual of a given age is expected to live if 
current mortality rates continue to apply” [87]. It is common that the descriptive 
measures do not provide a measure of health-related severity experienced by the 
patients and do not provide any explicit information of the health-related quality of 
life, or differences therein between conditions. Neither do they address cause and 
effect. A limitation and challenge of existing prevalence estimates is not the 
calculation, but the underlying framework and methodology identifying the 
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conditions. For example, several studies have shown substantial prevalence 
differences between self-reported and register-identified conditions [60, 95, 96], 
although other studies show varying differences [97–105].  
While descriptive epidemiological measures overall provide general statements on 
the occurrence of disease also using characteristics such as sex, age, class, 
occupation, race, calendar period and geographical localization, analytical 
epidemiology searches for causes and effect as well as classification, or outcome of 
disease [90]. The case of lung cancer and tobacco is a well-known example, along 
with survival analysis of any cancers; moreover, the randomized controlled trial 
(RCT) can be considered a specialized analytic epidemiology [90]. The used burden 
measures are excess risk, relative risk, odds ratio and population-attributable risk. It 
is outside the scope of the current thesis to explain these measures in detail (please 
see references for further details [54, 87, 89, 90]). One common challenge shared 
with other research areas is identifying cause and effect, more specifically 
attributing health outcomes to a single disease due to double counting because of 
high co-morbidity or multiple risk factors [90]. Yet, this is particularly a data 
problem depending on study or data possibilities, but certainly an issue to address 
within every framework identifying the conditions and other aspects of the study 
design, including handling competing risks statistically.  
The last two branches, theoretical and clinical epidemiology, do not provide any 
explicit new disease burden measures. Theoretical epidemiology is based on and 
creates mathematical computer models to simulate disease occurrence, or the effect 
of preventive interventions; clinical epidemiology is applied to patients and clinical 
problems, not whole populations [90].  
Within the three specified disease burden categories, epidemiological measures are 
the most explicit; moreover, they are also the foundation for developing economic 
and health quality measures [54, 106]. For instance, the prevalence is used to 
calculate aggregated costs and quality of life impacts on illness – and is as such a 
crucial measure of disease burden across disciplines. Nevertheless, a limitation of 
the epidemiological measures is that they cannot provide an overall measure of 
overall health status or change therein [54]. For example, if disease population 
prevalence indicators show a decline, but mortality rates are up, there is no way of 
concluding whether the population as a whole is better off or not. Consequently, 
various epidemiological measures function as health indicators, but shape the basis 
and complement higher aggregated population health measures such as the EQ-5D, 
Quality of Well-Being (QWB) or Subjective Well-being (SWB) [54, 107–109]. 
Economic burden  
Economic burden of disease measures are commonly described in terms of health-
care spending, both across time and at a single point in time [54]. Examples are the 
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health-care spending of GDP mentioned in section 1.1, but also the mean per capita 
spending is a classic macro-level economic burden measure. However, even though 
health-care spending accounts for a large proportion of the full burden of disease, 
other components, such as non-medical spending, of economic disease burden are 
of importance. In short, non-medical spending includes lost work days, impacts 
from increased morbidity or early mortality, and the effect on family members’ 
employment situation – or patients’ and family members’ psychological well-being 
[54]. Through best practice, economic burden estimates endeavour to obtain the full 
burden of conditions – the “opportunity costs” of illness; this includes the value of 
both non-health and health outcomes foregone by a disease [54].  
Economic burden of disease is often valued by COI as described earlier and its 
roots go back to the 1960s and beyond. However, some technical limitations and 
research trends have not been yet described, which is why this is done briefly here. 
Several studies have shown that costs vary extensively, even within the same 
disease [110–112]. Thus, over time, several attempts have been made to standardize 
COI. For example, in 1982, Hodgson and Meiners recommended including both 
direct and indirect costs in COI as well as six different points of best practice in 
how to apply costs [113]. Direct costs are defined as medical and non-medical 
spending on diagnosing, managing, treating and living with a disease, i.e. doctor 
visits, costs of transportation, family household expenditures etc. Indirect costs 
identify the productivity losses due to the lack of ability to work, but also 
psychosocial costs such as the “financial strain or uncertainty over a person’s future 
health and well-being” [54].  
Hundreds of COI studies exist and have estimated costs fully or partially within and 
for different conditions and often with different results [54]. In response, attempts at 
further standardization have included generating a national US catalogue of uniform 
estimates of direct and indirect costs for 75 diseases or risk factors in 2000 and 
2006 [54, 114]. Moreover, newer research consensus guidelines standardizing 
disease cost estimation were created in 2009 based on a research workshop [115], 
while at the same time, the WHO also published their guidelines [116]. More 
guidelines exist (see, for example, this review [112]), but the important point here is 
simply that there are plenty of existing COI guidelines regarding estimating costs. 
Nevertheless, the research focus in question has commonly been on how to account 
for costs, and less on identifying the conditions. Yet, the relevance of linking micro 
data of conditions to costs is recognized as a central challenge [56], as well as the 
importance of a standardized framework and methods for identifying conditions 
[54, 55]. However, none of these studies, to the best of the author’s knowledge, 
provide a framework for using registers to do so and the challenges in doing so (see 
descriptions of challenges in the following sections).  
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CBA and WTP – also described earlier – are other measures of economic burden 
that are often closely related. A key advantage of the WTF method is that it is able 
to capture all the benefits of a disease prevention in a single measure, including the 
prevention of productivity loss and out-of-pocket medical spending, not to mention 
pain and suffering [54]. Nevertheless, besides the already mentioned limitations, 
CBA and WTP are more complex, costly and time-consuming than many other 
measures. Nevertheless, welfarist health economists (see appendices A–B) often 
prefer WTP, arguing that it is consistent with economic theory about maximizing 
personal utility [117]. 
Quality of life burden  
HRQoL burden measures quantify a group’s or person’s self-reported perceived 
physical and mental health at a chosen point in time. Thus, these measures are not a 
proxy of either expert judgment or single measures like pain or motion [54]. 
HRQoL burden measures are needed to generate, for example, QALYs, and were in 
general intensively developed from the 1990s and beyond. Several HRQoL 
measures exist – from disease-specific to generic measures. Hundreds of disease-
specific measures exist in all possible research areas, and are often used when 
generic measures are not evaluated to capture the condition’s health states as 
desired (see, for example, Catquest, THI or ADDQoL used for measuring HRQoL 
in relation to cataracts, tinnitus and diabetes, respectively [118–120]. However, 
despite enhancing the precision of measuring precise aspects of a disease, the large 
variety of disease-specific measures has limitations. For example, within diabetes, a 
system review identified 31 different burden measures, and for vision-specific 
instruments, a review identified 32, often measuring different aspects [118, 119]. 
One obvious limitation is that it leaves a lot of room for researchers and the 
industry to choose the instrument that shows the largest improvement for a new 
treatment or drug. Moreover, comparisons across different conditions are difficult 
or even impossible in general with disease-specific measures, but also even within 
conditions unless exactly the same measures are used.  
In contrast to disease-specific measures, generic HRQoL measures enable broad 
comparisons and evaluation of overall health across different domains or 
conditions. However, as several different generic and preference based HRQoL 
measures for QALY estimation exist, there is still some room for choosing the 
instrument that fits the condition best – or puts the treatment or drug in the best 
light. These instruments also have different dimensions, levels and measurements, 
although several overlap. For example, besides the EQ-5D already described, there 
is the Short Form 6D (SF-6D) and Health Utilities Mark (HUI). The SF-6D6 is a 
                                                          
6 The instrument was partly developed due to the popularity of the SF-36 in numerous 
studies, and the valuation is based on the standard gamble; as such, it ranges from 0 (death) 
to 1 (full health) and has a value of 0.3 as the lowest value. The SF-6D has trouble with floor 
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utility instrument with six dimensions that is based on 11 selected items from the 
SF-36 HRQoL questionnaire [121, 122]. The six dimensions relate to Physical 
functioning, Role limitation, Social functioning, Pain, Mental health and Vitality – 
all ranging from four to six levels of response describing 18,000 health states in 
total, of which 249 different health states were valued, and the rest were estimated 
using econometric modelling.  
The HUI is currently in two versions, the HUI2 and HUI3 – also based on the scale 
of 0.0 (death) to 1.0 (perfect health) [24]. The HUI3 has eight health dimensions – 
Vision, Hearing, Speech, Ambulation, Dexterity, Emotion, Cognition and Pain – 
with five or six response levels. There are 972,000 health states designated by the 
HUI3 in total. The HUI2 has seven dimensions: Sensation, Mobility, Emotion, 
Cognition, Self-care, Pain and Fertility. The valuation of the HUI is based on SG, 
and is not population preference valued in a Danish setting either. Notably, many 
other HRQoL preference-based instruments have been developed within the last 
few decades other than those referenced above, such as Quality of Well-being 
(QWB), 15D, AQoL, Rosser Classification of illness states and Index of Health-
related Quality of Life [25]. Further reading regarding these HRQoL instruments 
can be found in references [24, 25, 74]. Several of the different preference-based 
HRQoL measures described earlier can be used to define the QALY.  
Furthermore, in the early 2000s, two HRQoL instruments were created for use in 
America, one measuring the amount of time for which people are unhealthy, the 
“healthy days measures7” for both mental and physical health [123], while the 
Health and Activity Limitation Index (HALex) was created based on a self-
assessment of health and “limitations of five activities of daily living” from the US 
National Health Interview Survey (see details in reference [124]). 
Another kind of QoL measure is the Health-Adjusted Life Years (HALYs); these 
measures combine the impacts of disease mortality and HRQoL [125]. Historically, 
the HALYs were generated in order to improve epidemiological mortality measures 
and provide information about the severity of a health state or condition; this 
development occurred along with a decline in mortality rates, increasing life 
expectancies and a change from infectious disease towards (increasing) chronic 
disease, making mortality rates inaccurate as a population burden of disease 
measure [86]. The QALY, described earlier and thus not described in detail here, 
                                                                                                                                       
effects, which is why a second version is under development [24]. Besides the SF-6D and 
SF-36, there is also a shorter version called the SF-12 with eight dimensions [25, 121]. Only 
the SF-6D can be used for QALY estimation, but it is not population preference valued in a 
Danish setting.  
7 See http://www.cdc.gov/hrqol/hrqol14_measure.htm  
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and DALY are two common examples of HALYs; moreover, they also both depict 
the burden of disease within a single number on a scale from 0 to 1.0. The DALY is 
a part of the Global Burden of Disease Studies (GBD), one of the most 
comprehensive attempts made to create a framework of disease burden measures 
(also including prevalence) and estimates of disease burden for hundreds of 
conditions and risk factors with widespread use [54]. The understanding of burden 
of disease has in fact increasingly been associated with the GBD [86], although 
numerous other measures exist as stated earlier. The GBD study was started at the 
request of the World Bank in collaboration with the WHO in the early 1990s, and 
the first of several studies was published in 1993 based on data from 1990, while 
the latest study is from 2010 published in 2015 [3, 7, 94]. The aims of the GBD 
were originally: 
“To facilitate the inclusion of nonfatal health outcomes in debates on 
international health policy, to decouple epidemiological assessment 
from advocacy so that estimates of the mortality or disability from a 
condition are developed as objectively as possible”, and “to quantify the 
burden of disease using a measure that could be used for cost-
effectiveness analysis” [125, 126]. 
However, in recent times, the Global Burden of Disease Studies have not been 
officially directed at local health economic evaluation, as the later studies carefully 
state that the aim is to provide “essential input into global, regional and national 
health politics” [2, 7, 127, 128]. In particular, other studies criticize the lack of local 
estimates for use in national resource allocation and prioritization, and stress the 
need for national or subnational estimates [51]. 
One DALY can be seen as one year lost in healthy life due to death or disability, 
but is, however, rather complex in construction [86]. It is crucial to point out that 
while DALY assign disability scores to diseases (weighted by age stratum), QALY 
assign disability scores to health states (not weighted by age stratum/others) [54]. 
Moreover, the disability weights were initially created based on expert opinion – 
not population HRQoL preferences like the QALY; the argument was that self-
assessments of health constituted a particular problem when comparing 
internationally, because different populations have different attitudes about desired 
health [54, 129]. This approach generated some critics [130], especially in regard to 
the lack of a theoretical foundation – the legitimacy of using the estimates for 
societal prioritization as the estimates did not reflect the population preference in 
trade-off between life and QoL – for use in health economic evaluation, which was 
one of the WHO original aims; thus, this was later given up and the disability 
weights were later generated by global population preferences based on a mean of 
several countries and regions [24, 25, 131]. This was done as DALYs are aimed at 
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comparing on a global scale in contrast to the QALY; yet, critics8 argue that the 
DALY is too inaccurate for local or country-specific CEA [7, 9, 130]. 
In more detail, the DALY is attributable to specific illnesses, and for a certain 
population, equal to the sum of years of life lost (YLL) and years of life lived with 
disability (YLD), hence DALY = YLL + YLD [7, 9, 127, 128]. YLLs are calculated 
by multiplying the average life expectancy at the age of death (L) by the number of 
deaths for a given cause (N), hence YLL = L x N [126, 129]. YLD “multiplies the 
number of disability cases (I) by the average duration of the disease (L) and by a 
weighting factor (DW) that reflects the severity of the disease”, hence YLD = I x L 
x DW [54, 129].  
So, what are the limitations and potentials for improvement of the GBD 
framework? First of all, much has already been done to improve the DALY 
calculation as mentioned – including methods handling large amounts of missing 
data and strengthening varying data sources [3, 131, 132]. However, Murray et al., 
among others, suggests further use of data-related improvements, for example ICD-
10 codes and hospital discharge records [8]: 
“Hospital discharge data and outpatient data coded to ICD-10, despite 
issues of selection bias, have proven to be very useful in the assessment 
of the burden from many conditions; wider and more systematic 
collation of this data especially at the unit record level would be 
extremely useful.” The Lancet, 2012 [8] 
Moreover, the use of HRQoL measures has also been recommended as a 
supplement by the authors of the GBD: 
“Broader use of functional health status instruments such as SF-12 in 
surveys or in health service settings that also provide reliable diagnoses 
would strengthen the analysis of many conditions, including mental and 
behavioral, musculoskeletal, neurological, chronic respiratory, and 
diabetes.” The Lancet, 2012 [8]. 
Notably, this methodological recommendation is broadly consistent with earlier 
recommendations and issues within COI and health economic evaluation regarding 
the basic issues of data and a framework identifying conditions used for different 
                                                          
8 In addition, several studies have shown differences in costs across countries – in terms of 
actual costs, records and estimating costs – making transferability of results from health-care 
valuations problematic [21]; moreover, the HRQoL population-based preference values and 
clinical practice vary across countries.  
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burden estimates. Naturally, burden of disease estimates are only as good as the 
data and underlying methodology. Different data and methods naturally provide 
different burden estimates; also, different studies are often measured partially. Even 
the GBD studies consist of multiple and varying data sources and different data 
collection methods all put together using complex statistical methods [3, 131, 132]. 
Thus, these studies often show substantial differences in burden estimates within 
the same condition as mentioned. Therefore, there is room for improvement with a 
transparent standardized, uniform framework for identifying multiple conditions 
within health-care data; and for catalogues of uniform estimates of HRQoL and 
prevalence of multiple conditions for use in health economic evaluation, among 
others. 
The present thesis focuses on two crucial burden of disease measures: prevalence 
and HRQoL based on the EQ-5D.  
 
2.4. THE ERA OF BIG DATA – POTENTIALS, RECOMMENDATIONS 
AND DEFINITIONS: MAKING USE OF DATA  
As pointed out earlier, proper (use of) data is crucial for valid estimates of the 
different outcomes used for health economic evaluation. But equally important, the 
use of data could also generate several societal potentials.  
In “An OECD horizon scan of megatrends and technology trends in the context of 
future research policy”, the OECD and the Danish Ministry of Higher Education 
and Science describe megatrends as 10–20-year slow-moving trends with a socio-
economic impact, and technologies of societal importance from a research 
perspective [133]. One important recommendation is actual monitoring of diseases 
and shifting perspective to a preventive set-up, and interestingly in regard to this 
PhD, focusing on quality of life and health record systems is an important tool in 
addressing health-care challenges too:  
“Big data analytics may trigger some substantial changes in healthcare 
systems by enabling a shift from a reactive set-up that focuses on 
disease to a preventive setup that focuses on quality of life and well-
being (OECD, 2013d). Sharing health data, through electronic health 
record systems, for example, can increase efficient access to healthcare 
and provide novel insights into innovative health products and services 
(OECD, 2013e). Diagnosis, treatment and monitoring of patients may 
become a joint venture of analytical software and physicians. Clinical 
care may even become preventive in nature as big data analytics help 
discover pathologies before symptoms occur. On top of open research 
data, the connection of smart applications through the Internet of Things 
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(IoT) will enable the gathering of a wealth of health-related records, 
being self-reported or automatically tracked, on both sick and healthy 
people. New potential clinical trial participants will be more easily in 
reach. Broad data on exposures, outcomes and healthcare utilisation 
could be put together with deep clinical and biological data, opening 
new avenues to advance common knowledge, for instance on ageing-
related diseases, or to support interdisciplinary research, for instance on 
combined effects of cure and care (Anderson and Oderkirk, 2015)…” 
OECD, 2016 [133] 
In essence, HRQoL estimates of disease burden could possibly fuel societal trends 
towards prevention and thus better health if monitored continuously, especially if at 
the same time, in the author’s opinion, explicitly combined with already existing 
prevention politics and new measurable goals based on the very same data 
(prevention potentials are indirectly described in chapter 5 in regard to introduction 
to use the HRQoL estimates within health economic evaluation).  
The WHO has also recommended more automated use, reliable estimates and 
monitoring of conditions and risk factors within health care [1]. In short, there is no 
lack of recommendations for using big data within health care from global and 
leading institutions; moreover, in response, this PhD provides a register-based 
framework for monitoring chronic disease.  
Notably, in a Danish context, “big data” is not really a new term. Danish 
researchers have been exercising “big data analytics” for several decades using 
unique Danish registers or large nationwide surveys. Thus, even though the term is 
getting increasingly popular, it may seem “old news” for some. However, in the 
author’s opinion, the term “big data” is still justified as an umbrella for a trend of 
expanding data to different areas, for example social media and consumer data. But 
also, the size of data is increasing within existing areas, such as health care, for 
example, in terms of variables for monitoring, for example, organizational goals of 
treatments, health improvements or patient satisfaction. In this context, the need for 
big data analytics for making sense and optimal use of data is increasing, as the 
increasing data sources generate new possibilities used in combination. Moreover, 
existing data could still be used further, including combining data sources, as done 
within this PhD. 
Within the present thesis, big data are defined as population register data and/or 
survey data of a minimum of 50,000 respondents collected continuously. However, 
we will not use the term “big data” further, as the term does not add any precision 
to the term “data” here, but is merely a broad definition comprising all kinds of 
data. 
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2.5. REGISTERS AND POTENTIALS – WHEN IDENTIFYING 
CONDITIONS  
The registers included in the current thesis are mainly used for identifying chronic 
conditions. Scandinavian countries have a long tradition of reporting different 
conditions, treatments and others at the micro level in national health registers. The 
Danish tradition goes back to the 18th century with the Danish Twin Registry, 
Danish Registry of Cerebral Paresis and more [134] – and even longer if you 
include church birth registers.  
Register data are usually collected for public administration such as management 
and claims, control functions and surveillance [135]. There are several advantages 
to register-based studies. First, the data are already collected, continuously collected 
and thus cost-effective and easily accessible. Secondly, registers contain doctor-
reported diagnoses and medicine, among other things, and despite limitations such 
as selection bias, they do not, for example, have recall bias or have trouble with 
non-responders. Also, advantages are large study size and population coverage as 
well as reduced likelihood of differential misclassification [136]. Although another 
advantage is the lack of bias due to non-responders [135], this only partly applies 
when combining survey and register data, as done in paper 3.  
Another advantage is that register data are updated yearly, comes with affiliated 
quality declarations, undergo ongoing quality testing by full-time employees for the 
full Danish population and therefore have no missing values on a comprehensive 
variety of variables. Accordingly there’s no response due to misinterpretation of 
questions, wrong check marks, perhaps half-true or missing answers whenever the 
reason is that the respondent, for example, does not know, forgets or will not 
answer etc. The register data are created from identical criteria for each variable and 
are not dependent or subject to individual bias.  
Register data are collected population wide full scale since registrations are 
mandatory be law. Data are collected from, for example, the National Board of 
Health, but also IRS (income and occupation etc.) or when citizens record addresses 
and other mandatory information at the city hall etc. Furthermore, educational 
institutions automatically record when a citizen has finished his or her education, 
the hospital record birth date etc. All these data are mandatorily reported to 
Statistics Denmark by the responsible public data controller who revived or created 
the data.  
 
Table 2-1 shows the size of some essential included register data from current 
studies. In 2014, there were more than 21.4 million contacts with hospitals, private 
specialists and GPs.  
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Table 2-1. Contacts with hospitals, GPs and specialized doctors, Denmark, 2009–
2014 
Source: Statistics Denmark 1/3/2016, http://www.statistikbanken.dk/  
While all diagnoses of hospital in- and outpatients are reported in registers, this is 
not the case for GP and private specialists. To ensure inclusion of these chronic 
conditions also treated in the primary sector, the study included several other 
registers including medication and GP health services. These registers are 
summarized in chapter 3.  
 
2.6. DEFINING CHRONIC CONDITIONS AND CHALLENGES  
A key point of the PhD is defining chronic conditions as it set out the foundation. 
The literature and authorities have several, although similar, suggestions for 
definitions of chronic conditions. For example, the WHO defines a chronic disease 
as: 
“Noncommunicable – or chronic – diseases are diseases of long duration 
and generally slow progression. The four main types of 
noncommunicable diseases are 1. cardiovascular diseases (like heart 
attacks and stroke), 2. cancer, 3. chronic respiratory diseases (such as 
chronic obstructed pulmonary disease and asthma) and 4. diabetes. [137] 
See: 
http://www.who.int/features/factfiles/noncommunicable_diseases/en/ind
ex.html  
 2009 2010 2011 2012 2013 2014 
Public and private hospitals 
and clinics – all 
7,496,098 7,738,695 8,007,830 8,297,679 8,534,966 8,591,692 
- hospitalizations 1,157,172 1,197,206 1,207,761 1,239,128 1,245,161 1,279,051 
- outpatients 6,338,926 6,541,489 6,800,069 7,058,551 7,289,805 7,312,641 
GPs – all contacts 11,640,041 11,733,941 11,877,864 11,337,669 11,447,165 11,132,224 
 - Consultations 5,021,894 5,004,369 5,127,817 5,067,024 5,110,388 5,006,647 
 - Home visits 374,106 349,744 343,489 341,321 338,568 275,156 
 - Phone consultations 4,408,531 4,310,533 4,337,740 4,248,743 4,191,013 3,903,992 
 - Email consultations 653,114 796,298 967,353 1,114,465 1,254,979 1,402,561 
 - Consultations, prevention 1,182,396 1,272,997 1,101,465 566,116 552,217 543,868 
Private specialist doctors (e.g. 
eye, ear, skin, obstetrics) – all 
1,512,219 1,544,877 1,580,607 1,608,411 1,643,575 1,681,555 
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In this context, “chronic” is not defined as (definitely) not curable, but “only” as a 
disease of long duration, slow progression and non-communicable. Moreover, 
chronic conditions are specified to a limited number of disease areas.  
The Danish National Board of Health defines a chronic disease as follows, and 
though similar, some differences exist: 
2005: “Chronic disease has one or more of the following characteristics: 
The disease is persistent, has permanent consequences, due to 
irreversible changes, requires a lengthy treatment and care and/or a 
special rehabilitation” [18].  
2012: “Chronic disease is defined by the Board of Health as a ‘disease 
that has a long-term course or is constantly recurring’ [64]. 
Although not explicitly contradictory, the definitions do vary. For example, the 
2005 definition is more explicit in terms of persistence and permanence. In contrast, 
the 2012 definition does not stress “permanent”, but only refers to the condition as 
being “long-term”. However, the National Board of Health emphasizes that the 
definition is not well defined [64]. Yet, similarly to the WHO definition, a disease 
is long-term and being cured is not ruled out, therefore the health state is not 
infinite. This is important as many chronic conditions either reoccur periodically 
(like allergies, among others) or can be partly cured, “put to sleep” (for example 
HIV), or even cured in the long term as new technologies emerge (for example 
ulcers).  
The above definitions, however, are too unspecific to be used in register research. 
They lack a more specific time frame for inclusion/exclusion of conditions. This is 
especially important as different chronic conditions can have a different “long-
duration” or “long-term” course, and since “chronic”, despite the mainstream use of 
the word, in reality might not be life-long as indicated above. Furthermore, none of 
the definitions actually define whether the condition requires treatment or not, or 
has any influence on health, although this is implied. This is, however, clearer in 
this definition by Hwang et al., which is the definition the current study is based 
upon:  
“We defined a person as having a chronic condition if that person’s 
condition had lasted or was expected to last twelve or more months and 
resulted in functional limitations and/or the need for ongoing medical 
care” [41, 138, 139]. 
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First of all, the definition includes a time frame in contrast to other definitions. 
Secondly, “disease” is interchanged with “condition” unlike the previous 
definitions. Although the two words are often used interchangeably, the term 
“condition” is preferred as it is considered to be more closely connected to a “state 
of health”, which might change in line with real-life chronic conditions, unlike a 
classic understanding of disease that historically originates from communicable 
disease. This is important as the focus is on a wide range of illnesses, where some 
perhaps do not necessarily have a long duration and are relatively easily cured or 
have health state changed (such as “glaucoma”, “cataract”, “gastric ulcer”, 
“renal/ureteral calculus”, “cholelithiasis” and more). However, it is recognized that 
the term “condition” might be unclear in regard to some “health conditions” such as 
overweight and alcohol dependency, which are actually also defined within the 
ICD-10 coding system. As such, overweight and alcohol dependency are excluded 
as chronic conditions (see supplementary material of reference [140]).  
Although the Hwang et al. definition includes the necessary “minimum inclusion 
time” that is universal for every chronic condition (minimum 12 mouths’ duration), 
it does not have a “maximum inclusion time”, which is also needed in register 
research. A maximum inclusion time is less important within self-reported 
conditions, where a person has started having a condition at the specific survey 
time. If the condition usually lasts longer than 12 months, then it is present and 
chronic if self-reported. However, in register research, there is not a respondent 
statement of conditions, but often a random report of conditions across different 
times. As a survey is combined with register-based conditions, it is essential to 
know if a condition identified, for example, once in a register 10 years back in time 
is still present at the time of the survey. This is the “maximum inclusion time”, and 
is crucial in order to ensure a correlation between the condition and the HRQoL. As 
the maximum inclusion times differ across conditions, no existing definition 
comprises the precision and definition needs of register research. Thirdly, the 
definition opens to include several medications and treatment registers as it also 
comprises “medical treatment”.  
All the presented approaches have a rather broad definition of chronic conditions. 
Hwang et al.’s definition is used to select which overall conditions are to be 
included as chronic conditions, as it comprises most operational dimensions also 
corresponding to the used registers, for example the use of medicine, but the 
definition is modify by adding maximum inclusion times to fit the challenges of 
using ICD-10 diagnoses and register data. In this respect, it is the intention to 
provide a new framework of differential inclusion times including clinical 
suggestions of individual maximum inclusion times for each of the 199 identified 
chronic conditions for future use in research and by health-care professionals. This 
is presented in the results section and represents a methodological contribution of 
this PhD thesis as, to the best of the author’s knowledge, it has not been done 
before.  
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As ICD-10 diagnosis codes only exist within secondary care, the main challenge, 
for those chronic conditions only treated in primary care, is to include using 
registers other than the NPR as the aim is to capture a representative disease 
population. However, we expect that many chronic patients treated in primary care 
are also treated in secondary care at some time and thus reported with a diagnosis at 
some time, and for many more severe and common conditions such as heart 
conditions and cancers, they are mainly reported and diagnosed in secondary care. 
So how big is the problem really? It depends on the condition and severity. In 
general, less severe conditions are treated in primary care and thus many most 
likely would not be considered chronic according to the overall definition, although 
more than half of all contacts are within primary care as seen in Table 2-1. 
Yet, less severe cases of chronic lung diseases, such as COPD, type 2 diabetes and 
others, are treated in primary care, while other less severe eye and ear diseases are 
treated by private specialists without reporting diagnoses. Consequently, we used 
the previously mentioned medication and service registers to identify these. The 
extent and differences in prevalence between only using NPR diagnosis codes and 
several registers are shown for some conditions in section 4.2 and paper 1B.  
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CHAPTER 3. DATA AND METHODS  
3.1. THE REGISTERS  
The Danish National Registers contain various high-quality microdata for the entire 
Danish population. All registers contain a unique 10-digit personal identification 
number (the CPR number) for each individual. This allows record linkage at the 
individual level of data across time from complete national registers used in the 
current study. Naturally, this use is regulated by law, and therefore the current PhD 
received permission from the Danish Data Protection Agency to link the survey 
data with relevant register data using the Statistics Denmark “researcher service” 
(The project number is 702835, with permissions given in autumn 2012 and later , 
learn more at http://www.dst.dk/en/TilSalg/Forskningsservice.aspx). This is a user 
platform providing relevant register data and the statistical packages SAS and 
STATA all managed on Statistics Denmark’s secured servers from a secured 
remote desktop, so confidentiality is ensured.   
The following registers were included: 
 The National Patient Register (NPR) [141]  
 The Danish Psychiatric Central Research Register (PCRR) [142] 
 The National Health Service Register (NHSR) [143]  
 The Danish National Prescription Register (DNPR) [144]  
 The Danish Civil Registration System (CRS) [145]  
 The Population’s Education Register (PER) [146] 
 The Income Statistics Register (ISR) [147] 
 
The Danish National Patient Register (NPR) [50, 140, 141, 148]. The NPR contains 
data on diagnoses, patient types, treatments, surgeries, dates and more from all 
public and private nationwide hospital treatments. This is reported for every patient 
contact at the individual level, and comprises in- and outpatients and emergency 
patients [141]. However, diagnoses of emergency patients were excluded from the 
current study as the validity thereof was not shown adequately [149, 150]. The 
register was initially established in 1977 for administrative use, although it has 
progressively been used for research. From 1994, the use of ICD-10 codes was 
employed with more than 22,000 different codes [141], and one year later, somatic, 
psychiatric and emergency patients were included in the register. Finally, from 
2003 private hospitals and private clinics were integrated in the NPR as a result of 
the upcoming of private health care in Denmark. The NPR is founded on the 
attending doctor’s diagnosis reports and is reported at discharge for each patient. 
The reporting to the NPR is mandatory by Danish law, and is collected on a daily 
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basis on data servers. Further data descriptions can be found at:  
http://www.dst.dk/da/TilSalg/Forskningsservice/Data/Andre_Styrelser.aspx 
The Danish Psychiatry Central Research Register (PCRR) [142]. The PCRR was 
employed to increase the accuracy of psychiatric diagnoses from the NPR. It was 
first founded in 1938, and was made national in 1969. The PCRR comprises data on 
nationwide psychiatric in-, out and emergency patients’ ICD-10 diagnoses at 
Danish psychiatric hospitals from 1995 [142]. As with the NPR, the data are 
reported by the attending physicians, and include information about diagnoses, 
discharges, dates, places of treatment and types of referral, among other things. 
Further data descriptions and documentation can be seen here:  
http://www.kea.au.dk/file/Psykiatriske%20Centrale%20Forskregister/VARIABES
KRIVELSE%202011.pdf  
The National Health Service Register (NHSR) [140, 143, 151]. The NHSR was first 
compiled in 1984 and contains information regarding services of publicly funded 
primary care health professionals including data about all GPs, dentists, medical 
specialists, psychologists, physiotherapists, chiropractors and chiropodists. The 
NHSR is used for economic settlement of the provided services with the 
government, and is reported electronically every week through the physicians’ 
invoices to the Regional Health Administration and later the National Board of 
Health [143]. The NHSR was integrated into the present study to link services (e.g. 
lung tests, diabetes tests, blood samples, different laboratory tests, referrals to 
specialists and more) to diagnoses and conditions where possible. See further data 
documentation and descriptions at:  
http://www.dst.dk/en/Statistik/dokumentation/documentationofstatistics/health-
insurance-statistics  
The Danish National Prescription Register (DNPR) [140, 144, 152]. The DNPR 
contains data on all non-hospital-prescribed medicine for all Danish citizens at an 
individual level; the register was established in 1994. All medications are reported 
using the Anatomical Therapeutic Chemical (ATC) classification system; 
moreover, the register includes date and from 2003 partly indication codes 
providing information on the conditions treated with the drugs. Notably, the DNPR 
does not provide data on drugs dispersed at hospitals and over-the-counter (OTC) 
drugs. The validity of the register is heightened as all Danish pharmacies are 
required by law to electronically report dispensed prescriptions to the Danish 
Medicines Agency. High-quality data are ensured as all drug packages have a drug 
article number matching a labelled barcode, which is why inter/intra-observer bias 
and information bias are unlikely to occur. Naturally, this does not ensure or report 
consumption of the drugs (primary non-compliance); hence the DNPR is a 
surrogate measurement of the patient’s actual ingestion of the drug [144]. Within 
the current study, the DNPR is used to link specific drugs to specific conditions 
among patients treated in the primary care sector. Further data descriptions can be 
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found at:  
http://www.dst.dk/da/TilSalg/Forskningsservice/Data/Andre_Styrelser.aspx 
The Danish Civil Registration System (CRS) [140, 145, 153]. The CRS includes the 
names, gender, age/birth dates, residence, ethnicity and more of all persons alive 
and living in Denmark. The entire Danish population aged 16 or more totalled 
4,555,439 inhabitants on 1st January 2013. The CRS was established in 1968, while 
information on ethnicity, immigrants and their descendants was first recorded from 
1991. See more details about the CRS at:  
http://www.dst.dk/da/Statistik/dokumentation/Times/cpr-oplysninger.aspx and 
http://www.dst.dk/Site/Dst/SingleFiles/kvaldeklbilag.aspx?filename=611d9cb3-
442d-42b8-9b68-e27950059130Immigrants_and_Descendants_2016   
The Population’s Education Register (PER) [146]. The PER contains a variety of 
individual-level information about education, type and name, enrolment, time of 
enrolment, length, and most importantly highest completed educational level and 
time thereof. An eight-digit code enables transformation into the International 
Standard Classification of Education (ISCED). The register only provides 
information about education of more than 80 hours’ duration authorized by the 
Danish Ministry of Education. The register was started in 1977, although several 
data breaks and changes exist [146]. See also: 
http://www.dst.dk/da/Statistik/dokumentation/Times/uddannelseregister 
 
The Income Statistics Register (ISR) [147]. The ISR was first established in 1970 
and contains more than 160 variables including salaries, capital income, taxes, 
entrepreneurial income, private pension contributions, public transfer payments, 
payouts and socio-economic status [147]. In the current study, we use the family 
equalized income variable provided by Statistics Denmark. See: 
http://www.dst.dk/da/TilSalg/Forskningsservice/Dokumentation/hoejkvalitetsvariab
le/personindkomster.aspx and  
http://www.dst.dk/da/Statistik/dokumentation/Times/moduldata-for-indkomst--
forbrug-og-priser/famaekvivadisp.aspx  and  
http://www.dst.dk/da/Statistik/dokumentation/Times/personindkomst/socio02.aspx  
 
 
3.2. CURRENTLY USED DEFINITION OF CHRONIC CONDITIONS  
For completeness, as mentioned earlier, the current study is based upon the 
following definition of chronicity by Hwang et al.:  
“We defined a person as having a chronic condition if that person’s 
condition had lasted or was expected to last twelve or more months and 
resulted in functional limitations and/or the need for ongoing medical 
care.” Hwang et al., 2001 [41, 138, 139] 
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Another challenge is time, as previously mentioned, as chronicity varies across 
conditions, and since the definition does not account for the maximum inclusion 
times needed using registers (as we look back in time from the survey time). 
Therefore, the following four inclusion categories were created to comprise the 
different levels of chronicity across conditions on average:  
1. Category I: Stationary to progressive chronic conditions (no time limit 
equals inclusion time going back from the time of interest, for as long as 
valid data were available. In the current study, this starting point was 
defined by the introduction of the ICD-10 diagnosis coding in Denmark, in 
1994); 
2. Category II: Stationary to diminishing chronic conditions (10 years of 
register inclusion time, to the time of interest); 
3. Category III: Diminishing chronic conditions (5 years of register 
inclusion time, to the time of interest); and  
4. Category IV: Borderline chronic conditions (2 years of register inclusion 
time, to the time of interest). 
 
Source: adapted from Hvidberg et al. [140], see 
http://sjp.sagepub.com/content/early/2016/04/19/1403494816641553.full  
 
These four categories were applied to all registers and conditions. The full medical 
categorization of all conditions into one of the four categories is found in paper 1. 
3.2.1. PANEL OBJECTIVES, PROCESS AND MEDICAL RATIFICATION  
Two kinds of definitions were created: complex definitions, including several 
registers as this was considered medically necessary in order to capture the full 
disease population, and simple conditions solely using NPR diagnosis register data. 
In practice, existing literature also formed and inspired some of the suggested 
definitions as described in paper 1/1B [140]. 
A medical expert panel was established in order to categorize, review and ratify the 
register-based definitions. The objectives of the expert panel were as follows:  
 “Selecting the ICD-10 codes of chronic conditions  
 Ensuring grouping of the chronic conditions into clinically 
meaningful groups  
 Ratifying the four overall inclusion times and assigning one of the 
four inclusion times to each of the chronic conditions  
 Assessing conditions in need of complex definitions, reviewing and 
ratifying these” 
 
Source: adapted from Hvidberg et al., supplementary material page 3 [140], see 
http://sjp.sagepub.com/content/44/5/462  
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In order to archive consensus over the objectives, the panel process seen in Table 
3-1 – in part inspired by the Delphi method [154] – was carried out:  
Table 3-1. The process  
I. The panel of medical experts: A medical panel of seven doctors, including a “core panel” of two 
doctors from the co-authors of the manuscript. The corresponding author acted as coordinator of the 
process. 
II. Process and rounds: The rounds were performed bilaterally, by meetings, phone and email, 
between the coordinator and each expert. When conducted by personal meeting or phone, the main 
conclusions were incorporated into the manuscript for the next round, or for the external doctors not 
among the authors, and also by a separate summary thereof by email. The contributions of the 
external experts were, however, finally reviewed and approved by the authors. At least six full 
rounds were carried out (many more if bilateral email correspondence and other communications 
are included).  
III. Personal meetings: Three bilateral personal meetings were carried out with the corresponding 
author and with Søren Paaske Johnsen, Ib Rasmussen and Martin Bach Jensen, respectively, as well 
as email correspondence including a summary of the discussed conclusions.  
IV. Conference calls/email: Several conference calls were held with Charlotte Glümer, Søren Paaske 
Johnsen, Ib Rasmussen, John Hyltoft and Kaare Dyre Palnum, as well as email correspondence 
including a summary of the discussed conclusions either in the form of a separate summary or by 
incorporation into the manuscript.  
V. Questions: A core of systematic questions were asked for each meeting or contact, including the 
option of further discussion and comments.  
VI. Anonymity: Anonymity, as in the traditional Delphi method, was only partially ensured as the 
corresponding author handled the comments bilaterally, and by incorporating the comments into the 
manuscript mostly with anonymity. However, all participants knew each other by name, and some 
named comments for discussion were also implemented in the manuscript if asked for.  
VII. Time of process: The process started in late 2013 and finished in early 2016. 
Source: adapted from Hvidberg et al., supplementary material page 3 [140], see 
http://sjp.sagepub.com/content/44/5/462  
 
The contents of the process and steps are further described in more detail in the 
supplementary material of paper 1 [140].
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3.3. THE SURVEY SAMPLES  
The Danish National Health Profiles (NHP) are a comprehensive nationwide survey 
with a total of 298,550 invited citizens conducted to moniter/survey public health 
every fourth year [155–159]. The survey includes questions on health-related 
quality of life, health behaviour, morbidity, consequences of illness, social 
relations, socio-demographic characteristics and more.  
The NHP contained six mutually exclusive random subsamples: one in each of the 
five Danish regions (see Figure 3-1) and one national random sample sampled by 
the National Institute of Public Health (NIPH). All regional samples were further 
subsampled – or stratified – by municipalities, with a minimum of 2000 individuals 
included, while the NIPH’s national data were not subsampled. Some regions, 
including the North Denmark Region (NDR), have chosen to include more than the 
minimum requirement of 2000 individuals to enable more detailed geographic 
analysis in larger municipalities.  
The survey data were collected from February to April 2010/2013, sampled from 
the Danish Civil Registration System, which is a national register of the entire 
population. A simultaneous mixed-mode approach was used to collect the data for 
all six samples. All included individuals received a letter of introduction that briefly 
described the voluntariness, purpose and content of the survey. The included 
individuals were invited to either fill in an enclosed paper questionnaire or complete 
a web questionnaire using a unique user name. A minimum of two postal reminders 
in all samples were used; further details of the samples and data collection can be 
found in reference [155].  
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Figure 3-1. Map of Denmark and the municipalities. Source: adapted from A.I. 
Christensen et al., Figure 1 [155]. 
 
  
North Denmark Region 
Population: 657,000 (14.2%) 
Municipalities: 11. 
 
Central Denmark Region 
Population: 997,000 (21.5%) 
Municipalities: 19. 
 
 
Region of Southern Denmark  
Population: 961,000 (20.8%) 
Municipalities: 22. 
 
 
Region Zealand  
Population: 657,000 (14.2%) 
Municipalities: 17. 
 
 
Capital Region of Denmark  
Population: 1,355,000 (29.3%) 
Municipalities: 29. 
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3.3.1. THE QUESTIONNAIRE 
The standard questionnaire included 52 core questions identical for all six samples. 
In addition, every region or NIPH can include extra unique questions of interest 
besides the identical 52 core questions [155]. The extra survey questions differ, but 
relevant for this study, we used the full Cohen’s Perceived Stress scale (10 
questions) and the five EQ-5D questions version 2. Only the NIPH and NDR have 
included the EQ-5D besides the core questions.  
Table 3-2. Summary of questionnaire core questions  
Topics Indicators 
Socio-demography 
Marital status, cohabiting status, number of children in the household, 
education and occupation 
Quality of life and health 
Stress (three questions from the Perceived Stress Scale) and the 12-item 
Short-Form Health Survey v2 (SF-12 v2).  
Anthropometry Self-reported weight and height 
Diet Food frequency and self-rated dietary habits 
Smoking Smoking frequency and smoking quantity 
Alcohol 
Alcohol consumption – quantity and frequency, type of alcoholic 
beverages, binge drinking and CAGE-C 
Physical activity Leisure time physical activity and self-rated physical condition 
Health promotion and 
prevention 
Readiness for health behaviour change (physical activity, weight, diet, 
smoking, alcohol), help and support for smoking cessation 
Social relations 
Contact with family, friends, colleagues or fellow students in leisure time, 
neighbours, people from the Internet, social support, help with practical 
problems, loneliness 
Morbidity, symptoms and 
contact with health services 
Long-standing illness, specific diseases (asthma, allergy, diabetes, 
hypertension, heart attack, angina pectoris, stroke, chronic obstructive 
pulmonary disease, osteoarthritis, rheumatoid arthritis, osteoporosis, cancer, 
migraine, transient mental disorder, persistent mental illness or disorder, 
back disorder, cataract, tinnitus), pain or discomfort (pain or discomfort in 
the shoulder or neck, pain or discomfort in the back or lower back, pain or 
discomfort in the arms, hands, legs, knees, hips or joints, fatigue, headache, 
sleeping problems or insomnia, melancholy/depression or unhappiness, 
anxiety/nervousness/restlessness or apprehension) and contact with the 
general practitioner 
Absence from work Absence due to illness, discomfort or injury 
Source: adapted from A.I. Christensen et al. [155], Table I.  
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3.3.2. THE SAMPLES IN COMPARISON AND DIFFERENCES IN HRQOL 
The included data used for estimating EQ-5D-based HRQoL in paper 3 consist of 
three survey samples, one sample from 2010 from the NIPH and two samples from 
the NDR from 2010 and 2013, with a total of 56,988 respondents. The EQ-5D was 
not present in the NIPH sample from 2013 or in other regional samples. Naturally, 
this asymmetric national sample constitutes challenges in pursuit of creating 
nationally representative estimates. Consequently, a comprehensive summary of the 
samples and differences is provided in what follows. 
All invited individuals within samples were randomly chosen, aged 16 years or 
older and resident in Denmark on 1st January 2010 or 2013. The rather large 
sample size was needed to be able to create reliable estimates of the 199 chronic 
conditions. However, since the samples were stratified in different geographic 
sections (including municipalities), and since the NDR is over-represented, the 
responses have several different sampling probabilities, making national 
representativeness a challenge. These statistical challenges and solutions are 
addressed later in detail in regard to the use of weights and regression. Notably, all 
NDR estimates in Table 3-3 are nationally standardized by age, gender and 
education, as done in paper 3, to be as close as possible to national estimates.  
The small NIPH NDR 2010 sample of 1,646 respondents actually differs slightly 
from the other NDR samples, by not only having the highest mean EQ-5D of all 
regions, but also differences in gender, education and age. These differences also 
persisted without standardization of the two NDR samples, and the socio-economic 
status levels were very different’ as seen in Table 3-4. In comparison, other studies 
showed mostly worse health in the NDR in most different health measures 
compared to other regions [156–159].  
Another issue was the three-year time differences between samples. In line with 
previous studies, samples across time were combined in order to increase the 
sample size [41, 43]. This could constitute a problem if any medical advancement, 
public health programmes or changed societal conditions, such as the labour 
market, impacted on and changed the HRQoL. Yet, there were no overall 
indications thereof, as the EQ-5D mean difference across the 2010 and 2013 sample 
was relatively small.  
In conclusion, the NDR and NIPH national differences in the EQ-5D mean were 
small and almost identical – especially in an international context – and although 
partly significant, this is not surprising due to the large samples.   
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Table 3-3. Respondent characteristics of the included samples (NDR and NIPH) 
sorted by regions 
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Table 3-4. Population, samples by regions and their responses in comparison  
 
Denmark 
populatio
n 2010 
% 
 
NIPH 
complete 
sample 
 
All 
samples 
combined 
NDR 
populatio
n 2010 
% 
NDR 
2013: 
North 
Denmark 
Region 
NDR 
2010: 
North 
Denmark 
Region 
NIPH 
2010: 
North 
Denmark 
Region 
NIPH 
2010: 
Central 
Denmark 
Region 
NIPH 
2010: 
Region of 
Southern 
Denmark 
NIPH 
2010: 
Capital 
Region of 
Denmark 
NIPH 
2010: 
Region 
Zealand 
Total, N/n 4,460,874 15,165 56,988 475,637 18,431 23,392 1,646 3,567 3,415 4,385 2,152 
Gender            
Men 49.2 49.1 50.8 49.9 49.2 50.0 52.1 48.4 50.3 48.2 48.5 
Women 50.8 50.9 49.2 50.1 50.8 50.0 47.9 51.6 49.7 51.8 51.5 
Age            
16–24 years 13.6 13.5 13.7 13.9 14.2 13.9 15.2 14.6 12.1 13.8 11.8 
25–34 years 14.9 14.8 14.7 13.5 14.3 13.5 12.6 15.7 12.8 18.6 10.3 
35–44 years 18.0 18.0 17.6 16.6 16.7 16.7 17.2 19.3 17.4 18.0 17.3 
45–54 years 17.1 17.2 17.3 17.5 17.6 17.6 17.0 16.7 19.5 15.6 17.9 
55–64 years 16.2 16.2 15.9 16.9 15.3 16.9 18.1 15.5 16.9 14.7 18.3 
65–74 years 11.6 11.6 11.9 12.1 12.7 12.2 10.8 10.5 11.1 11.4 14.9 
75+ years 8.7 8.7 8.8 9.5 9.3 9.3 9.2 7.7 10.2 7.9 9.5 
Education            
Missing 4.3 3.8 3.8 3.8 2.9 3.3 3.3 3.8 3.8 4.7 2.1 
No education / training, ref. 31.9 28.2 30.2 36.6 29.2 34.2 32.8 29.4 32.3 22.1 29.5 
Short education 43.8 45.5 45.2 43.5 46.5 44.9 47.1 45.5 45.6 42.5 50.4 
Middle education – bachelor 13.6 14.8 14.4 12.1 15.5 13.3 12.7 14.2 14.0 17.1 13.7 
Higher education – master’s degr. 6.4 7.7 6.5 4.0 5.9 4.4 4.1 7.0 4.3 13.6 4.4 
Family Equalized Income            
< 100.000 kr. (< £9,500 ) 8.2 7.0 6.6 6.6 6.1 6.8 7.4 7.3 6.3 8.6 4.3 
100,000-199,999 kr.  
(£9,500–£19,000) 
42.5 41.9 42.8 40.4 39.1 46.3 45.0 43.5 43.8 37.7 43.2 
200,000–299,999 kr. 
 (£19,000–£28,500) 
34.5 35.8 36.0 36.0 37.1 35.4 35.9 36.4 36.7 34.1 36.9 
300,000–399,999 kr. 
 (£28,500–£38,000) 
10.7 11.4 10.8 12.1 13.0 8.8 8.4 9.8 10.2 13.9 12.3 
400,000+ kr. (£38,000+) 4.1 3.9 3.7 4.8 4.7 2.8 3.3 3.1 3.0 5.7 3.3 
OECD poverty            
OECD poverty, family income 8.1 7.0 6.4 7.7 5.5 6.8 7.3 7.3 6.3 8.5 4.3 
Socio-economic grouping            
Retired, age 18.2 18.6 19.1 19.7 20.3 19.9 18.3 16.8 19.8 17.2 22.6 
Retirement (pre-senior retirement) 3.0 3.3 3.5 3.6 3.2 4.0 4.4 3.2 3.5 2.2 4.7 
Early retirement, health 5.2 4.6 4.6 5.3 4.7 4.6 4.3 4.6 6.4 3.7 3.9 
Seekleave, other leave etc. 1.1 1.0 1.2 1.3 1.3 1.2 1.3 1.2 0.6 0.9 1.0 
Unemployed, social benefits 2.3 1.7 1.8 2.1 1.8 1.7 2.1 1.7 1.7 1.9 1.3 
Unemployed min. 6 months 1.3 1.2 1.5 1.5 1.7 1.5 1.8 1.1 1.1 1.2 1.2 
In training, education 6.3 7.1 7.8 6.5 9.0 7.3 7.8 7.8 7.0 6.9 6.4 
Employed 58.3 59.2 57.8 56.4 55.8 57.2 56.2 60.6 56.8 62.3 56.6 
Others not in workforce 4.2 3.3 2.7 3.6 2.2 2.6 3.8 3.0 3.2 3.8 2.3 
Family type            
Married couples 51.0 52.9 53.6 53.3 52.4 55.5 57.4 53.0 56.8 46.4 57.1 
Registered partners  0.2 0.2 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.3 0.1 
People living togehter 5.1 4.3 5.1 5.6 5.4 5.1 6.0 4.4 3.6 3.9 4.9 
Cohabiting couples 8.9 8.8 9.2 9.4 9.4 9.1 7.6 9.7 8.7 9.4 7.4 
Single (incl. non-resident children) 34.9 33.8 31.9 31.6 32.6 30.2 28.9 32.9 30.8 39.9 30.5 
Source: National Health Profiles 2010, 2013 and national population registers 2010/2013. Sample 
percentages are weighted, but not nationally standardized so as to enable regional comparisons. UK 
currency estimates are rounded and calculated based on DK/UK rates of 16-03-2016. 
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3.4. STATISTICAL ANALYSIS  
3.4.1. REGRESSION MODELLING – THE ALDVMM  
The problem with the EQ-5D arises from its highly skewed, non-normal 
distribution and its several gaps [50]. Of particular concern is the fact that the EQ-
5D generates 243 discrete values, and has varying and several numbers of classes 
and a high mass of 1 (ceiling effect), as seen in Figure 3-2. This creates a problem 
for the estimations of most regression models, as the majority will estimate values 
in the gap from 0.838 (DK) to 1, while others do not estimate negative values or 
even non-existing values above 1. Hence, the EQ-5D is defined as a limited 
dependent variable as it’s restricted and is not higher than 1 or lower than -0.624 
(DK). So far, no real agreement exists on which regression model is best suited for 
the EQ-5D [50]. Therefore, we tested and compared conventional regression mean 
models such as OLS and TOBIT with the ALDVMM in paper 2.  
 
 
 
 
 
 
 
 
 
 
Figure 3-2. Histogram of the EQ-5D, National Health Profiles 2010/2013. Source: 
adapted from Hvidberg et al. [50]. 
The ALDVMM is intended to handle the distribution(s) of the EQ-5D instrument; 
recent studies have found the ALDVMM superior to other regression models 
traditionally used [160–163].  
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The ALDVMM is founded on two innovations reflecting the key structures of the 
distinctive EQ-5D distribution [160]. The first innovation is managing the problems 
arising from a limited dependent variable such as the EQ-5D with a gap with no 
values from 0.838 to 1 based on the DK EQ-5D value set. This is done assuming yi 
is 1 when the latent variable y
*
i is greater than the last discrete value (0.838) before 
1 and equal to y
* 
– thereby forming a new distribution. The second innovation uses 
the first innovation, the adjusted, limited dependent variable distribution, within a 
mixture model, with c components. Therefore, the ALDVMM treats the EQ-5D like 
a flexible number of identified c components unique to each EQ-5D distribution 
that is used to form a new density. Thus, in contrast to the majority of other mean 
regression models, the ALDVMM is not linear between variables. Further details 
can be found in references [160, 163].  
Moreover, mixture models such as the ALDVMM are not as easy to use as other 
traditional regression models. One reason for this is the existence of numerous local 
maxima located in each c component that need to be identified for the likelihood 
function. It cannot be assumed that the reliable model has been found solely by 
running the ALDVMM program in STATA: “To identify the global maximizer, at 
the very least, it is important to try different sets of random starting values and to 
select the solution with the highest likelihood function” [163]. Therefore, it is 
essential to have hands on and manually start with a minor number of covariates as 
well as components when fitting mixture models, and then use each model as a 
stepping stone to generate models with more covariates and components. 
Consequently, the ALDVMM requires extensive effort, consideration and 
documentation. Details from regression modelling of the present study can be found 
in paper 2.  
3.4.2. WEIGHTING AND NON-RESPONSE  
The three samples had multidimensional weights computed by Statistics Denmark 
taking both sampling designs and non-response into account [164]. The weights 
were computed using GLM regression and auxiliary variables from national 
population registers. A unique personal identification key (CPR) of all invited 
persons was used to combine survey and register data [155]. However, because the 
two NDR samples resemble around two-thirds of the samples, but only one tenth of 
the country’s population, the two NDR samples were further standardized by 
national gender, age and educational levels [165]. This was done by combining the 
standardization with the existing multidimensional weights by Statistics Denmark.  
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Principle and the auxiliary variables used 
The basic principle in multidimensional weighting is to divide the population into a 
given number of separate tables which are all recreated in calculations. For 
example, gender and age are calculated in one table and geography is calculated 
separately in another table. This way you avoid having to include all variables in 
every stratum/table. Here, Statistics Denmark has chosen and done the 
computations based on the sample’s original stratification design (regions, 
municipalities etc.) and iterative tests of main effects and interactions with auxiliary 
variables in different tables and combinations for best model fit [164].  
The multidimensional weights were computed based on register information about 
sex, age, region, municipality of residence, income, highest completed educational 
level, ethnic background, marital status, occupational status, owner/tenant status, 
hospitalization in 2007 (yes/no), number of visits to the general practitioner in 2007 
and thus important scientist inquiry protection – for all individuals living in 
Denmark on 1st January 2010/2013 [155].  
But why choose exactly these variables? Accounting for all for non-response would 
require that we know the precise information on non-response for every variable in 
the survey. Since we do not have this as register information, we use auxiliary 
variables from registers that we know are well correlated with crucial survey 
variables and usually important.  
Choosing auxiliary variables and final model 
First the correlations between non-responders and as many register variables as 
possible are identified using logistic regression with response/non-response as 
dependent variable. Significant variables indicate explanatory power with non-
response, and non-significant ones are deselected.  
Secondly, four separate general linear regression models are run with the survey 
variables considered most important, as dependent variables (=responses, here 
“prolonged illness”, self-rated health, BMI and smoking) with all register variables 
as covariates. Here the best correlations once again are identified and used to help 
in choosing the best auxiliary variables.  
On the basis of an evaluation of all models, the final auxiliary variables for the 
weight computation are chosen iteratively, namely non-significant variables are 
rejected in securing best model fit; however, a sudden experience in modelling is 
required and used. The final models with main effects and interaction are shown in 
Table 3-5 for the two different weights provided:  
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Table 3-5. Weight 1: Non-response model used in regression, gi (individually) 
Sample Models used in weight estimation 
NIPH 
GP-visit*hospitalization*age*gender 
Socioeconomic status*familytype*income*region 
Ethnicity*home-owner*moved  
GP-visit, hospitalization, age, socioeconomic status, familytype, gender, 
income, ethnicity, region.  
NDR 
GP-visit* age*gender 
familytype*income 
GP-visit, hospitalization, socioeconomic status, familytype, income, 
ethnicity, municipalities.  
Gender* municipalities, age* municipalities 
Source: Adapted from Mejldahl [164], page 1.  
  
The fundamentals of the multidimensional weights  
The sample weights are computed using generalized regression estimator (GREG) 
as the multidimensional approach of choice, which underlined makes it possible to 
use many more different background variables in the estimation of the weight than 
a traditionally “after stratification9” approach [164]. First, the chosen auxiliary 
variables are used to estimate a chosen dependent variable, y, in a regression model, 
for example GLM:   
𝑦𝑘 =  𝛽1𝑥1𝑘 + 𝛽𝑗𝑥𝑗𝑘 + 𝑒𝑘 
The choice of y is actually not of importance for estimating the weight, but the x1-
xj’s are [166], though it is presumed – and tested – that y and x’s are well correlated 
[164]. Hence the generalized regression estimator (GREG) can be written as: 
?̂? = ∑
𝑁
𝑛
∗ 𝑔𝑖
𝑛
𝑖=1
∗ 𝑦𝑖  
                                                          
9 A traditional and simple “after stratification” approach is to calculate weights using typically gender, 
age (for example 5 age intervals) and geography (here 5 regions or 11 municipalities). For every one of 
the strata combinations (for example 2*5*5 = 50 strata) the design weight (N/n) is calculated (N = total 
population size in strata and n = sample responses in strata). The problems emerge when more variables 
are added, for example just five income intervals (2*5*5*5 = 250) add 5 times more cell combinations. 
This can make the estimation more unreliable due to the risk of cells with 0 observations and as a 
consequence quickly requiring larger samples [166]. Thus, there is a limitation to the number of 
explanatory variables that can in fact be included before the model gets unreliable [214]. Increasing the 
number of explanatory variables would in fact enrich the precision of the weights – so-called 
multidimensional estimation – reducing skewness in non-response as well as reducing random sample 
error, making it a worthy method to correspond to the increasing non-response [164, 166].  
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where 𝑦𝑖 is the i’th individual, (N/n) is the design weight that adjusts for the 
stratification, and (gi) is a regression estimate that adjusts for non-response. The 
main point and difference from traditional post-stratification weights is that the gi 
and the design weight are independent of each other, making it possible to include 
many more auxiliary variables in the estimation of the non-response.  
The design weight (N/n) depends only on population size (N) and the responders in 
the sample (n) and is usually used to compensate for disproportionate stratification 
– as here where subsampled by municipalities – or over/under-sampling of specific 
cases. Remember that the minimum requirements were 2000 individuals per 
municipality for each of the five regions regardless of the population size of the 
municipality and that most regions, including the NDR, have chosen to include 
more than 2000 individuals; in addition there are a different number of individuals 
included for most municipalities. As a consequence, the included individuals have 
asymptotic probability extractions in municipalities as well as regions. The design 
weight corrects this so that the sample is weighted to correctly represent the entire 
Danish population (NIPH sample) or region (NDR sample etc.). The weights total 
the number of responses in each sample. 
The other component (gi) of the weight adjusts for non-response using regression 
based on information from the chosen auxiliary variables (see Table 3-5).This 
correction is of course done to compensate for the fact that persons with certain 
characteristics are not as likely to respond to the surveys; in fact, the experience is 
that increasing the number of social factors in particular – rather than demographic 
factors – significantly impacts on the non-response correction [166].  
Table 3-5 shows the final model with the chosen (also social) auxiliary variables, 
interactions and main effects for the gi. Notice that geography in terms of regions 
and municipalities is included, adjusting correctly in different subsamples and 
geographic areas. The gi’s purpose is to reduce uncertainty (standard errors) as well 
as eventual skewness (bias) due to non-responses. Following that, the weight for the 
i’th individual can be written as:  
 𝑣𝑖 =  
𝑁
𝑛
∗ 𝑔𝑖 
The weights total the sample size. For further details and reading see [164, 166, 
167]. 
3.4.3. MISSING DATA  
Missing values have the potential to undermine the outcomes of research and 
recommendations in, for example, clinical studies or health economic evaluation. 
This is a common and unavoidable problem that is often ignored or overlooked in 
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the medical literature and health economic evaluation, although flexible methods 
exist to deal with problems caused by missing data [50, 168, 169].  
In this PhD’s paper 2, missing values were imputed using auxiliary data from 
national registers and surveys. This was done for education, partnership, children 
and income. As the used register variable of education had missing values, the 
education survey variable was used to impute the missing values. For partnership 
and children, the survey variables were preferred, and the register variables were 
used to impute missing values. The advantages are that these imputed values are 
truly based on true known data about the respondent, not a regression estimated 
probability as in a multiple imputation (MI) approach. The results are seen in Table 
3-6 and further programming details can be found in the supplementary material of 
paper 3.  
Table 3-6. Missing values of the EQ-5D and the covariates of the three combined 
samples of paper 3  
Source: adapted partly from Hvidberg et al. [50]. Data source: National Health Profiles 2010, 2013. 
n=56,988. 
 
 
Missings in samples 
before imputation 
Missings in samples 
after imputation 
 n Per cent  n Per cent 
EQ-5D utility score  1,372 2.4  1,372 2.4 
- EQ-5D: Mobility 659 1.2  659 1.2 
- EQ-5D: Self-care 723 1.3  723 1.3 
- EQ-5D: Usual activities 772 1.3  772 1.3 
- EQ-5D: Pain/discomfort 798 1.4  798 1.4 
- EQ-5D: Anxiety/depression 884 1.5  884 1.5 
Gender 0 0  0 0 
Age at 1st January 2010 or 2013 0 0  0 0 
Ethnicity  0 0  0 0 
Partnership in 2010 or 2013 846 1.5  0 0.0 
Children living at home at age 15 or below in 2010 or 2013 2,654 4.7  698 1.2 
Education on October 2010 or October 2013 1,233 2.2  297 0.5 
Family income in the last of calendar year 2009 or 2012 1 0.0  0 0.0 
All 199 conditions in 2010 or 2013 0 0.0  0 0.0 
Sample variable 0 0.0  0 0.0 
Total missing accumulated – regression models 1–3 paper 3 4,913 8.6  2,263 4.0 
Social networks – loneliness 992 1.7  992 1.7 
Cohen’s Perceived Stress Scale 2,794      4.9  2,794      4.9 
BMI 1,956 3.4  1,956 3.4 
Smoking 1,171 2.1  1,171 2.1 
Alcohol intake 4,860 8.5  4,860 8.5 
Exercise 1,608 2.8  1,608 2.8 
Fruit intake 1,497 2.6  1,497 2.6 
Total missing accumulated - regression model 4 paper 3 13,120 23,0  12,943 22.7 
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As the chronic conditions and other variables were based on registers, we had no 
missing values within these variables. The disadvantage of our approach, however, 
is that we cannot impute values of EQ-5D and other survey variables as no auxiliary 
register variables exist. The gold standard would be to apply MI chained equations 
[168] – besides the imputation based on the auxiliary information. Nevertheless, 
due to the fairly low number of missings in the EQ-5D score and as the ALDVMM 
function did not support MI, we exchanged the advantages of MI of the remaining 
survey variables for the advantages of model estimation precision using the 
ALDVMM. All missing values of the independent survey variables were included 
with a separate dummy. Consequently, all study estimates in paper 3 had 2.4 per 
cent missing values due to the missing values of the dependent variable EQ-5D, and 
linear estimates of stress and BMI could not be calculated due to the inclusion of 
the dummy variables.  
Testing and exploration of the missingness function of the EQ-5D was done by 
logistic regression. This could not rule out a possible missing at random (MAR) 
pattern [50]. Combined with the relatively high number (22.7 per cent) of 
accumulated missing values from health risk factors, stress and loneliness, and the 
lack of a possibility of linear estimates of BMI and stress within current model, it is 
recommended that future studies incorporate MI and chained equations along with 
the ALDVMM. Notably, a full imputation model was applied in paper 4 using OLS 
regression. 
Therefore, a chained MI model was actually created, although it could not be 
applied using the ALDVMM. For future use, we briefly describe the model in 
accordance with recommendations in the following [168, 169]:  
An MI chained equation model for future use  
To avoid analytic bias, (almost) all applied variables from the main analysis were 
included in the chained MI model. However, to make the MAR assumption most 
plausible, further possible variables related to missingness were incorporated [168, 
169], based on the initial descriptive missingness analyses. This included the five 
EQ-5D domains separately (ordinal), variability of samples (nominal), gender, age 
(in interaction with gender and age splined to account for non-linear correlations), 
ethnicity (nominal), education (ordinal), children below 15 years of age living at 
home (or not), in a relationship or not, family equalized income (continuously), 
often lonely or not, socio-economic status (five categories, nominal), Cohen’s 
Perceived Stress Scale (10 dimensions, ordinal), BMI (continuous), smoking daily, 
binge drinking (five categories, ordinal), exercise as recommended or not, fruit 
intake as recommended or not, self-reported health (five dimensions, ordinal), long-
standing illness or not, and finally, 18 self-reported dichotomous conditions from 
the original survey. A trade-off was applied between the number of included 
variables and having a functioning MI model [168], which is why the 215 chronic 
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conditions were not included. Instead, the 18 broadly defined self-reported 
conditions comprising many of the same register-based conditions were included to 
ensure some estimation based on chronic conditions in the model. 
The MI was computed with 20 imputations, each of which had 20 iterations. 
RSEED was set to 1978. All imputation was done with the survey weights 
incorporated [170, 171]. The EQ-5D score from the five imputed domains was 
finally obtained using the MI PASSIVE function. There were no reported problems 
of perfect prediction or non-convergence. 
Since there were different missing values for different samples, the three samples 
were added in the Stata “by” option to impute the samples separately and correct for 
different missingsness. Thus, the samples were treated as recommended for 
different “treatment arms” [168]. 
For sensitivity analysis and validation, the observed and imputed values for the 
chosen variables/conditions as well as the overall mean should be compared. 
Furthermore, a complete case model (CCA), a crude imputation model and an 
extreme case model (with different extremes such as 0.25, 0.5, 0.75 and 1 of the 
EQ-5D imputed for all missing values) could also be compared to the final 
imputation model.  
3.4.4. WEIGHTING AND IMPUTATION – THE DIFFERENCES IN 
OVERVIEW  
Figure 3-3 shows the entire sample, non-responders, responders and the relationship 
between weighting and imputation. Weighting and imputation are separate but 
complementary methods.  
 
  
54 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-3. Non-responders, responders, weighting and imputation. 
 
3.4.5. DATA MANAGEMENT AND DATA ANALYSIS  
Primary data management 
All primary data management of survey and register variables, including 
programming of the defined chronic conditions, was done in SAS 9.4 by the author. 
Different MACRO programming was done to make smother and smaller programs, 
but even so the total programming comprises more than 200 pages.  
  
Non-responders:  
(39.8%) 
 
Register auxiliary 
covariates for non-
responders: 
- Gender  
- Age 
- Education 
- Income 
- Residents 
- Hospitalization  
- GP visit  
- Ethnicity 
- Municipalities 
- Moved 
- Socio-economic 
status 
- Family type 
 
 
Missing 
values: 
 
responders 
with at least 1 
missing value  
(total 22.7% of 
cases of the 
60.2% of 
responders) 
Individual weights created for 
every respondent based on 
known information from non-
responder covariates from 
registers.  
Responders: 
 (60.2%) 
Survey covariates  
for responders:    
- EQ-5d    
- Gender and age 
- Education 
- Smoking   
- BMI    
- Alhohol    
- Diet  
- Stress   
- Loneliness  
- Etc.     
 
 
Weighting 
Imputa
tion 
Missing values 
are estimated for 
all cases using 
regression and 
known covariates 
from survey  
 
– and 
“added”/imputed 
to the sample 
again. 
MI  
imputation: 
Imputation using auxiliary 
variables from either 
register or sample.  
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Data analysis  
Population-based frequencies of the conditions were outputted from SAS using the 
TABULATE function, and prevalences were calculated in Microsoft Excel 2010 – 
and likewise for the survey non-response estimates.  
All other data analysis, including mean estimation, regression modelling and 
imputation, was mainly done in Stata 14 using the svy, svy set, means, sum, 
logistic, regress, regress, TOBIT, aldvmm, predict, margins and estimates functions. 
See papers for more details regarding each paper.   
All data analysis and data management were done on Statistics Denmark remote 
research servers.  
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CHAPTER 4. RESULTS AND 
SUMMARIES OF PAPERS  
4.1. OBJECTIVE 1: TO ESTABLISH REGISTER-BASED 
DEFINITIONS OF CHRONIC CONDITIONS  
4.1.1. BACKGROUND AND PURPOSE 
No single framework or definitions exist for identifying all ICD-10-based chronic 
conditions with the use of big data in respect of public national health-care registers 
and ICD-10 codes. Thus, the potentials uncovering the different burdens of most 
possible chronic conditions are not yet unleashed.  
In short, the purpose of this study was to medically review, identify and discuss a 
comprehensive range of register-based definitions of chronic conditions and the 
challenges and pitfalls while defining chronic conditions with the use of several 
registers in combination. The aim was to include all ICD-10-based chronic 
conditions based on the definition and by evaluation and opinion of the involved 
medical experts. However, as this includes expert opinions, the included conditions 
are not absolute, but open for discussion. In essence, this study aims to create a 
methodological framework of definitions for future use with different outcomes of 
interest when exploring chronic conditions. As such, this study is a thesis 
contribution to one solution for “making sense” of the big health-care data in regard 
to chronic disease.  
Purpose in summary:  
 to medically review, identify and discuss a comprehensive range of 
register-based definitions of chronic conditions and the challenges and 
pitfalls when defining chronic conditions with the use of registers  
 to create a methodological framework of definitions for future use by 
others with different outcomes of interest when exploring chronic 
conditions 
4.1.2. SUMMARY AND RESULTS OF PAPER 1: THE REGISTER-BASED 
DEFINITIONS 
The register-based definitions were defined based on data from nationwide Danish 
public health-care registers, and internationally recognized classification systems 
such as the ICD-10 and ATC.  
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A medical review of the chronic conditions was carried out as described in the 
previous methods section and in the paper. One hundred and ninety-nine chronic 
conditions and subgroups were identified and defined. One of the innovations is the 
four clinical and differentiated inclusion time categories into which all of the 
medically identified chronic conditions were divided. The results can be seen in 
paper 1. The definitions were defined based on ICD-10 and ATC codes, but also GP 
services and others from several registers.  
One of the important challenges was how to identify conditions where no ICD-10 
codes exist as some conditions were treated outside hospitals where no diagnosis 
codes were reported. This was partly solved by including multiple registers such as 
prescribed medications and using general practitioners’ services and others used for 
treating chronic conditions. This was done for 35 conditions based on a medical 
assessment. Table 4-1 shows selected differences between solely using ICD-10 
codes and the importance of using multiple registers to ensure the validity of the 
definitions; for example, the prevalences range from approximately 3 to 23 times 
difference, underlining the importance of using multiple registers for some 
conditions. Future studies should further validate the definitions based on, for 
example, comparison with medical records.  
The study provides a medically reviewed catalogue of register-based definitions of 
199 chronic conditions for use in research and health-care planning within different 
areas of interest. The paper includes a thorough discussion of strengths, challenges 
and pitfalls, and is, to the best of the author’s knowledge, the largest collection of 
definitions currently compiled in a single study based on a uniform methodology.  
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Table 4-1. Examples of impact using complex algorithms  
* Not complex defined condition. c Complex defined condition. Full Denmark population estimates 
based on a sample of N = 4,555,439 citizens aged 16 or more on 1st January 2013.  
Source: adapted from Hvidberg et al., supplementary material [140], see  
http://sjp.sagepub.com/content/44/5/462  
 
4.2. OBJECTIVE 2: TO ESTIMATE THE POPULATION-BASED 
PREVALENCE RATES OF THE 199 CHRONIC CONDITIONS   
4.2.1. BACKGROUND AND PURPOSE 
So far no studies have provided prevalence estimates comprising most possible 
chronic conditions within a single study based on an entire country’s population. 
Yet, in Denmark, the prevalence of a few conditions ranging from approximately 4 
to 18 are continuously monitored by the government and the NIPH and others – but 
using different methods and thus yielding different results [57, 58, 60, 64, 95, 96, 
155–157]. Moreover, existing studies show that up to 40–50 per cent of the 
population have one or more chronic conditions or long-standing illness [60, 156], 
but studies show varying prevalence and do not include all chronic conditions. 
Thus, there is a need for reliable estimates based on uniform methods showing the 
basic epidemiology of chronic disease.  
In this section, we provide population estimates of the basic epidemiology: the 
prevalence of selected estimates of the 20 most prevalent of the 199 chronic 
conditions. The full prevalence catalogue of all 199 conditions can be found in 
Cond. 
no. 
Condition ICD-10 code/definition Category Full population estimates 
for Denmark 
     N Per cent 
- Hypertensive diseases* I10–I15 Cat. III 316,037 6.9 
21 Hypertensive diseases c I10–I15 and/or prescribed medicine Cat. III 1,060,043 23.3 
- Ulcers* K25–K27 Cat. IV 6,702 0.1 
28 Ulcers c K25–K27 and/or prescribed medicine Cat. IV 157,379 3.5 
- Psoriasis* L40 Cat. I 15,232 0.3 
29 Psoriasis c L40 and/or prescribed medicine Cat. I 65,469 1.4 
- Depression* F32, F33, F34.1, F06.32  Cat. III 91,534 2.0 
12 Depression c 
F32, F33, F34.1, F06.32 and/or 
prescribed medicine 
Cat. III 454,933 10.0 
- Bipolar affective disorder* F30–F31 Cat. II 6,427 0.1 
11 Bipolar affective disorder c F30–F31 and/or prescribed medicine Cat. II 22,669 0.5 
- ADHD*  F90 Cat. I 15,453 0.3 
14 ADHD c F90 and/or prescribed medicine Cat. I 42,908 0.9 
60 
paper 2 in the appendix. Furthermore, the population estimates are compared to the 
samples in paper 3 for the 20 most prevalent conditions. 
There are two main purposes. First, the full population-based prevalence estimates 
are crucial, as described earlier, as an epidemiological measure of disease burden, 
as well as being useable for COI, and a source of new basic knowledge in general. 
Secondly, the comparison of the population estimates to the samples in paper 3 
(indirectly) gives insights into the representativeness of the samples in paper 3 
(unique survey sample response rates for all 199 conditions are also provided in 
appendix A for the interested reader). This enables the reader to identify 
problematical conditions and qualify discussion on the reliability of the 
conditions/results of objective 3.  
Purpose in summary:  
 to create estimates of basic epidemiological disease burden: estimate full 
population prevalence of the 199 chronic conditions (paper 2) 
 to compare population prevalence to the survey sample/survey response 
used for EQ-5D preference scores in order to give insights into the 
representativeness and sample bias of the survey sample in paper 3 
 
4.2.2. SUMMARY AND RESULTS OF PAPER 2: NATIONAL 
PREVALENCE RATES – AND COMPARISONS TO SAMPLES IN 
PAPER 3 
Besides estimating the prevalences of the 199 chronic conditions, the aim of paper 2 
was to summarize characteristics in regard to gender and age, and regional 
differences among the 199 chronic conditions. The comparison to the sample in 
paper 3 is not a part of paper 2 and is solely done in the thesis.  
The study population in paper 2 was set to all 4,555,439 Danish resident citizens 
aged 16 or more on 1st January 2013. We used several different national registers 
from 1994 to 2012, including the NPR, using the ICD-10 diagnosis codes of all 
private and public hospitals’ in- and outpatients as well as prescription medicine, 
GP services and others as described earlier.  
A total of 65.6 per cent of the nationwide population aged 16+ had one or more 
chronic condition. The most prevalent diseases are found among diseases of the 
circulatory system, diseases of the respiratory system, diseases of the 
musculoskeletal system and connective tissue and endocrine, nutritional and 
metabolic diseases, while cancers, for example, only account for a small fraction 
compared to each of the latter mentioned disease groups. The sample prevalence 
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estimates are in general fairly close to the national population prevalences, although 
there are small variations for some conditions and disease groups.  
To the best of the author’s knowledge, paper 2 provides the most wide-ranging 
catalogue of prevalence rates and characteristics established on a national 
population yet made. The prevalence rates and characteristics of the 199 chronic 
conditions provide fundamental information for future estimates of the basic 
epidemiological burden of disease for use in economic, aetiological and other 
research, and in health-care planning in general.  
The sample estimates are included in order to discuss these briefly later. 
 
Table 4-2. The 20 conditions with the highest population-based prevalence 
Cond. Conditions ICD-10 Population Survey samples 
no.   N Per cent n Per cent 
79 Hypertensive diseases c I10–I15 1,060,046 23.3 23,826 25.2 
105 Respiratory allergy c J30, except J30.0 841,685 15.4 15,689 16.6 
33 Disturbances in lipoprotein circulation and other lipids c E78 652,242 14.3 15,083 15.9 
183 Depression c 
F32, F33, F34.1, 
F06.32 
454,933 10.0 9,096 9.6 
105A Chronic lower respiratory diseases c J40–J43, J47 418,120 9.2 8,402 8.9 
109 Asthma, status asthmaticus c J45–J46 361,129 7.9 7,134 7.5 
29 Diabetes type 2 c E11 242,177 5.3 5,641 6.0 
108 Chronic obstructive lung disease (COPD) c J44, J96, J13–J18 216,184 4.7 4,303 4.5 
127 Gonarthrosis [arthrosis of the knee] M17 178,811 3.9 4,021 4.3 
122A 
Inflammatory polyarthropathies and ankylosing 
spondylitis c 
M05–M14, M45 165,944 3.6 3,265 3.5 
165 Osteoporosis c M80–M81 158,813 3.5 3,060 3.2 
112 Ulcers c K25–K27 157,379 3.5 4,113 4.3 
42 Migraine c G43 149,866 3.3 3,007 3.2 
80A Ischaemic heart diseases I20–I25 139,173 3.1 3,286 3.5 
26 Diseases of the thyroid c E00–E04, E06, E07 131,908 2.9 2,422 2.6 
48 Mononeuropathies of upper limbs  G56 122,395 2.7 2,270 2.4 
124 
Inflammatory polyarthropathies – except rheumatoid 
arthritis c 
M074–M079, 
M10–M14, M45 
115,945 2.5 2,402 2.5 
91 Atrial fibrillation and flutter I48 112,342 2.5 2,582 2.7 
126 Coxarthrosis [arthrosis of the hip] M16 104,115 2.3 2,316 2.4 
128 
Arthrosis of first carpometacarpal joint and other 
arthrosis 
M18–M19 91,101 2.0 1,616 1.7 
- Having at least one chronic condition n/a 2,989,441 65.6 38,590 67.7 
Source: partly adapted from paper 2. c Complex defined condition. All estimates are non-weighted.  
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Table 4-3. The 20 conditions with the lowest population-based prevalence 
Cond. 
no. 
Conditions ICD-10 Population Survey samples 
  N Per cent n Per cent 
34 Cystic fibrosis c E84 947 0.02 8 0.01 
166 Osteoporosis in diseases classified elsewhere  M82  1,007 0.02 30 0.03 
30 Diabetes, others c E12–E14 1,117 0.02 27 0.03 
139 Dermatopolymyositis M33 1,137 0.02 25 0.03 
140 Systemic sclerosis M34 1,675 0.04 20 0.02 
168 Disorders of continuity of bone M84 1,865 0.04 53 0.06 
58 Disorders of the choroid and retina H31–H32  1,900 0.04 60 0.06 
55 Corneal scars and opacities H17 2,173 0.05 68 0.07 
83 AMI complex/other  I23–I24  2,969 0.07 45 0.05 
20 Haemolytic anaemias  D55–D59  3,055 0.07 38 0.04 
138 Systemic lupus erythematosus M32 3,376 0.07 57 0.06 
164 Fibromyalgia M797 3,399 0.07 45 0.05 
141 Kyphosis, lordosis  M40  4,160 0.09 86 0.09 
2 Human immunodeficiency virus [HIV] disease B20–24 4,229 0.09 39 0.04 
110 Bronchiectasis J47  4,362 0.10 78 0.08 
40 Demyelinating diseases of the central nervous system  G36–G37    4,571 0.10 91 0.10 
1 Chronic viral hepatitis B18 4,584 0.10 49 0.05 
4 Malignant neoplasms of digestive organs 
C15–C17; C22–
C26 
4,839 0.11 111 0.12 
13 Malignant tumour of the male genitalia C60, C62–C63  5,194 0.11 88 0.09 
107 Emphysema J43 5,557 0.12 143 0.15 
- Having at least one chronic condition n/a 2,989,441 65.62 38,590 67.7 
Source: partly adapted from paper 2. c Complex defined condition. All estimates are non-weighted. 
 
  
63 
Table 4-4. Prevalence of the overall disease groups  
Conditions ICD-10 Population Survey samples 
  N Per cent n Per cent 
B – Viral hepatitis and human 
immunodeficiency virus [HIV] disease 
B18, B20–B24 8,813 0.2 31 0.1 
C – Malignant neoplasms 
C00–C99; D32–D33; D35.2–
D35.4; D42–D44  
229,331 5.0 3,072 5.4 
D – In situ, benign and neoplasms of 
uncertain or unknown behaviour and 
diseases of the blood and blood-forming 
organs and certain disorders involving the 
immune mechanism 
D00–D09; D55–D59; D60–D67; 
D80–D89 
116,560 2.6 1,314 2.3 
E – Endocrine, nutritional and metabolic 
diseases  
E00–E14; E20–E29; E31–35; 
E70–E78; E84–E85; E88–E89 
877,433 19.3 12,888 22.6 
G – Diseases of the nervous system 
G00–G14; G20–G32; G35–G37; 
G40–47; G50–64; G70–73; G80–
G83; G90–G99 
561,054 12.3 6,698 11.8 
H – Diseases of the eye and adnexa and 
diseases of the ear and mastoid process 
H02–H06; H17–H18; H25–H28; 
H31–H32; H34–H36; H40–55; 
H57; H80,H810; H93, H90–H93 
448,176 9.8 6,578 11.5 
J – Diseases of the respiratory system 
J30.1; J40–J47; J60–J84; J95, 
J97–J99 
1,210,598 26.6 17,647 31.0 
I – Diseases of the circulatory system 
I05–I06; I10–28; I30–33;I36–
141; I44–I52; I60–I88; I90–I94; 
I96–I99 
1,254,427 27.5 14,516 25.5 
K – Diseases of the digestive system 
K25–K27; K40, K43, K50–52; 
K58–K59; K71–K77; K86–K87  
329,337 7.2 4,617 8.1 
L – Diseases of the skin and subcutaneous 
tissue 
L40 65,469 1.4 747 1.3 
M – Diseases of the musculoskeletal 
system and connective tissue 
M01–M25: M30–M36; M40–
M54; M60.1–M99 
1,032,808 22.7 13,588 23.8 
N – Diseases of the genitourinary system N18 20,162 0.4 238 0.4 
Q – Congenital malformations, 
deformations and chromosomal 
abnormalities 
Q00–Q56; Q60–Q99 124,898 2.7 1,351 2.4 
F – Mental and behavioural disorders F00–99 683,194 15.0 6,353 11.1 
 
Having at least one chronic condition 
n/a 2,989,441 65.6 38,590 67.7 
Source: partly adapted from paper 2. All estimates are non-weighted. 
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4.3. OBJECTIVE 3: TO ESTABLISH EQ-5D-3L PREFERENCE 
SCORES FOR 199 CHRONIC CONDITIONS  
4.3.1. BACKGROUND AND PURPOSE 
As the costs and individual burdens of chronic conditions are increasing, the 
development of tools and reliable estimates for prioritization is essential to 
maximize the utility of societal resources. Furthermore, there is a need for 
standardized disease burden measures identifying the conditions with the greatest 
need and potential for improving HRQoL. For this, the use of the EQ-5D is desired 
as the EQ-5D and the QALY are the preferred disease of burden measures within 
health economic evaluation and are recommended by American and British 
authorities [24, 27, 42, 85]. However, existing estimates are often measured 
partially, and results thus vary across studies within the same condition. Therefore, 
there is a need for further standardization of estimates in order to decrease the 
variability of estimates and provide researchers with a uniform, reliable tool.  
Although older, standardized preference catalogues of multiple conditions exist, 
and the current research aims to improve existing research by using doctor-reported 
ICD-10 conditions, for more conditions, with new more precise regression methods 
that are mean based, as preferred within health economic evaluation [25] in contrast 
to existing catalogues, and by adding new variables such as stress, social network, 
BMI and behavioural risk factors of importance in health economic evaluation.  
The main purpose of paper 3 was to create a catalogue of EQ-5D 3L preference 
scores for 199 nationwide representative chronic conditions for use within future 
health economic evaluation.  
However, a crucial part of the methodological debate from the literature including 
paper 1 has been differences in results between self-reported and register-based 
conditions. The current data provide a unique opportunity to qualify this debate 
further by comparing HRQoL between self-reported and register-based conditions 
from exactly the same sample. Therefore, we also provide new estimates thereof not 
presented in the papers for discussion.  
Moreover, an important underlining issue is the reliability and representativeness of 
the samples, as this naturally impacts on the reliability of the estimates, since the 
study is based on three asymmetric samples: one for the whole of Denmark and two 
for the North Denmark Region. Thus, a short summary of prevalence and survey-
response differences is presented in the following.  
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Main purpose in regards to thesis: 
 to create an improved catalogue of EQ-5D preference scores for 199 
Danish nationally representative chronic conditions for use in future health 
economic evaluation 
Subpurposes within the thesis: 
 to present and compare HRQoL (and prevalence) across self-reported and 
register-based conditions for discussion 
 to briefly summarize the main results of prevalence rates and survey 
response rates across conditions for discussion  
 
4.3.2. SUMMARY AND RESULTS OF PAPER 3: EQ-5D PREFERENCE-
BASED SCORES  
The 199 defined and identified register-based chronic conditions were combined 
with the Danish National Health Profile Surveys including the EQ-5D. Three 
survey samples from 2010 and 2013 with a total of 56,988 respondents were 
included and combined with registers comprising their chronic conditions using a 
unique personal identification number (CPR). A total of seven registers were 
included comprising the conditions with the use of ICD-10 diagnosis codes, 
medications, GP services and others within the period 1994–2013.  
The EQ-5D index scores for all conditions were obtained by incorporating DK 
national tariffs (UK and US tariffs are planned for later). In contrast to existing 
research, the current catalogue uses mean scores and is based on the ALDVMM.  
The unadjusted EQ-5D preference scores and adjusted ALDVMM regression 
estimates of 199 conditions were calculated and presented in Table 4-6 shows the 
20 conditions with the worst HRQol. Four regression models, all with the EQ-5D as 
the dependent variable, were introduced to accommodate different health evaluation 
requirements: model 1 adjusted for all conditions; model 2: adjusted for the 
conditions gender and age and the accumulated number of co-morbidities; model 3: 
model 2 + education, partnership, children, income and ethnicity; and finally model 
4: model 3 + behavioural risk factors, BMI, stress and social networks (see paper 3 
for all unadjusted and full regression estimates of all 199 conditions).  
Overall, conditions within mental and behavioural disorders, diseases of the 
nervous system, diseases of the musculoskeletal system and connective tissue, and 
endocrine, nutritional and metabolic diseases showed some of the lowest HRQoL 
(see Table 4-7) This also applies for the adjusted regression estimates in paper 3.  
66 
Paper 3 is, to the best of the author’s knowledge, the largest study in terms of the 
wide-ranging number of chronic conditions, the sample size and the uniform 
methodology. The study is the first of its kind to use doctor-reported ICD-10 
chronic conditions, new regression methods designed to handle the EQ-5D and 
nationally representative adjusted mean-based EQ-5D preference scores of the 199 
chronic conditions. The catalogue of preference scores will assist and be useful to 
international researchers and health-care analysts, without the costs and burden of 
primary data collection. In contrast to existing studies, the estimates can also – to 
some extent – model different severities of conditions and thus different levels of 
potential health gains. The study provides new insights into potential health gains 
and differences in HRQoL within an unprecedented number of conditions as well as 
health risks. 
Table 4-5. Frequency and percentages of the five dimensions of the EQ-5D based 
on the three samples. Weighted and complete cases 
Source: adapted from paper 3, supplementary material. Source: National Health Profiles 2010, 2013. All 
estimates are non-weighted. 
  
 Mobility Self-Care Usual Activities Pain/Discomfort Anxiety/Depression 
 
n (%) n (%) n (%) n (%) n (%) 
No NIPH 2010 12,694 (84.8% ) 14,315 (95.6% ) 11,396 (76.2% ) 8,307 (55.5% ) 11,737 (79.0% ) 
problems NDR 2010 19,303 (83.4% ) 21,963 (94.9% ) 17,411 (75.3% ) 12,546 (54.3% ) 18,225 (78.9% ) 
 NDR 2013 15,501 (83.3% ) 17,579 (94.9% ) 13,777 (74.3% ) 9,821 (53.0% ) 14,524 (78.3% ) 
 Combined 47,499 (83.8% ) 53,858 (95.0% ) 42,585 (75.2% ) 30,675 (54.2% ) 44,486 (78.7% ) 
Some NIPH 2010 2,239 (15.0% ) 579 (3.9% ) 3,130 (20.9% ) 6,178 (41.3% ) 2,892 (19.5% ) 
problems NDR 2010 3,764 (16.3% ) 1,051 (4.5% ) 4,849 (21.0% ) 9,714 (42.0% ) 4,522 (19.6% ) 
 NDR 2013 3,034 (16.3% ) 852 (4.6% ) 4,158 (22.4% ) 7,999 (43.2% ) 3724 (20.0% ) 
 Combined 9,038 (15.9% ) 2,484 (4.4% ) 12,139 (21.4% ) 23,893 (42.2% ) 11,140 (19.7% ) 
Extreme NIPH 2010 40 (0.3% ) 77 (0.5% ) 427 (2.9% ) 474 (3.2% ) 236 (1.6% ) 
problems NDR 2010 74 (0.3% ) 131 (0.6% ) 861 (3.7% ) 867 (3.7% ) 342 (1.5% ) 
 NDR 2013 66 (0.4% ) 112 (0.6% ) 611 (3.3% ) 711 (3.8% ) 305 (1.6% ) 
 Combined 180 (0.3% ) 321 (0.6% ) 1,899 (3.4% ) 2,052 (3.6% ) 882 (1.6% ) 
 
Total 
combined 
56,717 (100% ) 56,663 (100% ) 56,622 (100% ) 56,620 (100% ) 56,508 (100% ) 
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Table 4-6. The 20 conditions with the lowest EQ-5D-based HRQoL, unadjusted  
Cond. 
no. 
Condition ICD-10 code n 
Unadjusted 
EQ-5D 
34 Cystic fibrosis 
c E84 4 0.303 
140 Systemic sclerosis M34 13 0.432 
164 Fibromyalgia M797 36 0.49 
160 Rheumatism, unspecified M790 113 0.515 
176 Dementia c 
F00, G30, F01, F02.0, F03.9, G31.8B, 
G31.8E, G31.9, G31.0B 
179 0.546 
188 Post-traumatic stress disorder F431 73 0.557 
36 
Systemic atrophies primarily affecting the central nervous 
system and other degenerative diseases  
G10–G14, G30–G32 70 0.583 
52 Cerebral palsy and other paralytic syndromes G80–G83  113 0.60 
185 Phobic anxiety disorders F40 78 0.611 
145 Other inflammatory spondylopathies M46 62 0.618 
151 Dorsalgia M54 621 0.619 
125 Polyarthrosis [Arthrosis] M15 169 0.629 
146 Spondylosis M47  924 0.629 
186 Other anxiety disorders F41 226 0.631 
147 
Other spondylopathies and spondylopathies in diseases 
classified elsewhere 
M48, M49  483 0.633 
166 Osteoporosis in diseases classified elsewhere  M82  16 0.636 
106 
Bronchitis, not specified as acute or chronic, simple and 
mucopurulent chronic bronchitis and unspecified chronic 
bronchitis 
J40–J42 182 0.641 
190 
Dissociative (conversion) disorders, somatoform disorders 
and other neurotic disorders 
F44, F45, F48 170 0.644 
96 Sequelae of cerebrovascular disease I69 513 0.645 
97 Atherosclerosis  I70 397 0.645 
194 Specific personality disorders F602, F604–F609 363 0.645 
149 Other intervertebral disc disorders  M51  501 0.646 
Source: adapted from paper 3. c = complex defined conditions. All estimates are weighted.  
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Table 4-7. The EQ-5D-based HRQoL based on disease groups 
Condition ICD-10 code n 
Unadjusted 
EQ-5D 
B – Viral hepatitis and human immunodeficiency virus [HIV] 
disease  
B18, B20–B24 31 0.760 
C – Malignant neoplasms 
C00–C99; D32–D33; D35.2–D35.4; D42–
D44  
2,947 0.78 
D – In situ, benign and neoplasms of uncertain or unknown 
behaviour and diseases of the blood and blood-forming organs 
and certain disorders involving the immune mechanism 
D00–D09; D55–D59; D60–D67; D80–D89 1,254 0.744 
E – Endocrine, nutritional and metabolic diseases  
E00–E14; E20–E29; E31–35; E70–E78; 
E84–E85; E88–E89 
12,412 0.783 
F – Mental and behavioural disorders F00–99 6,106 0.703 
G – Diseases of the nervous system 
G00–G14; G20–G32; G35–G37; G40–47; 
G50–64; G70–73; G80–G83; G90–G99 
6,698 0.747 
H – Diseases of the eye and adnexa and diseases of the ear and 
mastoid process 
H02–H06; H17–H18; H25–H28; H31–H32; 
H34–H36; H40–55; H57; H80,H810; H93, 
H90–H93 
6,309 0.779 
I – Diseases of the circulatory system 
I05–I06; I10–28; I30–33;I36–141; I44–I52; 
I60–I88; I90–I94; I96–I99 
16,990 0.783 
J – Diseases of the respiratory system J30.1; J40–J47; J60–J84; J95, J97–J99 14,087 0.81 
K – Diseases of the digestive system 
K25–K27; K40, K43, K50–52; K58–K59; 
K71–K77; K86–K87  
4,462 0.744 
L – Diseases of the skin and subcutaneous tissue L40 722 0.789 
M – Diseases of the musculoskeletal system and connective 
tissue 
M01–M25: M30–M36; M40–M54; M60.1–
M99 
13,163 0.755 
N – Diseases of the genitourinary system N18 224 0.698 
Q – Congenital malformations, deformations and chromosomal 
abnormalities 
Q00–Q56; Q60–Q99 1,323 0.814 
All  - 55,616 0.852  
Source: adapted from paper 3. All estimates are weighted. 
 
4.3.3. DIFFERENCES IN HRQOL (AND PREVALENCE) OF SELF-
REPORTED AND REGISTER-BASED CONDITIONS – AND INDIRECT 
SAMPLE MEASURES OF REPRESENTATIVENESS  
For later methodological discussion, additional results are presented in regard to 
differences in HRQoL and prevalence rates between self-reported and register-
based conditions based on the EQ-5D. The estimates are all based on exactly the 
same samples giving a unique opportunity for comparisons, but only for 18 self-
reported conditions; also, some limitations exist due to a lack of diagnostic 
precision with the self-reported conditions due to broadly defined disease 
categories, which is why the register-reported conditions in some cases have more 
diagnoses reported.  
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For most conditions, the mean age of the self-reported (SR) conditions is lower than 
that of the register-reported conditions (RR), except for some chronic lower 
respiratory diseases, and to some extent cancers and diabetes.  
However, the age differences are not necessarily reflected in differences in the 
HRQoL. For example, asthma and allergies have a similar HRQoL, which is barely 
significantly different even though sample size are rather high. The same applies for 
diabetes, high blood pressure, heart attack and stroke. Moreover, the HRQoL is 
barely significantly different for arthrosis, migraine or common headaches – even 
though n and age are different between SR and RR.  
Relatively large, mostly significant differences in HRQoL, and partly for age and n, 
exist for most heart conditions (except heart attack and high blood pressure), lung 
diseases, rheumatoid arthritis, cancers, herniated or other back conditions, mental 
illness, cataracts and to some extent osteoporosis and tinnitus. 
Table 4-8. The unadjusted EQ-5D-3L-based HRQoL and prevalences of self-
reported conditions and register-based conditions in comparison  
Cond. 
no. 
Conditions ICD-10 
Per 
cent 
n  
Mean 
age  
Mean 
age SD 
Mean 
EQ-5D  
EQ-
5D SE 
n/a SR – Asthma   6.3 3,523 46.4 19.3 0.781 0.0047 
108 
RR – Asthma, status 
asthmaticus 
J45–J46 7.4 4,107 52.3 19.4 0.779 0.0042 
n/a SR – Allergies  16.3 9,077 42.8 16.9 0.835 0.0023 
103 RR – Respiratory allergy J30, except J30.0 17.6 9,792 50.2 18.3 0.819 0.0024 
n/a SR – Diabetes all types  5.1 2,814 62.3 15.0 0.751 0.0053 
28 RR – Diabetes type 1 E10 0.5 284 45.1 15.7 0.801 0.0154 
29 RR – Diabetes type 2 E11 5.8 3,253 65.6 13.2 0.752 0.0048 
n/a SR – High blood pressure   20.3 11,299 62.8 13.8 0.785 0.0023 
76 RR – Hypertensive diseases I10–I15 26.1 14,504 64.8 14.0 0.776 0.0021 
n/a SR – Heart attack   1.1 624 66.9 13.3 0.663 0.0122 
77 RR – Heart failure 
I11.0, I13.0, I13.2, 
I42.0, I42.6, I42.7, 
I42.9, I50.0, I50.1, 
I50.9 
0.7 369 72.4 13.8 0.678 0.0151 
n/a SR – Angina  1.9 1,051 60.7 17.5 0.653 0.0103 
79 RR – Angina pectoris I20 2.3 1,253 66.3 11.6 0.725 0.0078 
78 RR – Ischaemic heart diseases I20–I25 3.6 2,017 67.9 12.0 0.719 0.0066 
n/a SR – Stroke (hjerneblødning)  1.4 759 64.8 15.5 0.628 0.0117 
92 RR –Stroke 
I60, I61,I63–I64, 
Z501 (rehabilitation) 
1.5 812 68.6 13.2 0.707 0.0093 
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n/a SR – Chronic bronchitis  4.6 2,545 61.5 16.0 0.695 0.0059 
104 
RR – Chronic lower respiratory 
diseases 
J40–J43, J47 9.1 5,046 55.0 17.3 0.782 0.0036 
105 
RR – Bronchitis, not specified as 
acute or chronic, simple and 
mucopurulent chronic bronchitis 
and unspecified chronic 
bronchitis 
J40–J42 0.3 182 67.3 12.3 0.641 0.0292 
106 RR – Emphysema J43 0.1 76 62.9 12.4 0.706 0.0266 
107 
RR – Chronic obstructive lung 
disease (COPD) 
J44, J96, J13–J18 4.4 2,435 61.3 17.7 0.733 0.0060 
n/a SR – Arthrosis   21.4 11,918 61.8 14.3 0.725 0.0023 
n/a RR – Arthrosis  M15–M19 8.3 4,589 64.2 14.1 0.739 0.0037 
n/a SR – Rheumatoid arthritis   5.5 3,044 58.0 15.8 0.674 0.0051 
122 
RR – Inflammatory 
polyarthropathies and ankylosing 
spondylitis 
M05–M14, M45 3.6 2,008 60.3 15.8 0.726 0.0057 
n/a SR – Osteoporosis   3.3 1,832 69.7 13.2 0.678 0.0071 
165 RR – Osteoporosis M80–M81 3.3 1,817 71.8 11.0 0.710 0.0066 
n/a SR – Cancers all  2.5 1,408 63.2 14.4 0.734 0.0073 
 
RR – Malignant neoplasms 
disease group C (all) 
C00–C99; D32–
D33; D35.2–D35.4; 
D42–D44  
5.3 2,947 64.9 14.6 0.780 0.0045 
n/a 
SR – Migraine or common 
headache 
 13.6 7,579 44.1 15.9 0.755 0.0031 
42 RR – Migraine G43 3.7 2,042 47.1 13.8 0.747 0.0035 
43 RR – Other headache syndromes G44 0.3 143 44.8 14.4 0.700 0.0265 
n/a SR – Temporary mental illness  8.7 4,859 45.3 17.4 0.672 0.0038 
n/a SR – Long-lasting mental illness  3.8 2,113 44.1 17.2 0.625 0.0066 
n/a 
SR – Both temporary and long-
lasting mental illness 
 9.9 5,669 44.9 17.5 0.674 0.0036 
n/a 
RR – Mental and behavioural 
disorders disease group F 
F00–F99 11.0 6,106 50.7 18.5 0.703 0.0037 
n/a 
SR – Herniated or other back 
conditions 
 13.1 7,280 52.8 15.9 0.705 0.0030 
n/a 
RR – Diseases of the 
musculoskeletal system and 
connective tissue, disease group 
M 
M01–M25: M30–
M36; M40–M54; 
M60.1–M99 
23.7 13,163 57.0 17.6 0.755 0.0023 
n/a SR – Cataracts  3.8 2,113 71.7 13.1 0.727 0.0064 
57 
RR – Diseases of the eye lens 
(cataracts) 
H25–H28  1.7 928 73.5 11.7 0.761 0.0086 
n/a SR – Tinnitus - 10.3 5,721 55.3 16.7 0.799 0.0031 
73 RR – Tinnitus H931  0.6 350 63.6 13.3 0.776 0.0139 
SR=self-reported, RR=register-reported. All estimates are weighted. Data source: National Health 
Profiles 2010, 2013. n=56,988. 
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As seen in the previous section, most of the register-based survey prevalence 
estimates are fairly close to national population prevalence estimates (see Table 4-2 
to Table 4-4 and appendix A for all sample prevalences). However, within 
“Endocrine, nutritional and metabolic diseases” and “Diseases of the respiratory 
system”, the sample prevalences are slightly higher for the population estimates. On 
the other hand, prevalences of “Diseases of the circulatory system” and “Mental 
and behavioural disorders” are slightly lower than those of the population 
prevalences. All in all, the sample prevalences are slightly higher than the 
population estimates by around 2 percentage points, from 65.6 to 67.7 per cent.  
Comparing the SR prevalences to the RR prevalences (see Table 4-8) shows that 
eight of the 18 conditions have either slightly higher or much higher SR than RR 
prevalences (heart failure, rheumatoid arthritis, arthrosis, migraine or common 
headache, cataracts, tinnitus and partly the two times mental illness). Migraine or 
common headache, arthrosis, cataracts and tinnitus all have much higher 
prevalences defined as more than twice the size of the compared estimate.  
Prevalences of osteoporosis and stroke are almost the same for SR and RR. 
The rest, eight of the 18 conditions, have higher or much higher RR prevalence 
including diseases of the musculoskeletal system and connective tissue, cancers, 
lung conditions, high blood pressure and diabetes, while asthma and allergy have 
close to the same estimates, although slightly higher RR prevalence.  
Possible non-response bias could be indicated by differences in survey response 
across conditions. The survey data give a unique possibility of estimating survey 
responses for each condition as we also have the non-respondents’ register-based 
chronic conditions of all the respondents from the invited sample.  
Appendix A shows all survey response rates of the sample. The survey response 
ranges from 18.9 (mental retardation) to 82.2 per cent (fibromyalgia). Interestingly, 
mental conditions top the list of the 20 conditions with the lowest survey response 
(ranging from 18.9 to 45.4 per cent), but also other common stigmatizing conditions 
such as HIV and hepatitis are among the 20 conditions with the lowest survey 
response. On the other hand, other severe conditions such as fibromyalgia and 
systemic lupus erythematosus have the highest survey response, although the 
majority of the conditions with the highest survey response are less severe 
conditions. Notably, the survey response rates of the variable measuring the number 
of co-morbidities as an indicator of disease severity are fairly constantly within 2–5 
co-morbidities, but lower for conditions with 0–1 condition, and only marginally 
lower for 6–7+ comorbidities.  
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4.4. OBJECTIVE 4: TO PRESENT A CASE EXAMPLE OF HRQOL 
ANALYTICS OF A SURVEY-BASED CHRONIC CONDITION 
AND LIMITATIONS OF REGISTER-BASED DEFINITIONS 
4.4.1. BACKGROUND AND PURPOSE 
Often, HRQoL estimates of chronic conditions are presented based on one 
condition and one single study, and thus not one study comprising 199 conditions as 
in paper 2. In contrast to existing papers, a case example based on the condition 
myalgic encephalomyelitis (ME)/chronic Fatigue Syndrome (CFS) was included. 
This allows exemplification of the state of the art of detailed HRQoL analysis in 
comparison to paper 2 and some limitations of register-based conditions.  
ME/CFS is a severe and widespread illness affecting 0.2 to 0.4 per cent of different 
populations [172]. The primary purpose of paper 4 was to estimate EQ-5D-3L 
HRQoL scores with Danish time trade-off values. The secondary aims were to 
explore whether the results were influenced or not by other conditions using 
regression, to compare the results to 20 other conditions and to display ME/CFS 
patient characteristics for use in medical practice.  
Purpose in relation to the thesis: 
 to show a case example of HRQoL analytics of a chronic condition 
 to discuss and identify the limitations of other papers in relation to 
register-based conditions based on the case 
 
4.4.2. SUMMARY AND RESULTS OF PAPER 4: HRQOL FOR PATIENTS 
WITH ME/CFS 
The study identified several interesting methodological aspects. Although the 
condition is common worldwide and severe, it cannot be identified using registers, 
although you would expect a complex and severe condition to be diagnosed and 
reported at hospitals within the ICD-10 coding system. There may be several 
reasons for this, as discussed in the paper. Consequently, this condition can only be 
identified by self-reported conditions or by a medical screening of patients using the 
ICD-10 and the newest clinical diagnostic criteria at this time. Notably, the study 
used a rather controversial approach as the sample was based on all members of the 
Danish ME/CFS Patient Association in 2013 (n=319). Thereof, 105 ME/CFS 
patients gave valid responses to the questionnaire, including the EQ-5D. Issues of 
sampling methods were discussed in the paper.  
73 
Unadjusted EQ-5D-3L mean and median scores were calculated. The means of the 
condition were compared to the Danish population mean and to the mean of 20 
other conditions. Moreover, adjusted OLS regression estimates were calculated, 
adjusted for gender, age, educational level and co-morbidity of 18 self-reported 
conditions.  
The unadjusted EQ-5D-3L HRQoL mean score of ME/CFS was 0.47 [0.41–0.53], 
while the population mean was 0.85 [0.84–0.86]. The unadjusted median was 
different to the mean – 0.584 [0.53–0.64] compared to a population median of 
0.824 [0.82–0.83]. Thus, the medians of conditions were significantly higher than 
the mean estimates. Furthermore, the mean-based regression disutility estimates 
were calculated as being -0.29 [-0.21–0.34] for ME/CFS patients. The 
characteristics of ME/CFS patients were different from the national population in 
regard to gender, relationship, employment etc. 
Moreover, the EQ-5D-based HRQoL of ME/CFS was not only significantly lower 
than the population mean, but also the lowest of all the compared conditions. The 
adjusted regression analysis confirmed that poor HRQoL of ME/CFS was distinctly 
different from, and thus not a proxy of, an impact from other included conditions. 
Nevertheless, further studies are required to exclude the possibility of selection bias 
of the study.  
 
4.5. SUMMARY  
In paper 1, a framework of register-based definitions was defined based on a 
medical assessment, existing research and seven different registers comprising 199 
conditions and subgroups thereof. Thirty-five conditions and subgroups had 
complex definitions compiled using the different registers in combination in order 
to ensure the best possible inclusions of the conditions by medical assessment. The 
definitions can be used by other researchers and health-care professionals for 
measuring different outcomes of interest using big data. In the current PhD, the 
framework of definitions was the basis used for the outcomes in papers 2 and 3.  
In paper 2, prevalence rates and characteristics of the 199 conditions were presented 
based on the nationwide population of 4,555,439 Danish citizens aged 16 and older 
on 1st January 2013. Seven different national registers from 1994 to 2012 were 
used. A total of 65.6 per cent of the national population had one or more chronic 
conditions, and the most prevalent conditions were found within diseases of the 
circulatory system (I), diseases of the respiratory system (J), diseases of the 
musculoskeletal system and connective tissue (M) and endocrine, nutritional and 
metabolic diseases (E). While the prevalences provide important basic 
epidemiological burden estimates, another aim was to compare the prevalences of 
the population to the sample of paper 3 in order to assess the reliability thereof. In 
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general, the sample prevalence estimates are, overall, fairly simular to the national 
population prevalences, though small differences exist across some conditions and 
disease groups.  
While paper 2 provides the basic prevalences of the objective sizes of the 
conditions, paper 3 generates estimates of the severity and subjective EQ-5D 
HRQoL burden of disease mean estimates for the 199 chronic conditions, and is 
thus complementary to paper 2. The study was based on the Danish National Health 
Profile Surveys, including the EQ-5D, from 2010 and 2013 with a total of 56,988 
respondents. The survey combined with registers containing information about the 
chronic conditions for each respondent using a unique personal identification 
number (CPR). One hundred and ninety-nine chronic conditions had EQ-5D index 
scores calculated and presented. Both unadjusted and adjusted estimates were 
calculated. The adjusted estimates were based on the ALDVMM designed to handle 
the skewed distribution of the EQ-5D and mean-based contrary existing research. 
Four regression models and new variables – behavioural risk factors, BMI, stress 
and social networks – were introduced to accommodate different health evaluation 
requirements for future use in health economic evaluation. Generally, chronic 
conditions within mental and behavioural disorders (F group), diseases of the 
nervous system (G group), diseases of the musculoskeletal system and connective 
tissue (M group), and endocrine, nutritional and metabolic diseases (E group) had 
some of the lowest HRQoL.  
Finally, paper 4 is a case example of HRQoL analytics of a single chronic 
condition, in contrast to paper 3. The paper also discussed and identified limitations 
of register-based conditions based on the case and literature. The unadjusted 
HRQoL EQ-5D-3L-based mean score for ME/CFS patients was 0.47 [0.41–0.53], 
compared to the Danish population mean of 0.85 [0.84–0.86]. Moreover, the 
adjusted mean-based regression disutility estimates for ME/CFS patients were -0.29 
[-0.21–0.34]. The ME/CFS patient characteristics were dissimilar to the national 
population regarding gender, relationship, employment etc. Additionally, the EQ-
5D-based HRQoL of ME/CFS patients was the lowest of all the compared 
conditions within the study. The adjusted regression model confirmed that the poor 
HRQoL of ME/CFS patients was markedly different from, and not a proxy of, any 
possible impact from other embraced conditions. The study also found that the 
ME/CFS patients, although a common condition, cannot be identified based on 
registers. The possible reasons were discussed in the paper; however, consequently, 
this is an example of a condition that can only be identified by using a medical 
screening of patients or by self-reported conditions as done in the study. 
Nonetheless, further studies are necessary to exclude possible study selection bias. 
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CHAPTER 5. DISCUSSION AND 
PERSPECTIVES 
5.1. IMPACTS OF METHODS – AND THE SAMPLES 
Methods matter: The impact on HRQoL and prevalence of different methods 
The validity, pros and cons of register-based methods and data are discussed in 
detail in paper 1, and thus not discussed here. Yet, the empirical grounds for related 
discussion are expanded within the current thesis. Moreover, it is not the intention 
to provide a detailed statistical analysis of overlapping conditions like other studies 
[95, 173], but merely to generate further input to the discussion by illustrating the 
overall differences between each method (see results of Table 4-8).  
In line with earlier studies [57, 58, 60, 64, 95, 96, 155–157], the present study has 
shown that different study methods yield different results in regard to both 
prevalences and HRQoL (see Table 4-8). However, most existing HRQoL studies 
are based on single conditions using one sampling method (SR or RR). Thus, the 
current study is, to the best of the author’s knowledge, one of the first to show that 
even within the same sample, there are differences in HRQoL for some conditions 
depending on both SR and RR. Notably, other studies have already shown 
differences in prevalences, as also identified here [60, 95, 96]. Hence, the current 
thesis further supports the argument that a uniform, transparent methodology and 
appropriate data are of great importance to the validity of the results, and for 
accessing the validity and statistical uncertainties, and to the decision-makers, so 
that decisions are made based on the most solid grounds possible within health care. 
There may be several reasons for the differences. At an aggregated level, some 
conditions may be either treated in primary care and still not reported or self-treated 
and thus not reported. SR might also include special kind of patients: not severe 
enough or wanting medical treatment, but still severe enough to have an impact on 
HRQoL. However, possible reasons are mainly speculation, as the thesis do not 
provide empirical evidence on explanations and can thus only theorize about 
explanations. 
In detail, the results of the current thesis also indicate that some conditions are more 
exposed to differences than others. First of all, the differences vary between 
HRQoL and prevalence depending on methodology, i.e. SR and RR conditions. For 
example, there are no real differences in SR and RR prevalences of stroke and 
osteoporosis, while the same conditions all have different HRQoL. On the other 
hand, there are no real differences in SR and RR HRQoL for hypertension, heart 
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attack, arthrosis, migraine and to some extent tinnitus, while their prevalences all 
differ.  
In regard to HRQoL, differences between SR and RR estimates exist among heart 
conditions such as angina, stroke, lung diseases, rheumatoid arthritis, osteoporosis, 
cancers, mental illness, back conditions, cataracts and to some extent tinnitus. For 
these conditions, except for tinnitus, the HRQoL RR estimates are lower than those 
of the SR conditions, and at the same time, the RR disease populations are mostly 
older too. However, there do not seem to be any systemic shared explanations 
across disease areas for the differences as they cover many different disease groups, 
except perhaps that most of the conditions are either mostly severe or multifaceted. 
Thus, the reliability of these SR conditions could be questioned due to possible 
patient or recall bias increased by the complexity of the conditions. Furthermore, it 
is recognized that the SR conditions might lack the precision to fully enable 
comparability due to the broadly defined conditions within the questionnaire, such 
as, for example, lung diseases, mental illness, cancers and back conditions. 
Nevertheless, the SR HRQoL estimates for cataracts might be preferred as the 
register data are known to be limited due to treatment outside hospitals and limited 
medical data thereof. Finally, it is worth mentioning that less severe and common 
conditions such as allergies, asthma, migraine and to some extent tinnitus do not 
show significant differences in HRQoL estimates between SR or RR conditions.  
In regard to prevalence, the differences between SR and RR estimates primarily 
exist among hypertension, heart attack, angina, lung conditions, arthrosis, 
rheumatoid arthritis, osteoporosis, cancers, migraine, cataracts and tinnitus. Again, 
it is hard to identify any systemic differences across disease areas. Nevertheless, 
hypertension, angina, lung conditions, osteoporosis and cancers have considerably 
higher prevalence estimates for RR conditions, while asthma, allergies, diabetes and 
stroke have borderline higher prevalence for RR conditions. The higher prevalence 
could indicate that the RR conditions capture more of the less severe patients 
among, for example, angina, stroke, lung diseases, cancers, back conditions, as, for 
example, these conditions also have better HRQoL than could be expected from 
less severe patients (see Table 4-8). However, arthrosis, rheumatoid arthritis, 
migraine, cataracts and tinnitus all have higher SR prevalence. These conditions 
have in common that they include a broad range from severe to less severe patients 
that are not necessarily treated or treatable (except for cataracts) or perhaps self-
treated. Moreover, especially for arthrosis and rheumatoid arthritis, the medication 
is often used for several diseases or bought as OTC drugs. Consequently, the 
conditions are not all register reported and several have difficulty being identified 
solely based on registers.  
So, there are differences, but what methodology, SR or RR, to use and when? First 
of all, it depends on the purpose. If the study needs the precision of doctor-reported 
diagnosis or ICD-10-based conditions then the RR conditions should be the main 
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choice as this precision is not provided in most SRs. On the other hand, if the 
purpose is to get an overall and broad estimate for use in public health research, SR 
might be the appropriate choice – especially in the case of migraine, tinnitus, 
rheumatoid arthritis, cataracts and arthrosis. On the other hand, the large differences 
among, for example, cancers could indicate some SR recall bias or respondent 
confusion regarding their own illness as SR is around half the size of RR, and we 
do not expect the large differences in prevalence to be caused by register error. 
Moreover, the SR HRQoL is significantly lower than that of the cancer RR 
conditions, thereby indicating that the RR conditions actually capture more less 
severe cancers than the SR conditions. This also applies to other only severe and 
complex conditions including hypertension, angina and ischaemic heart diseases, 
chronic lung diseases, diseases of the musculoskeletal system and connective tissue, 
and to some extent heart attack and mental illness.  
In addition, the SR HRQoL is noticeably lower for many severe conditions such as 
heart conditions and lung conditions, but also arthrosis, rheumatoid arthritis and 
osteoporosis, which cannot solely be explained by higher RR prevalence (with 
relatively more less severe conditions to increase the HRQoL). There may be a 
correlation between SR conditions and identifying those with lower HRQoL. One 
explanation might be that SR better includes those with actual functional limitations 
of a disease than RR conditions, which use medically defined inclusion times that 
may not suit every individual. But it could also be that the less severe patients have 
not self-reported the condition even though it exists.  
On the other hand, some SR conditions might still not be accurately captured 
compared to the definition of chronic conditions, as they could include more 
conditions that do not have any real “functional limitations” due to the illness or 
“ongoing need for medical care” identified in the registers, for example arthrosis, 
cataracts or tinnitus. It could be argued that conditions with functional limitations or 
ongoing need for medical care most likely would, at some point in time, be reported 
in registers when people seek health care when the “limitations” become functional 
– although it is recognized that some treated patients might not be reported or 
identified even so (for example arthrosis, cataracts, migraine and tinnitus, as 
discussed in paper 1).  
In summary, the best suited method depends on purpose, data possibilities and the 
condition. Moreover, it should also be evident that there might be several possible, 
sometimes contradicting explanations for the differences from methodology. The 
current study cannot provide definite explanations, but merely identify differences 
and theorize about explanations. Within the literature, the two discourses, the SR 
and RR, are usually compared, divided and disputed, yet it is often implied that RR 
is the gold standard [97–104, 174–176] – except for in the GBD studies, which mix 
different data sources and methodologies within and across countries [3, 126, 131, 
132, 177]. Notably, this is most likely needed within the GBS as uniform data 
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quality is difficult to obtain across countries with very different resources, data 
infrastructures and populations. However, an SR and RR combined methodology 
within Western countries could possibly improve, despite not being doctor reported, 
the validity for some RR conditions not identified properly in registers such as 
migraine, tinnitus, rheumatoid arthritis and to some extent arthrosis (“to some 
extent” as many do not have any functional limitations due to the disease, which is 
why there is a risk of over-reporting). It was also showed that the disputed 
condition ME/CFS was not identified properly within registers, perhaps due to 
cultural medical differences and diagnostic practices across countries. Therefore, 
ME/CFS and other disputed or stigmatized conditions might benefit from a 
combined methodological approach, if possible and economically feasible, until 
other medical diagnostic practices materialize in register reports. Nonetheless, an 
expert review should identify further conditions at risk of not being reported. In the 
author’s opinion, a mixed approach might be a lesser evil and complementary for 
the conditions that are known not to be properly RR reported, although it may be 
argued that this is done at the cost of losing full uniformity of methodology. On the 
other hand, severe conditions such as cancers, heart and most lung diseases, mental 
illness and others are for the most part recommended used based on RR definitions 
as long, when detailed diagnosis is needed, as many patients most likely cannot 
identify the correct diagnosis.  
Response rates – and the impact on samples 
The knowledge of differences in survey response rates across conditions could 
indirectly give an indication of the reliability of the conditions’ estimates. However, 
no gold standard exists for good response rates, although an acceptable response 
rate as a rule of thumb is usually set at around at least 50 per cent [178, 179]. In 
theory, a response rate of 20 per cent may give just as reliable estimates as a 
response rate of 90 per cent if the samples are equally distributed across the “true” 
disease population.  
Nevertheless, it cannot be ruled out that conditions with relatively low survey 
response rates have different and possibly lower HRQoL than those of the estimated 
results in paper 3, as the strongest patients responded to the survey. Several survey 
response rates differ widely across conditions (see appendix A for an overview of 
all survey response rates across conditions). This might indicate that low response 
rates are correlated with higher disease severities, such as, for example, mental 
conditions that have low HRQoL. However, only 27 out of 199 conditions have 
lower than 50 per cent response rates, most of which are mental conditions. In 
general, most conditions have relatively high response rates, indicating above 
average reliability in regard to the rule of thumb of a 50 per cent response rate. Yet, 
some response rates also indicate possible issues with mental conditions within 
surveys and that the HRQoL thereof might be even lower. This also applies to 
several other disease areas with low response rates.  
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As the survey response rate is only an indication of possible non-response bias, 
further studies are needed on specific possible indications as no real evidence exists 
in regard to implications between the size of the response rate and non-response 
bias. Ideally, each response (disease) population of the sample should be compared 
with the full populations’ socio-.economic and other variables in order to assess the 
reliability fully. However, this comprehensive work is beyond the scope of the 
present thesis and has therefore not been done.  
 
5.2. INTRODUCTION TO USING THE EQ-5D PREFERENCE 
SCORES WITHIN CUA, STRENGTHS AND LIMITATIONS 
The main advantage of an “off-the-shelf” catalogue of preference scores for health 
states is its uniform methodology ensuring standardized estimates free of different 
biases across studies – besides being easily and cost-effectively accessible. As such, 
any advantages as well as disadvantages in terms of validity and reliability derived 
from the study design apply to all estimates and conditions, and will also apply to 
any future CEA/CUA and research studies based on these estimates. In addition, the 
catalogue eliminates the need to search for and combine different estimates from 
different studies and different, possibly not comparable study methods.  
Overall, the EQ-5D-3L preference catalogue sheds light on which patients and 
conditions fare worst, how severe each conditions is, and what the potential health 
gains are if the illness is eradicated or its start delayed. The improves existing 
catalogues in several areas: new regression modelling which respects the 
characteristics of EQ-5D-3L, different specifications and models for analysts to 
choose from for health economic evaluation, and finally the use of ICD-10-based 
doctor-reported conditions, added variables of health risks, BMI, and quality social 
network in regard to loneliness constituting several new opportunities and 
methodological contributions to the research field. However, there is one limitation 
in particular:  
“If the goal is to estimate the impact of treatment intervention on disease 
severity within specific study populations, primary data collection of 
preference-based HRQoL scores in a randomized controlled trial (RCT) 
may be more appropriate. On the other hand, the estimates in this 
catalogue may be preferable for simulating the impact of postponing, 
preventing or curing chronic conditions. This is particularly true of 
measuring the effectiveness of interventions in the community where 
nationally representative estimates are important or where primary data 
collection may not be feasible.” Sullivan et al. [49] 
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Modelling disease severity of special interest could constitute a problem as the 
register definitions do not have any clinical differentiated disease severities defined. 
In addition, many RCTs target specific disease populations, for example GOLD 
classification 1–4 of COPD, which is why the estimates of the catalogue may not be 
appropriate as the study population of the current study is defined as a nationally 
representative sample of chronic conditions, not specific subgroups thereof. 
However, if the relevant conditioning variables are in one of the four regression 
models which characterize the disease population of interest, then the analyst can 
condition on them and get different estimates of the effects similar to the specific 
disease population using the ALDVMM. When the covariates are set to different 
values, they would output different marginal effects unlike the linear regression for 
which the marginal effect will be the same regardless of the group you are looking 
at. Naturally, this approach assumes that the effect is the same as clinical defined 
groups based on the conditioning variables. Future research could investigate this 
assumption further. Moreover, other solutions using the different components of the 
regression model exist for modelling disease severity using the catalogue as 
described later. Finally, several other useful possibilities exist, including 
“simulating the impact of postponing, preventing or curing chronic conditions”. 
Existing literature has already described modelling within health economic 
evaluation in detail, and therefore the following descriptions of how to model and 
use the estimates are not designed as a replacement for the existing literature, but as 
a supplement that is also partly inspired by referenced studies [41, 42, 49, 50].  
Material provided for CUA – and comments on modelling for future users 
For complex, non-linear modelling, Excel and Stata .ster files containing full 
parameter estimates and covariance matrices  of regression models 1-4 will be 
provided and should be used by experienced health economist modellers and 
statisticians. Please bear in mind that present author is not among this group of 
people; nevertheless, the following illustrations are intended as an introduction and 
may still provide useful information and inspiration for future modellers.  
The parameter estimates allow the computation of the effects of different chronic 
conditions (singly or jointly) on EQ-5D-3L. The covariance matrix of the estimated 
parameters is required by analysts to undertake Probabilistic Sensitivity Analysis 
(PSA) (current version may be provided to the ph.d committee on request). The 
effects in complex models, i.e. models with comorbidities and/or use of additional 
covariates, should be predicted with programming in Excel or Stata based on the 
formula for the EQ-5D prediction provided on page 739 in reference [163]. 
In the future - when final validated - the Excel and stata .ster files will most likely 
be published on the http://www.dchi.aau.dk/forskning/web-ressources/ website 
along with an interactive online calculator. This work is currently still in progress. 
The calculator will expectedly be based on the formula for the EQ-5D prediction 
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provided in reference as mentioned [163]; it will enable the modeller to get an 
estimate of the specific health status needed from each of the four regression 
models.  
Up until now, EQ-5D preferences catalogues have usually been modelled additive 
[41–43, 49]. That is, the change in EQ-5D-3L of developing two chronic conditions 
simultaneously is assumed to be the sum of developing each of the two chronic 
conditions in isolation. For additive or single condition modelling and comparisons, 
the regression based disutility’s provided within paper 3 may be sufficient. Also, an 
example of an additive model is provided in appendix B). Yet, multimorbidity and 
complex modelling of several covariates is in reality properly not linear, why 
additive models most likely are wrong reflections of disease burden.    
This issue has been discussed in the literature [46, 180–189] and has been shown 
that in general the estimated change in EQ-5D-3L when using the separate 
estimates additively is too large. One of the reasons might be that the two diseases 
might share some common effects and by adding them up there is double counting. 
Thus, for years, researches have sought methods to handle and incorporate 
comorbidity or “joint health states” in models (for example additive, multiplicative, 
best-of-pair, worst-of-pair, minimum and adjusted decrement estimator methods 
have been proposed) [181, 186]. The non-linear and different properties of the 
ALDVMM along with the study-data containing the 199 chronic conditions within 
a single study provides new powerful possibilities for more precisely identifying 
and estimating joint health states uniquely contrary other single or even other multi 
condition studies as they do not comprise the same number of conditions.  
Modelling impact/cure for an explicit condition 
The marginal disutility regression estimates in paper 3 represent the average across 
the population of each individual’s marginal decrement in EQ-5D-3L preference 
scores for each condition after controlling for co-morbidity, gender, age and so 
forth, depending on the regression model of choice. In addition to the previous 
example, a cure for a condition is thus equivalent to the marginal disutility of the 
regression estimates. A simple model of a cure for ulcers, for example, may be 
modelled as an decrease in the EQ-5D preference score of -0.0289 (based on 
regression model 2 of paper 3), and standard errors can be used to calculate 95% 
confidence intervals for use in the probabilistic sensitivity analysis [49]. However, 
for more complex models with for example more comorbidities, the modeller will 
need use the excel or Stata .ster files later provided on the webpage, which has all 
parameter estimates and the full variance covariace matrix for proper sensitivity 
analysis.  
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Modelling an average population with one given condition – baseline 
On the other hand, the unadjusted EQ-5D mean scores reflect not only the chronic 
condition, but also the impact of co-morbidities, age, gender and other 
characteristics of the Danish disease population. The unadjusted EQ-5D preference 
mean score may be used for modelling a baseline for the average disease 
population. For example, a baseline score for an average population with ulcers can 
be modelled as 0.707 (=the unadjusted utility), and the impact of a cure for the 
disease population can be calculated as 0.7359=0.707+0.0289. However, please 
bear in mind that using the margin dy/dx function in Stata, the combined disutilities 
of the ALDVMM components are actual calculated as marginal effect for the whole 
population (all n of sample) with ulcer rather than the marginal effect for the 
smaller population with ulcers. This technical detail is little known although the 
margins command is widely used. However, the results are still comparable to other 
estimates based on the margins command commonly used.  
Modelling different severities of conditions 
Previous preference catalogues have been criticized for missing preference values 
by level of condition severity, which in particular constitutes a problem as many 
treatments or interventions mainly move patients from moderate to mild health 
states [48, 50]. However, when primary data collection is not feasible, and even 
though the register-based definitions or EQ-5D estimates do not incorporate 
specific clinical disease severity, the estimates may be used to model severity if 
some assumptions are made. For modelling different severities of the average 
disease population baseline, the different EQ-5D estimates of the 25
th
 or 75
th
 
percentile of the condition of interest can be used to represent either a worse or 
better health condition (can be found in appendix to paper 2). Naturally, these 
estimates also reflect the differences in co-morbidities, age, gender and other (also 
unobserved) characteristics associated with differences in severity of the disease 
population. A similar approach can be taken using the adjusted regression estimates 
when modelling disease severity by assuming, for example, that a 50 per cent 
increase or decrease in marginal decrement reflects the impact of severe or mild 
disease on, for example, rheumatoid arthritis [49]. A mild case of rheumatoid 
arthritis could be modelled as 0.725 (=0.710 + 0.5*0.0297), and a severe case could 
be modelled as 0.696 (=0.710 - 0.5*0.0297). 0.710 is the unadjusted mean of 
rheumatoid arthritis, and 0.0297 the adjusted disutility of ALDVMM model 2– all 
based on the estimates of paper 3.  
However, a third and new possibility for modelling disease severity exists in the 
form of the ALDVMM regression model as it provides marginal estimates of the 
identified components for every chronic condition. This can be done as each 
component represents different areas, with low/high scores, of the EQ-5D 
distribution. Thus, each component can be seen as a different severity of a 
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condition, with the lowest numbered components as the most severe cases on 
average – although a statistically identified severity can still not be compared with a 
clinically defined disease severity. Nevertheless, this approach is at least as feasible 
as the previously mentioned ways to adjust severity using the catalogue, and 
perhaps better, as the components are not arbitrary cut points, but identified from 
the distribution of the actual EQ-5D preference scores. For example, modelling not 
a cure but an impact in moving from a severe to a milder health state of, for 
example, COPD or sclerosis could be done by subtracting the estimates of, for 
example, component 1 from component 2. A move from a moderate health state to 
the mildest health state of a condition could be modelled using the marginal 
disutility of component 2 subtracted from the estimate of component 3, if the model 
has three components. The difference is the potential gain of the move from one 
health state to another. The baseline disease population could be modelled as the 
unadjusted average of the condition of interest subtracted from the difference in 
marginal disutility of the chosen components. However, as always, the choice 
should be clear and thoroughly discussed using appropriate sensitivity analysis. In 
summary, the different identified ALDVMM components may provide new 
possibilities and level of detail to previous catalogues that can be used for 
modelling different disease severities or subgroups.  
The four different regression model/estimates – and recommendations for use 
An essential improvement to existing catalogues is the extra added regression 
models and estimates. The different models and disutility estimates are made to 
accommodate different needs within health economic evaluation. For example, 
NICE recommends/requires adjustment of gender and age (similar to regression 
model 2 of the current study), while existing catalogues by Sullivan et al. adjust for 
co-morbidities, gender, age, education, income, ethnicity, socio-economic status 
and family size (equal to regression model 3 of the current study). Moreover, some 
health economics evaluators may prefer an estimate only adjusted for co-
morbidities as their first choice when modelling (equal to regression model 1 of the 
current study). Finally, new analytic possibilities arise from adding new variables to 
model 3 such as health risks, BMI, stress and social network as these variables – as 
seen earlier – have a major impact on the HRQoL and could thus be important for 
future studies and modelling (equal to regression model 4 of the current study). 
Notably, the choice of regression model estimates should be thoroughly discussed 
and documented by future users, and it is recommended that estimates of other 
models are presented and used for sensitivity analysis in order to avoid the risk of 
choosing a model that suits the desired results best. 
Thus, the different models reflect different health economics modelling needs – and 
the regression model and coherent estimates should therefore be used according to 
specific needs and possible government or other requirements for the study of 
interest. However, multiple estimates increase the risk of confusion and possible 
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“bias selection” in order to provide the most positive results of interest. 
Consequently, the minimum requirement should be to: 
 clearly present which regression model and coherent estimates are used,  
 clearly argue for the choice in a transparent manner,  
 presenting a sensitivity analysis using the other regression estimates.  
Further requirements and guidelines for regression modelling can be found in 
references [190–192]. Although the choice of regression model/estimates depends 
on the study of interest and government regulations, a few recommendations are 
provided in regard to present thesis:  
The estimates of regression model 1 should be chosen when the population of 
interest needs to correspond to the national disease population only adjusted for co-
morbidities – as the estimates reflect the disutility of the chronic condition of 
interest including effects of age, gender and all other characteristics of the disease 
population. It is expected to be of interest for the majority of health economics 
evaluations. 
The estimates of regression model 2 should be chosen when the population of 
interest needs to correspond to the national disease population adjusted for co-
morbidities, gender and age, but all other disease population characteristics still 
need to be comprised in estimates (such as BMI, income, education and other 
covariates). This might be of importance when analysing and comparing different 
conditions adjusted for these basic covariates in order to compare and identify 
which condition has the most health gain, or when it is necessary to identify the 
“clean” effect from one condition of interest “free” (adjusted) of only gender and 
age differences, for example, an RCT. This might also be of interest when 
comparing an RCT population of interest to a national population. Finally, model 2 
(or 1) should be used when the study is aimed at NICE or other government 
agencies with similar requirements or just in general recommended in order to keep 
the models simple and adjusted only for the most basic variables in order to include 
and reflect most characteristics of the chronic condition of interest. 
The estimates of regression model 3 should be chosen when the population of 
interest needs to correspond to the national disease population adjusted for co-
morbidities, gender, age, family equalized income, education, ethnicity, partnership 
and children living in household, but all other disease population characteristics still 
need to be comprised in estimates. As such, this model is suitable when the purpose 
is to analyse different impacts of classic socio-economic equality, or model 
different patient populations of interest according to specific socio-demographic 
distributions of interest.  
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The estimates of regression model 4 should be chosen when the population of 
interest needs to correspond to the national disease population adjusted for the 
variables of model 3 and social network, stress, BMI, smoking, exercise, and 
alcohol  and fruit intake. This model is suitable when the purpose is to analyse 
different impacts of classic socio-economic equality, and other aspects of health 
inequality such as social health risks, network and stress. These estimates enable 
further modelling in order to create different patient populations of interest based on 
known disease populations within RCT or other studies. 
Mixing estimates of the different models within the same study, HTA or similar, is 
not recommended as it is not consistent. Finally, please note that regression models 
and estimates may change in final versions of paper 3, and, therefore, should only 
these final estimates be used in future CUA. 
 
5.3. IMPLICATIONS OF USE IN PRIORITY SETTING, STRENGTHS 
AND LIMITATIONS  
Honeycutt et al. pinpoint eight different potential uses of burden of illness measures 
in general (see Figure 5-1) [54]. In the following, this framework is used for placing 
the potentials of the current thesis in a broader policy context. The grey highlighted 
text in Figure 5-1 indicates topics in which the thesis is expected to be of use to the 
author.  
 
1. Setting Priorities for Resource Allocation 
a. Health services 
b. Prevention 
c. Research 
2. Monitoring and Evaluating Policy 
a. Cost-effectiveness analysis (CEA) of individual interventions 
b. Monitoring performance of health systems 
3. Monitoring Population Health 
4. Identifying Disparities 
5. Understanding the Burden of Morbidity and Assessing Morbidity/Mortality 
Trade-offs 
6. Budgeting for Future Health Expenditures 
7. Improving Measurement of National Income and Inflation 
8. Identifying Opportunities for International Development 
 Technology transfer to low-income nations 
 Neglected diseases 
 Reductions in burden may increase human capital formation 
 
Figure 5-1. Potential uses of burden of illness measures. Source: adapted from 
Honeycutt, 2011 [54]. 
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Setting priorities for resource allocation 
 
In general, burden of illness measures can play a role in setting priorities for 
resource allocation solely by identifying diseases with considerable needs for 
medical care and preventable risk factors [54] (although it can be debated whether 
resource allocation can be properly done without CEA/CUA). For this, 
epidemiological prevalence measures of size and HRQoL burden measures such as 
the QALY and EQ-5D of the current thesis can play an important role. Moreover, 
the burden estimates of the current thesis can in combination complement each 
other and give birth to policy setting dilemmas. For instance, it may not be the most 
prevalent conditions or the conditions with the highest mortality that have the worst 
HRQoL severity. Or it might be that the most prevalent and severe conditions are 
neglected and need decision-makers’ attention. For example, one of the most 
important insights from the GBD studies in 2004 was that depression was the third 
leading cause of burden worldwide based on DALYs, even though it did not rank 
among the 20 most mortal conditions measured in life years lost [193]. 
 
Similar dilemmas derived from estimates of the current thesis could potentially 
generate new policies and priorities (obviously, this also requires solid public 
debate and presentation of results to health care professionals, decision makers and 
politicians besides a publication of a single thesis). For instance, cancers 
(combined) and several heart conditions have relatively high prevalence and 
mortality, but for many of these conditions, the HRQoL is relatively high too10. At 
the same time, these conditions already have high priority among politicians, and 
within research and the health-care system, including relatively high financing. This 
issue, “the injunction to rescue identifiable individuals in immediate peril, 
regardless of the  cost”, is discussed in the literature under the name “rules of 
rescue”  [194]. 
On the other hand, there are several other conditions, such as musculoskeletal and 
psychiatric conditions, that have both relatively high prevalence and low HRQoL 
and at the same time do not have the same priority setting or financing. The 
comprehensive number of conditions and results from the current thesis puts this 
dilemma into a new perspective. Yet, future studies should generate QALYs and 
thus include mortality in the equation. Nevertheless, the results might still outline a 
historical division between easily understandable, often physical and highly mortal 
conditions that currently have high political priority, and more complex, often less 
mortal conditions with relatively lower HRQoL. In essence, this is also a classical 
dilemma and a trade-off between mortality and QoL.  
                                                          
10 Notably, there may be an impact of mortality on HRQoL as the survivors might be the 
strongest patients. Thus, future conclusions should be based on studies using the QALY so 
that mortality is included too.  
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Whereas the priority setting for health-care services may frequently focus on 
treatments for particular illnesses, the priority setting for prevention frequently 
focuses on specific, modifiable risk factors such as those used within the present 
study described in chapter 3, Table 3-2. In contrast to existing EQ-5D catalogues, 
the current study includes risk factors, but also stress, social networks and other 
variables essential for providing estimates for use in prevention and calculating the 
potentials of prevention. However, ideally, risk factors should methodically be 
linked to specific conditions and their consequences using, for example, attributable 
fractions or similar methods when the estimate of risk factors etc. is needed for a 
specific disease [54, 195]. However, this is not done, despite the fact that the 
catalogue provides estimates of risk factors adjusted for all chronic conditions that 
can be used for modelling prevention potentials. Yet, it cannot be ruled out – as we 
have not done any regression interactions due to the large number of 
conditions/variables – that estimates from interactions between risk factors etc. and 
conditions vary across conditions. Future studies should explore this, but also 
conduct analysis of which conditions/co-morbidities may cluster and provide 
interactions that influence results. Nevertheless, there is a trade-off between 
complexity and keeping it simple; and increased complexity does not necessarily 
provide more useful estimates.  
Although understanding the burdens of illness, including the size and severity, is an 
inescapable first step in generating priorities, “these measures alone do seldom 
provide enough information to make informed resource allocation decisions” [54]. 
For example, they say little about whether there are currently obtainable 
interventions that can treat the illness, the cost of interventions, or how much of the 
burden can be reduced by the interventions. Therefore, it is crucial to understand 
that burden estimates in general, and those of the present thesis in particular, are an 
initial starting point, and thus are means for others to generate actual health 
economic evaluations for decision-making:  
 
Monitoring and evaluating policy and monitoring population health 
 
Burden of illness measures can also be used to monitor and evaluate health policies. 
For instance, combining burden measures with information about interventions, 
costs and outcomes may be used to evaluate interventions in CEA [54]. 
Specifically, the preference scores can be used in CEA/CUA as described in the 
previous section.  
 
Changes in burden of diseases measures at the aggregate level and/or for specific 
illnesses may be tracked over time to identify whether the general performance of 
the health-care system is improving or adjustments to policies are required. For this, 
the framework of definitions for the 199 chronic conditions can be used in 
combination with any burden measure of interest collected at the micro level. In 
particular, the framework could be used for monitoring the prevalence/incidence 
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rates or EQ-5D of the 199 chronic conditions over time, and thus whether these 
burdens are decreasing. Moreover, the prevalence rates (and the register framework 
in a Danish setting could be used for identifying individual costs linked to diseases) 
of the current thesis can be used for generating cost-of-illness (COI) estimates in 
future studies to inform decision-making and monitor health-care expenditures of 
chronic conditions as mentioned earlier. Combined, the estimates, prevalence, EQ-
5D/QALY and costs could be used for discovering whether changes in health-care 
spending correspond to changes in burden estimates over time. 
More specifically in a Danish context, burden of disease estimates could also be 
used for monitoring the results of national and local health agreements and policies. 
Since the structural reforms in 2007, local regional governments and municipalities 
have been obligated to generate agreements on interventions to improve public 
health [196, 197]. However, the indicators used for monitoring the health policies 
are mostly organizationally minded and less patient and health related:  
 Prevention of hospitalizations among the elderly 
 Acute medical short-term admissions 
 Acute admissions among adult COPD patients 
 Acute admissions among adult citizens with type 2 diabetes  
 Acute somatic readmissions within 30 days 
 Acute somatic readmissions within 30 days among adult COPD patients 
 Acute somatic readmissions within 30 days among adult citizens with type 
2 diabetes  
 Acute psychiatric short-term admissions 
 Acute psychiatric readmissions within 30 days 
 Finishing days (somatic) 
 Finishing days (psychiatry) 
 Waiting for general rehabilitation 
 Rehabilitation plans for general rehabilitation 
 
Source: Danish National Board of Health and Health Data Agency, 2015 [198, 
199]. 
 
There might be several reasons why these measures are not directly health-related 
burden measures. First, it may be difficult (or risky politically) to generate policies 
that can actually improve health burdens significantly in the eyes of the public at an 
aggregate level. Secondly, and more importantly in this regard, the policies may not 
in their current form be able to actually generate measurable improvements on 
health, thus leaving less meaning and incitement measuring policies at an aggregate 
level. In addition, it may be technically difficult to link numerous and often not 
evidence-based policy initiatives to changes in burden measures. However, this is 
an opportunity to generate operational measurable policies aimed at improving 
QoL; for example, political goals regarding health status or prevalence could be set 
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based on specific burden measures known to be sensitive to the interventions of the 
policy. Thus, there is the potential for implementing burden measures such as the 
EQ-5D, QALY, SF-12 and prevalence or other burden measures – such as those of 
the National Health Profiles described in chapter 3. 
 
Identifying disparities 
 
Many health policies aim to decrease health inequalities, including the above-
mentioned health agreements11. Health equity, not to be confused with equal access 
and use of health services [11], has also been a research concern for years with 
numerous, comprehensive publications including several initiated by the 
government [18, 19, 60, 96, 156, 157, 159, 200–203].  
 
Inequality is important within health economic evaluation because the potentials for 
health gains are often found within the disparities. Epidemiological inequalities 
have for a long time focused on life expectancy, mortality, prevalence and 
incidence etc., as well as inequalities within socio-demographic variables such as 
gender, age, ethnicity, education, income, geography, work status, family status etc. 
in relation to different burden outcomes such as HRQoL, stress, QWB, morbidity 
and health risk, among others. For example, self-rated health is valued as being 
relatively less good for single, early-retired people and others outside the labour 
force, and people with only a primary education, but similar tendencies exist within 
other outcomes including diseases, lost life-years and mortality etc. [19, 156]. 
However, estimates have not been accessible within existing EQ-5D preference 
score catalogues for health economic evaluation.  
 
Thus, the present catalogue of EQ-5D preference scores generates new possibilities 
for modelling health inequalities within health economic evaluation, as described in 
more detail in the previous section, as the catalogue provides numerous new 
variables used for identifying health inequalities. As all the variables, including 
conditions, socio-demographics, health risk etc., are estimated within a single 
regression analysis, it is possible, in contrast to most other studies, to compare the 
size/strength of HRQoL differences and identify the highest disparities and 
inequalities across variables. Besides confirming the patterns of classic socio-
                                                          
11 “Order on health coordination and health agreements. Order No. 1569 of 12.16.2013 
Applicable. §4. The Regional Council and local councils in the region enter into a health 
agreement for the discharge of duties in the health field. The health agreement must include 
both citizens with somatic and mental illnesses. PCS. 4. The health agreement shall, as 
appropriate, be based on the following cross-cutting themes: division of work and 
cooperation, including knowledge sharing and health counselling between sectors, 
coordination of capacity, the involvement of patients and families, health equity, 
documentation, research, quality and patient safety.” Source: 
https://www.retsinformation.dk/forms/R0710.aspx?id=160777  
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demographic determinants, stress and loneliness in the current EQ-5D preference 
catalogue are two major determinants of HRQoL that might impact on future 
research and priority settings. In the author’s opinion, the main contribution to 
existing research is the precision of comparability from estimates due to the 
uniform single-study-based methodology and comprehensive number of variables 
and conditions.  
Moreover, paper 2 provides some information about health inequalities among the 
199 chronic conditions based on cross-sectional analysis using a few socio-
demographic variables besides prevalence estimates.  
 
Understanding the burden of morbidity and assessing morbidity/mortality 
trade-offs 
 
HRQoL measures may provide perspective on the trade-off between mortality and 
morbidity in policy settings by quantifying the role of morbidity [54]. For instance, 
in line with the example of depression within the GBD studies, there are examples 
of disease burdens that have relatively low mortality and severe HRQoL, which is 
naturally not discovered using mortality measures alone. The current catalogue of 
EQ-5D scores will be of assistance in quantifying the role of morbidity in health 
economic evaluation from more ICD-10-based conditions than in any other 
previous studies. 
 
Budgeting for future health expenditures and neglected diseases 
 
Economic burden measures such as COI or health-care service expenditures, 
specific treatments, medication or others of interest may be combined with 
epidemiological and public health trends in risk factors and socio-demographics. 
This may prove useful in predicting future health-care expenditures, including 
disparities within subgroups, at a national and local level [54]. However, the use of 
the current thesis is limited in terms of providing these economic estimates, 
although the framework of definitions for chronic conditions provides a basis for 
future studies generating COI estimates and estimating costs of chronic conditions 
using registers. Moreover, the National Health Profiles may provide estimates of 
trends for health risks and socio-demographics for the prediction of future health 
trends.  
Finally, the catalogue of both EQ-5D and prevalence scores could be used for 
identifying neglected diseases – to some extent – by comparing the prevalence and 
HRQoL of current catalogues in combination as mentioned earlier. Neglected 
diseases could have low prevalence and low HRQoL, for example fibromyalgia, or 
even high prevalence and low HRQoL, such as several mental and musculoskeletal 
diseases not commonly prioritized as mentioned. Within resource allocation, there 
may be a tendency to focus on common illnesses with high prevalence and severe 
burdens; yet, this is an oversimplification as rare illnesses may collectively have 
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large burdens [54]. Critical use of the burden estimates in the present thesis should 
account for this so that rare diseases still receive resources.  
 
However, an example of a neglected and common disease not captured within the 
register framework is ME/CFS in paper 4. As such, a crucial limitation of the 
framework of definitions could be the clinical culture, disease complexity and 
disagreements in aetiology and treatment preventing even common diseases from 
being reported (and treated) in registers [204].  
 
5.4. FUTURE RESEARCH EXPLORED AND SUMMARIZED  
Although suggestions for future research are continuously being noted, suggestions 
are summarized and some new ones are described here. 
Exploring multi-morbidity of utility estimates  
Though chronic conditions or long-term disorders are a major challenge for health 
care, “health systems are largely configured for individual diseases rather than 
multimorbidity… Better understanding of the epidemiology of multi-morbidity is 
necessary to develop interventions to prevent it, reduce its burden, and align health-
care services more closely with patients’ needs” [205, 206]. Multi-morbidity is also 
important as it puts a large burden on patients; but also since it reflects the reality 
of actual disease better than a single-view focus on disease whenever it is within 
research, hospitals or the health-care system in general.  
Little is known about estimating or combining utilities for comorbid (or ‘joint’) 
health states when the only data the analyst has access to the utilities of each 
condition from separate studies. Several joint health state prediction models have 
been suggested (for example, additive, multiplicative, best-of-pair, worst-of-pair, 
minimum and adjusted decrement estimator methods as mentioned earlier etc.), but 
no general consensus has been reached [181, 186]. From a statistical point of view, 
the multiplicative model recommended by Ara and Brazier [186] may be the best 
practical approximation, but not necessarily in line with actual data and reality. 
However, paper 3 of present study is not linear, nor multiplicative, but actually 
incorporates multi-comorbidity in the utility estimates in better alignment with the 
data due to the unique properties of the ALDVMM regression model; in addition, 
the enhanced possibilities in regard to multi-morbidity is facilitated by the fact that 
as much as 199 conditions and subgroups are uniquely included within a single 
study. These improvements are significant as the results may provide a solution to 
issues of multi-morbidity.  
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Future studies should explore the properties of comorbidities and their utility 
estimates of paper 3, and, if possible, identify systemic patterns or different clusters 
of conditions and their relationships to a get better understanding hereof. If 
possible, they could suggest new and differentiated joint health state prediction 
models based on the findings (may for example be done by simulation based on the 
earlier mentioned Stata .ster file). The inclusion of all the conditions within a single 
study gives future studies a unique opportunity as many other “joint health states” 
studies are based on a limited number of conditions often from different studies. 
Although it may be difficult to identify general patterns given the large number of 
combinations of the different sets of comorbidities, future studies might identify 
some patterns within large clusters of for example chosen common diseases.  
The register-based definitions of 199 chronic conditions 
In general, the register-based framework of 199 conditions can be applied onto an 
unlimited number of outcomes, including costs, HRQoL and others also mentioned 
below, as long as the conditions of interest are linked at the micro level to the 
outcome of interest. Moreover, the framework of definitions can be used by 
everybody, including health-care administrators within hospitals and governments, 
and insurance registers, as long as the data contain the ICD-10 codes, medication 
ATC codes and other variables defined within the framework. Therefore, there is an 
almost unlimited number of future studies derived from the framework.  
Future studies should further validate the register-based definitions based on, for 
example, comparisons with medical records. This is crucial since there are known 
diagnostic issues and controversies affected diagnostics such as, for example, 
shown within depression or similar conditions such as ME/CFS as mentioned [204, 
207].  
Future studies could also explore clusters of conditions using the registers, in order 
to support for example prevalence and incidence studies in regards to the 
importance of multi-comorbidity as mentioned. 
Finally, future studies could explore the possibilities and implications of combining 
SR and RR methods for identifying chronic conditions. For which conditions could 
this be beneficial or otherwise? Some register conditions are known for not 
providing valid prevalence estimates, such as diseases like cataracts and tinnitus, 
for example, which is why there may be some precision to gain for some 
conditions. The current study has already shown that the two often competing 
methods may complement each other in certain areas, and that RR-based conditions 
also have limitations like SR, although the use of SR conditions depends on the 
purpose of the study and the need for precise diagnosis etc.  
  
93 
Monitoring trends in disease prevalence and incidence 
Future studies could explore trends in prevalence – and incidence – rather than the 
single-point estimate of prevalence provided here, using the register-based 
framework of 199 chronic conditions. However, these studies should also take the 
growing number of diagnoses (“diagnostic inflation”) into account and explore 
whether this is a result of more disease or changes in diagnostic practices or the 
increasing productivity of country-specific diagnostics, as well, in contrast, possible 
under diagnosis of some diseases as debated [208–210]. Although the debate has 
been especially strong within the psychiatric field, an initial test of nationwide 
somatic ICD-10 codes also revealed an increasing number of somatic conditions by 
year.  
Identifying and monitoring trends in costs and COI 
Moreover, future studies could use the register-based framework for identifying the 
costs of health-care treatments and services by chronic condition. 
Future studies could use the prevalence rates of the current study for generating 
COI [21]. Another approach for generating COI estimates is to use the register 
framework to identify individual costs and link them to diseases at the micro level 
within national registers or insurance data that contain the same data and variables 
defined within the framework. This will most likely enhance precision, but may 
require some work.  
Monitoring trends within costs and COI for chronic conditions could inform 
decision-makers, but also be of interest to researchers making recommendations 
and forecasting health-care expenditures or disease burdens.  
Generating ratios of costs and EQ-5D/QALY – cost pr. perfect health or 
QALY 
One simple use of the framework and estimates is dividing the mean cost of a 
condition over (preferable adjusted) EQ-5D essentially generating mean cost pr. 
perfect health of each condition for comparison. This would improve the 
information of traditional COI - expectably easier to generate than CEA as many 
health care professionals have information on costs – although not a CEA. Future 
studies could generate national ratios, as well is this might be done by health-care 
professionals in local municipalities where cost, but not HRQoL, are usually 
known. However, it is recommended that future studies also explore implications of 
use for decision makers as it is not a traditional CEA comparing alternatives and 
interventions; and that were applicable, QALYs are used instead of preference 
scores. This approach might provide a simply, quick overview with more 
information for policy and decision makers than common practice. 
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Improvement of EQ-5D HRQoL estimates and QALY  
Future studies could explore the effects of regression interactions between risk 
factors etc. and conditions, as well as interaction with clusters of multi-morbidities 
that may influence results. Previous reference studies have recommended that 
complex epidemiological methods are used for linking conditions and health risk 
etc. [54] This could also be done in cohesion with reviewing the framework of 
definitions. There may be different pathways and methods both overlapping and 
accounting for this.  
Future studies could also generate a catalogue of QALYs for the 199 conditions, 
thereby including mortality in the equation of the burden estimate.  
Finally, future studies might incorporate multiple imputations and chained 
equations along with the ALDVMM as this cannot be done at the present time. 
However, the gains thereof may be limited, although it cannot be ruled out that it 
may have a smaller impact on regression model 4, that is the model with the most 
missing. 
  
5.5. EPILOG 
The thesis provides a standardized, transparent framework of definitions and 
estimates for use in future health economic evaluation and other research. It 
embraces new complex methods and data, setting new boundaries for use in for 
example regards to the comprehensive number of medical defined chronic 
conditions, as well as the new regression methods expanding the boundaries of 
classic additive and multiplicative regression models including handling 
comorbidities within complex econometric modelling. However, the methods and 
estimates are not without limitations as thoroughly discussed; thus future research 
will most likely explore and address these in more detail by for example validating 
the medical defined register based definitions as suggested. Moreover, most work 
from the thesis lies ahead, as the thesis merely provide a framework and estimates 
for future use in several research areas; and as seen in previous sections, the 
possible use is wide reaching far beyond this thesis. 
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Appendix A. Conditions and survey 
responses 
Table 5-1. The 20 conditions with the lowest survey response  
Cond. 
no. 
Condition 
 
ICD-10 code 
 
n 
invited 
survey 
Survey 
response,  
per cent 
196 Mental retardation F70–F79  244 18.9 
176 Dementia c 
F00, G30, F01, F02.0, F03.9, 
G31.8B, G31.8E, G31.9, G31.0B 
876 23.9 
197 Disorders of psychological development F80–F89 164 28.0 
177 
Organic, including symptomatic, mental 
disorders 
F04–F09 506 34.6 
1 Chronic viral hepatitis B18 49 34.7 
180 Schizophrenia c F20 413 35.4 
2 Human immunodeficiency virus [HIV] disease B20–24 39 35.9 
178 
Mental and behavioural disorders due to use of 
alcohol 
F10 1,068 37.0 
181 Schizotypal and delusional disorders F21–F29 555 38.0 
184 Mood (affective) disorders  F340, F348–F349, F38–F39  118 38.1 
198 Hyperkinetic disorders (ADHD) c F90 518 38.2 
188 Post-traumatic stress disorder F431 199 38.7 
199 
Behavioural and emotional disorders with onset 
usually occurring in childhood and adolescence 
F91–F99 637 39.9 
179 
Mental and behavioural disorders due to 
psychoactive substance use 
F11–F19 940 40.4 
182 Bipolar affective disorder c F30–F31 322 42.5 
67 Blindness and partial sight  H54  138 42.8 
36 
Systemic atrophies primarily affecting the 
central nervous system and other degenerative 
diseases  
G10–G14, G30–G32 171 44.4 
193 Emotionally unstable personality disorder F603 257 44.7 
52 Cerebral palsy and other paralytic syndromes G80–G83  265 45.3 
189 
Reactions to severe stress and adjustment 
disorders 
F432–F439 868 45.4 
c Complex defined condition. All estimates are non-weighted.  
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Table 5-2. The 20 conditions with the highest survey response 
Cond. 
no. 
Condition 
 
ICD-10 code 
 
Invited 
survey, n 
Survey 
response,  
per cent 
164 Fibromyalgia M797 45 82.2 
138 Systemic lupus erythematosus M32 57 80.7 
77 Other specified disorders of ear H938 480 75.6 
71 Other diseases of the inner ear  H83 1,254 73.3 
69 Otosclerosis  H80 230 73.0 
8 Malignant melanoma of skin C43 318 72.3 
14 Malignant neoplasm of prostate C61 643 71.4 
129 Acquired deformities of fingers and toes  M20  892 71.4 
167 
Adult osteomalacia and other disorders of bone 
density and structure 
M83, M85, except M833  852 71.4 
125 Polyarthrosis [Arthrosis] M15 246 71.1 
102 Varicose veins of lower extremities I83  718 71.0 
76 Tinnitus H931  1,134 70.4 
10 Malignant neoplasm of breast C50 1,015 70.0 
19 In situ neoplasms D00–D09 426 69.7 
132 Internal derangement of knee  
M230, M231, M233, M235, 
M236, M238 
189 69.3 
110 Bronchiectasis J47  78 69.2 
113 Inguinal hernia  K40 714 69.0 
73 
Other hearing loss and other disorders of ear, 
not elsewhere classified  
H910, H912, H913, H918, H930, 
H932, H933  
176 68.2 
40 
Demyelinating diseases of the central nervous 
system  
G36–G37    91 68.1 
159 Other enthesopathies M77 235 68.1 
All estimates are non-weighted.  
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Table 5-3. All 199 conditions and survey response  
Cond. Condition ICD-10 code n Per cent Per cent 
no.   
 
 
of sample 
Survey 
response 
Non-
response 
 
B – Viral hepatitis and Human 
immunodeficiency virus [HIV] disease 
B18, B20–B24 88 0.2 35.2 64.8 
1 Chronic viral hepatitis B18 49 0.1 34.7 65.3 
2 Human immunodeficiency virus [HIV] disease B20–24 39 0.1 35.9 64.1 
 C – Malignant neoplasms 
C00–C99; D32–D33; D35.2–
D35.4; D42–D44  
4,695 8.2 65.4 34.6 
3 
Malignant neoplasms of other and unspecified 
localizations 
C00–C14; C30–C33; C37–C42; 
C45–C49; C69; C73–74; C754–
C759  
421 0.7 61.0 39.0 
4 Malignant neoplasms of digestive organs C15–C17; C22–C26 111 0.2 61.3 38.7 
5 Malignant neoplasm of colon C18 421 0.7 65.6 34.4 
6 
Malignant neoplasms of rectosigmoid junction, 
rectum, anus and anal canal 
C19–C21 290 0.5 63.4 36.6 
7 Malignant neoplasm of bronchus and lung C34 305 0.5 54.4 45.6 
8 Malignant melanoma of skin C43 318 0.6 72.3 27.7 
9 Other malignant neoplasms of skin C44 219 0.4 60.3 39.7 
10 Malignant neoplasm of breast C50 1,015 1.8 70.0 30.0 
11 Malignant neoplasms of female genital organs C51–C52; C56–C58  183 0.3 62.8 37.2 
12 
Malignant neoplasm of cervix uteri, corpus uteri and 
parts unspecified 
C53–C55 234 0.4 63.7 36.3 
13 Malignant tumour of the male genitalia C60, C62–C63  88 0.2 63.6 36.4 
14 Malignant neoplasm of prostate C61 643 1.1 71.4 28.6 
15 Malignant neoplasms of urinary tract C64–C68  272 0.5 64.0 36.0 
16 Brain cancer c  
C71, C75.1–C75.3, D33.0–
D33.2, D35.2–D35.4, D43.0–
D43.2, D44.3–D44.5 (brain). 
C70, D32, D42 (brain 
membrane). C72, D33.3–D33.9, 
D43.3–D43.9 (cranial nerve, 
spinal cord) 
335 0.6 63.9 36.1 
17 
Malignant neoplasms of ill-defined, secondary and 
unspecified sites, and of independent (primary) 
multiple sites 
C76–C80, C97 580 1.0 58.1 41.9 
18 
Malignant neoplasms, stated or presumed to be 
primary, of lymphoid, haematopoietic and related 
tissue 
C81–C96 359 0.6 61.8 38.2 
 
D – In situ, benign and neoplasms of uncertain or 
unknown behaviour and diseases of the blood 
and blood-forming organs and certain disorders 
involving the immune mechanism 
D00–D09; D55–D59; D60–
D67; D80–D89 
2,252 4.0 58.3 41.7 
19 In situ neoplasms D00–D09 426 0.7 69.7 30.3 
20 Haemolytic anaemias  D55–D59  38 0.1 52.6 47.4 
21 Aplastic and other anaemias  D60–D63 343 0.6 51.0 49.0 
22 Other anaemias  D64 964 1.7 51.0 49.0 
23 
Coagulation defects, purpura and other 
haemorrhagic conditions 
D65–D69 358 0.6 63.7 36.3 
24 Other diseases of blood and blood-forming organs D70–D77 140 0.2 59.3 40.7 
25 Certain disorders involving the immune mechanism D80–D89  165 0.3 65.5 34.5 
 E – Endocrine, nutritional and metabolic diseases  
E00–E14; E20–E29; E31–35; 
E70–E78; E84–E85; E88–E89 
19,758 34.7 65.2 34.8 
26 Diseases of the thyroid c E00–E04, E06, E07 2,422 4.3 64.9 35.1 
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27 Thyrotoxicosis c E05  1,216 2.1 61.0 39.0 
28 Diabetes type 1 c E10 456 0.8 63.2 36.8 
29 Diabetes type 2 c E11 5,641 9.9 60.4 39.6 
30 Diabetes others c E12–E14 27 0.0 66.7 33.3 
31 Disorders of other endocrine glands E20–E35, except E30  423 0.7 61.0 39.0 
32 Metabolic disorders 
E70–E77; E79–E83; E85, E88–
E89 
386 0.7 60.1 39.9 
33 
Disturbances in lipoprotein circulation and other 
lipids c  
E78 15,083 26.5 66.7 33.3 
34 Cystic fibrosis c E84 8 0.0 50.0 50.0 
 G – Diseases of the nervous system 
G00–G14; G20–G32; G35–
G37; G40–47; G50–64; G70–
73; G80–G83; G90–G99 
10,900 19.1 61.4 38.6 
35 Inflammatory diseases of the central nervous system G00–G09 135 0.2 51.1 48.9 
36 
Systemic atrophies primarily affecting the central 
nervous system and other degenerative diseases  
G10–G14, G30–G32 171 0.3 44.4 55.6 
37 Parkinson’s disease c G20, G21, G22, F02.3 1,268 2.2 50.6 49.4 
38 Extrapyramidal and movement disorders G23–G26 172 0.3 64.5 35.5 
39 Sclerosis  G35 257 0.5 63.0 37.0 
40 
Demyelinating diseases of the central nervous 
system  
G36–G37    91 0.2 68.1 31.9 
41 Epilepsy c G40–G41 1,272 2.2 48.5 51.5 
42 Migraine c G43 3,007 5.3 67.9 32.1 
43 Other headache syndromes G44 253 0.4 56.9 43.1 
44 
Transient cerebral ischaemic attacks and related 
syndromes and vascular syndromes of brain in 
cerebrovascular diseases 
G45–G46  1,019 1.8 63.5 36.5 
45 Sleep disorders G47 710 1.2 65.5 34.5 
46 
Disorders of trigeminal nerve and facial nerve 
disorders  
G50–G51 337 0.6 63.2 36.8 
47 
Disorders of other cranial nerves, cranial nerve 
disorders in diseases classified elsewhere, nerve root 
and plexus disorders and nerve root and plexus 
compressions in diseases classified elsewhere  
G52–G55 182 0.3 62.6 37.4 
48 Mononeuropathies of upper limbs  G56 2,270 4.0 66.3 33.7 
49 
Mononeuropathies of lower limbs, other 
mononeuropathies and mononeuropathy in diseases 
classified elsewhere 
G57–G59 319 0.6 62.7 37.3 
50 
Polyneuropathies and other disorders of the 
peripheral nervous system 
G60–G64  501 0.9 61.5 38.5 
51 Diseases of myoneural junction and muscle G70–G73  92 0.2 60.9 39.1 
52 Cerebral palsy and other paralytic syndromes G80–G83  265 0.5 45.3 54.7 
53 Other disorders of the nervous system G90–G99    479 0.8 56.2 43.8 
 
H – Diseases of the eye and adnexa and diseases 
of the ear and mastoid process 
H02–H06; H17–H18; H25–
H28; H31–H32; H34–H36; 
H40–55; H57; H80,H810; 
H93, H90–H93 
10,393 18.2 63.3 36.7 
54 Disorders of eyelid, lacrimal system and orbit H02–H06 390 0.7 67.7 32.3 
55 Corneal scars and opacities H17 68 0.1 52.9 47.1 
56 Other disorders of cornea H18 214 0.4 63.1 36.9 
57 Diseases of the eye lens (cataracts)  H25–H28  1,559 2.7 62.3 37.7 
58 Disorders of the choroid and retina H31–H32  60 0.1 61.7 38.3 
59 Retinal vascular occlusions H34 212 0.4 58.0 42.0 
60 Other retinal disorders H35 1,416 2.5 56.1 43.9 
61 Retinal disorders in diseases classified elsewhere H36 313 0.5 57.8 42.2 
62 Glaucoma c H40–H42 1,536 2.7 58.4 41.6 
63 Disorders of the vitreous body and globe  H43–H45 219 0.4 62.6 37.4 
APPENDIX A. CONDITIONS AND SURVEY RESPONSES 
APP 5 
64 Disorders of optic nerve and visual pathways H46–H48  128 0.2 58.6 41.4 
65 
Disorders of ocular muscles, binocular movement, 
accommodation and refraction 
H49–H52 466 0.8 63.5 36.5 
66 Visual disturbances  H53 651 1.1 57.5 42.5 
67 Blindness and partial sight  H54  138 0.2 42.8 57.2 
68 
Nystagmus and other irregular eye movements and 
other disorders of eye and adnexa 
H55, H57 130 0.2 62.3 37.7 
69 Otosclerosis  H80 230 0.4 73.0 27.0 
70 Ménière’s disease c H810 212 0.4 67.9 32.1 
71 Other diseases of the inner ear  H83 1,254 2.2 73.3 26.7 
72 Conductive and sensorineural hearing loss H90 945 1.7 62.9 37.1 
73 
Other hearing loss and other disorders of ear, not 
elsewhere classified 
H910, H912, H913, H918, 
H930, H932, H933  
176 0.3 68.2 31.8 
74 Presbycusis (age-related hearing loss)  H911 2,573 4.5 61.3 38.7 
75 Hearing loss, unspecified  H919  1,781 3.1 67.2 32.8 
76 Tinnitus H931  1,134 2.0 70.4 29.6 
77 Other specified disorders of ear H938 480 0.8 75.6 24.4 
 I – Diseases of the circulatory system 
I05–I06; I10–28; I30–33;I36–
141; I44–I52; I60–I88; I90–
I94; I96–I99 
27,842 48.9 63.4 36.6 
78 Aortic and mitral valve disease c I05, I06, I34, I35 699 1.2 63.9 36.1 
79 Hypertensive diseases c I10–I15 23,826 41.8 63.4 36.6 
80 Heart failure c 
I11.0, I13.0, I13.2, I42.0, I42.6, 
I42.7, I42.9, I50.0, I50.1, I50.9 
688 1.2 55.7 44.3 
80.5 Ischaemic heart diseases I20–I25 3,286 5.8 64.1 35.9 
81    Angina pectoris I20 1,926 3.4 67.6 32.4 
82 
   Acute myocardial infarction and  
   subsequent myocardial infarction 
I21–I22 856 1.5 59.6 40.4 
83    AMI complex/other  I23–I24  45 0.1 66.7 33.3 
84    Chronic ischaemic heart disease I25 2,056 3.6 63.0 37.0 
85 
Pulmonary heart disease and diseases of pulmonary 
circulation 
I26–I28 292 0.5 56.2 43.8 
86 Acute pericarditis  I30 96 0.2 56.3 43.8 
87 Other forms of heart disease 
I31–I43, except I34–I35 and 
I42 
152 0.3 56.6 43.4 
88 Atrioventricular and left bundle branch block I44 341 0.6 56.3 43.7 
89 Other conduction disorders I45–46 235 0.4 57.9 42.1 
90 Paroxysmal tachycardia I47 970 1.7 64.0 36.0 
91 Atrial fibrillation and flutter I48 2,582 4.5 60.3 39.7 
92 Other cardiac arrhythmias I49 669 1.2 65.8 34.2 
93 
Complications and ill-defined descriptions of heart 
disease and other heart disorders in diseases 
classified elsewhere 
I51–52 85 0.1 63.5 36.5 
94 Stroke 
I60, I61,I63–I64, Z501 
(rehabilitation) 
1,577 2.8 54.5 45.5 
95 Cerebrovascular diseases I62, I65–I68 329 0.6 56.5 43.5 
96 Sequelae of cerebrovascular disease I69 1,126 2.0 48.7 51.3 
97 Atherosclerosis  I70 774 1.4 54.5 45.5 
98 Aortic aneurysm and aortic dissection  I71 197 0.3 62.4 37.6 
99 Diseases of arteries, arterioles and capillaries I72, I74, I77–I79 227 0.4 63.9 36.1 
100 Other peripheral vascular diseases I73 670 1.2 60.4 39.6 
101 Phlebitis, thrombosis of the portal vein and others  I80–I82 766 1.3 59.5 40.5 
102 Varicose veins of lower extremities I83  718 1.3 71.0 29.0 
103 Haemorrhoids c I84 1,628 2.9 66.5 33.5 
104 
Oesophageal varices (chronic), varicose veins of 
other sites, other disorders of veins, non-specific 
lymphadenitis, other non-infective disorders of 
I85–I99 , except I89 and I95 258 0.5 58.1 41.9 
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lymphatic vessels and lymph nodes and other and 
unspecified disorders of the circulatory system 
 J – Diseases of the respiratory system 
J30.1; J40–J47; J60–J84; J95, 
J97–J99 
23,217 40.7 62.5 37.5 
105 Respiratory allergy c J30, except J30.0 15,689 27.5 64.1 35.9 
106A Chronic lower respiratory diseases c J40–J43, J47 8,402 14.7 62.1 37.9 
106 
 Bronchitis, not specified as acute 
  or chronic, simple and  
 mucopurulent chronic bronchitis  
 and unspecified chronic bronchitis 
J40–J42 332 0.6 59.0 41.0 
107   Emphysema J43 143 0.3 55.9 44.1 
108 Chronic obstructive lung disease (COPD) c J44, J96, J13–J18 4,303 7.6 59.1 40.9 
109 Asthma, status asthmaticus c J45–J46 7,134 12.5 59.5 40.5 
110   Bronchiectasis J47  78 0.1 69.2 30.8 
111 Other diseases of the respiratory system J60–J84; J95, J97–J99  413 0.7 54.5 45.5 
 K – Diseases of the digestive system 
K25–K27; K40, K43, K50–52; 
K58–K59; K71–K77; K86–
K87  
7,793 13.7 59.2 40.8 
112 Ulcers c K25–K27 4,113 7.2 56.9 43.1 
113 Inguinal hernia  K40 714 1.3 69.0 31.0 
114 Ventral hernia K43 219 0.4 61.6 38.4 
115 Crohn’s diease  K50  335 0.6 63.9 36.1 
116 Ulcerative colitis  K51  583 1.0 65.7 34.3 
117 Other non-infective gastroenteritis and colitis K52 417 0.7 53.2 46.8 
118 Irritable bowel syndrome (IBS)  K58 924 1.6 63.2 36.8 
119 Other functional intestinal disorders K59  1,020 1.8 55.2 44.8 
120 Diseases of liver, biliary tract and pancreas  K71–K77; K86–K87  495 0.9 56.6 43.4 
 L – Diseases of the skin and subcutaneous tissue L40 1,152 2.0 64.8 35.2 
121 Psoriasis c L40 1,152 2.0 64.8 35.2 
 
M – Diseases of the musculoskeletal system and 
connective tissue 
M01–M25: M30–M36; M40–
M54; M60.1–M99 
21,155 37.1 64.2 35.8 
122 Infectious arthropathies M01–M03 166 0.3 61.4 38.6 
122A 
Inflammatory polyarthropathies and ankylosing 
spondylitis c 
M05–M14, M45 3,265 5.7 63.8 36.2 
123    Rheumatoid arthritis c 
M05, M06, M07.1, M07.2, 
M07.3, M08, M09 
1,426 2.5 66.8 33.2 
124 
   Inflammatory polyarthropathies 
    – except rheumatoid arthritis c 
M074–M079, M10–M14, M45 2,402 4.2 63.7 36.3 
125 Polyarthrosis [arthrosis] M15 246 0.4 71.1 28.9 
126 Coxarthrosis [arthrosis of hip] M16 2,316 4.1 65.8 34.2 
127 Gonarthrosis [arthrosis of knee] M17 4,021 7.1 66.9 33.1 
128 
Arthrosis of first carpometacarpal joint and other 
arthrosis 
M18–M19 1,616 2.8 65.8 34.2 
129 Acquired deformities of fingers and toes  M20  892 1.6 71.4 28.6 
130 Other acquired deformities of limbs  M21 432 0.8 66.4 33.6 
131 Disorders of patella (knee cap) M22  864 1.5 58.1 41.9 
132 Internal derangement of knee  
M230, M231, M233, M235, 
M236, M238 
189 0.3 69.3 30.7 
133 Derangement of meniscus due to old tear or injury M232  762 1.3 67.2 32.8 
134 Internal derangement of knee, unspecified M239  592 1.0 65.5 34.5 
135 Other specific joint derangements M24, except M240–M241  100 0.2 58.0 42.0 
136 Other joint disorders, not elsewhere classified  M25  311 0.5 62.7 37.3 
137 Systemic connective tissue disorders M30–M36, except M32,M34 755 1.3 64.0 36.0 
138 Systemic lupus erythematosus M32 57 0.1 80.7 19.3 
139 Dermatopolymyositis M33 25 0.0 60.0 40.0 
140 Systemic sclerosis M34 20 0.0 65.0 35.0 
141 Kyphosis, lordosis  M40  86 0.2 64.0 36.0 
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142 Scoliosis  M41 300 0.5 56.7 43.3 
143 Spinal osteochondrosis  M42  130 0.2 53.1 46.9 
144 Other deforming dorsopathies M43  444 0.8 64.4 35.6 
145 Other inflammatory spondylopathies M46 117 0.2 53.8 46.2 
146 Spondylosis M47  1,522 2.7 63.1 36.9 
147 
Other spondylopathies and spondylopathies in 
diseases classified elsewhere 
M48, M49  762 1.3 65.7 34.3 
148 Cervical disc disorders M50 207 0.4 64.3 35.7 
149 Other intervertebral disc disorders  M51  779 1.4 66.1 33.9 
150 Other dorsopathies, not elsewhere classified M53  146 0.3 64.4 35.6 
151 Dorsalgia M54 1,060 1.9 60.4 39.6 
152 Soft tissue disorders M60–M63, except M60.0  256 0.4 54.7 45.3 
153 Synovitis and tenosynovitis  M65  407 0.7 67.3 32.7 
154 Disorders of synovium and tendon M66–68  386 0.7 62.4 37.6 
155 
Soft tissue disorders related to use, overuse and 
pressure 
M70 278 0.5 65.1 34.9 
156 Fibroblastic disorders M72 792 1.4 67.4 32.6 
157 Shoulder lesions  M75 1,393 2.4 66.3 33.7 
158 Enthesopathies of lower limbs, excluding foot M76 180 0.3 62.2 37.8 
159 Other enthesopathies M77 235 0.4 68.1 31.9 
160 Rheumatism, unspecified M790 177 0.3 66.1 33.9 
161 Myalgia  M791 197 0.3 55.8 44.2 
162 Other soft tissue disorders, not elsewhere classified  M792– M794; M798–M799  133 0.2 66.9 33.1 
163 
Other soft tissue disorders, not elsewhere classified: 
pain in limbs 
M796 419 0.7 62.1 37.9 
164 Fibromyalgia M797 45 0.1 82.2 17.8 
165 Osteoporosis c M80–M81 3,060 5.4 62.8 37.2 
166 Osteoporosis in diseases classified elsewhere  M82  30 0.1 56.7 43.3 
167 
Adult osteomalacia and other disorders of bone 
density and structure 
M83,M85, except M833  852 1.5 71.4 28.6 
168 Disorders of continuity of bone M84 53 0.1 54.7 45.3 
169 Other osteopathies M86–M90 293 0.5 57.0 43.0 
170 
Other disorders of the musculoskeletal system and 
connective tissue 
M95–M99 403 0.7 63.8 36.2 
 N – Diseases of the genitourinary system N18 425 0.7 56.0 44.0 
171 Chronic renal failure (CRF) c N18 425 0.7 56.0 44.0 
 
Q – Congenital malformations, deformations and 
chromosomal abnormalities 
Q00–Q56; Q60–Q99 2,212 3.9 61.1 38.9 
172 
Congenital malformations: of the nervous, 
circulatory, respiratory system; cleft palate and cleft 
lip, urinary tract, bones and muscles, other and 
chromosomal abnormalities not elsewhere classified 
Q00–Q07; Q20–Q37; Q60–Q99 1,452 2.5 61.0 39.0 
173 Congenital malformations of eye, ear, face and neck Q10–Q18 330 0.6 62.4 37.6 
174 
Other congenital malformations of the digestive 
system 
Q38–Q45 142 0.2 57.0 43.0 
175 Congenital malformations of the sexual organs  Q50–Q56 333 0.6 60.4 39.6 
 F – Mental and behavioural disorders F00–99 12,769 22.4 49.8 50.2 
176 Dementia c 
F00, G30, F01, F02.0, F03.9, 
G31.8B, G31.8E, G31.9, 
G31.0B 
876 1.5 23.9 76.1 
177 Organic, including symptomatic, mental disorders F04–F09 506 0.9 34.6 65.4 
178 
Mental and behavioural disorders due to use of 
alcohol 
F10 1,068 1.9 37.0 63.0 
179 
Mental and behavioural disorders due to 
psychoactive substance use 
F11–F19 940 1.6 40.4 59.6 
180 Schizophrenia c F20 413 0.7 35.4 64.6 
181 Schizotypal and delusional disorders F21–F29.  555 1.0 38.0 62.0 
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182 Bipolar affective disorder c F30–F31 322 0.6 42.5 57.5 
183 Depression c F32, F33, F34.1, F06.32 9,096 16.0 52.8 47.2 
184 Mood (affective) disorders  F340, F348–F349, F38–F39  118 0.2 38.1 61.9 
185 Phobic anxiety disorders F40 167 0.3 47.9 52.1 
186 Other anxiety disorders F41 485 0.9 48.9 51.1 
187 Obsessive compulsive disorder (OCD) c F42 150 0.3 47.3 52.7 
188 Post-traumatic stress disorder F431 199 0.3 38.7 61.3 
189 Reactions to severe stress and adjustment disorders F432–F439 868 1.5 45.4 54.6 
190 
Dissociative (conversion) disorders, somatoform 
disorders and other neurotic disorders 
F44, F45, F48 332 0.6 53.9 46.1 
191 Eating disorders F50 89 0.2 60.7 39.3 
192 
Behavioural syndromes associated with 
physiological disturbances and physical factors 
F51–F59 98 0.2 59.2 40.8 
193 Emotionally unstable personality disorder F603 257 0.5 44.7 55.3 
194 Specific personality disorders F602, F604–F609 772 1.4 47.9 52.1 
195 Disorders of adult personality and behaviour F61–F69 276 0.5 46.0 54.0 
196 Mental retardation F70–F79  244 0.4 18.9 81.1 
197 Disorders of psychological development F80–F89 164 0.3 28.0 72.0 
198 Hyperkinetic disorders (ADHD) c F90 518 0.9 38.2 61.8 
199 
Behavioural and emotional disorders with onset 
usually occurring in childhood and adolescence 
F91–F99 637 1.1 39.9 60.1 
    0.0   
 Having no chronic conditions  32,818 57.6 56.1 43.9 
 Having 1 chronic condition  18,551 32.6 62.2 37.8 
 Co-morbidity: 2 conditions  12,224 21.5 64.0 36.0 
 Co-morbidity: 3 conditions  9,181 16.1 63.9 36.1 
 Co-morbidity: 4 conditions  6,435 11.3 63.7 36.3 
 Co-morbidity: 5 conditions  4,581 8.0 63.5 36.5 
 Co-morbidity: 6 conditions  3,286 5.8 61.0 39.0 
 Co-morbidity: 7 or more conditions  7,535 13.2 58.0 42.0 
 One or more chronic condition(s)  61,793 108.4 62.5 37.5 
 Samples:   0.0     
 Sample: NIPH 2010  25,000 43.9 60.7 39.3 
 Sample: North Denmark Region 2010  35,700 62.6 65.5 34.5 
 Sample: North Denmark Region 2013  33,911 59.5 54.4 45.6 
 Gender:   0.0     
 – Women  47,188 82.8 63.7 36.3 
 – Men  47,406 83.2 56.8 43.2 
 Age:   0.0     
 16–24 years  12,533 22.0 48.5 51.5 
 24–34 years  10,338 18.1 52.8 47.2 
 35–44 years  14,843 26.0 58.1 41.9 
 45–54 years  17,238 30.2 62.8 37.2 
 55–64 years  16,830 29.5 68.0 32.0 
 65–74 years  12,962 22.7 70.5 29.5 
 75+ years  9,850 17.3 55.2 44.8 
 Education:         
 – No education/training  28,527 50.1 53.3 46.7 
 – Students or in training  7,698 13.5 65.3 34.7 
 – Short education  39,438 69.2 63.3 36.7 
 – Middle education – bachelor etc.  11,639 20.4 72.4 27.6 
 – High education – master degree etc.  4,362 7.7 70.4 29.6 
 – Missing.  2,947 5.2 10.1 89.9 
 Ethnicity:(no non-response ethnicity of sample 3)        
 – Danish  74,153 130.1 73.6 26.4 
 – Other Western  2,178 3.8 53.7 46.3 
 – Non-Western  2,800 4.9 44.4 55.6 
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c = complex defined conditions. All estimates are non-weighted. Conditions marked ‘A, overlap with 
other conditions and are thus not counted twice [140].  
 
  
 Family Equalized Income:        
 < 100,000 kr. (< £10,000 )  6,171 10.8 40.7 59.3 
 100,000–199,999   41,162 72.2 55.7 44.3 
 200,000–299,999 kr. (£20,000–£29,999)  33,578 58.9 65.5 34.5 
 300,000–399,999 kr. (£30,000–£39,999)  10,079 17.7 69.9 30.1 
 400,000+ kr. (£40,000+)  3,570 6.3 69.9 30.1 
 Partnership:         
 – Having a partner  44,184 77.5 64.9 35.1 
 – Not married /not in a relationship  50,371 88.4 56.2 43.8 
 Children at home:         
 – No children at home  64,007 112.3 65.9 34.1 
 – Having children living at home under 15   16,023 28.1 88.1 11.9 
 – Missing   14,581 25.6 4.8 95.2 
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Appendix B. Example of additive 
modelling of an intervention for CUA 
The following example is a more simple, traditional additive modelling and is not 
recommended for use in future CUA, as the ALDVMM is able to model non-linear 
relationships reflecting the relationships of covariates more precisely thus unfolding 
the potentials of the results better. However, the additive example is included to 
give an understanding of the use of the estimates usually done and directly related 
to the EQ-5D estimates provided within paper 3 - and for comparative reasons with 
Sulivan et al. and others using additive regression modelling [41–43, 49].  
Notably: experienced modellers should use the “Excel” and Stata “.ster” files with 
full parameter estimates and covariance matrices of regression model 1-4 to model 
non-linear models of specific needs for use in CUA rather than additive linear 
models.  
Additive modelling an intervention to prevent/postpone heart failure  
The aim in this example is to model the effectiveness in QALYs of an intervention 
(for example, doctor-prescribed exercise or new medicine) that postpones the 
occurrence and development of heart failure and co-morbidities compared to an 
identical control group. In the control group, the patients develop heart failure and 
hypertension in year 3, diabetes type 2 and stroke in year 7, COPD and osteoporosis 
in year 12, and die in year 14. The intervention delays and changes the progression 
as the heart failure – and hypertension – is first added after five years, and only 
COPD and osteoporosis are added after 12 years. The first modelling step is to 
determine the baseline. In our example, the population mean has been used, but you 
could also argue that if/as the population is at high risk, the 25 unadjusted 
percentiles of the population mean could have been used [43]. Although this value 
is arbitrary, it may be assumed that it reflects the lower health-related quality of life 
of the heart failure population or other chronic conditions. Another solution to 
setting the baseline, however, could be to use the unadjusted preference scores of 
the co-morbidity variable similar to the condition of interest; for example, if the 
condition of interest has on average 3.7 co-morbidities, the baseline could be equal 
to a co-morbidity of 4 or 0.789. Moreover, all conditions are mapped based on the 
adjusted regression estimates seen in paper 3, regression model 2. Notably, which 
regression model estimates are used depends on the purpose of the study and 
variables needed.  
In the example, the QALY of the intervention group is 12.2 (9.8 discounted) and 
that of the control group 10.4 (8.6 discounted), or 1.8 (1.2 discounted) QALYs 
gained by the intervention. 
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Year 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 
Intervention 0.852 0.852 0.851 0.851 0.820 0.819 0.819 0.818 0.818 0.818 0.817 0.775 0.774 0.774 0.774 
Discounted* 0.852 0.803 0.779 0.756 0.707 0.686 0.666 0.646 0.627 0.608 0.590 0.543 0.527 0.512 0.497 
 
Control 0.852 0.852 0.820 0.820 0.820 0.819 0.789 0.789 0.788 0.788 0.788 0.745 0.745 0 0 
Discounted* 0.852 0.803 0.751 0.728 0.707 0.686 0.642 0.623 0.604 0.586 0.569 0.522 0.507 0 0 
 
 
 
 
 
 
Figure 5-2. Example of modelling a treatment and control with heart failure. 
* Discounted at 3 per cent per year (value/1.03t), where t = number of years. Arrow indicates from when 
and how long time that each disutility from condition, age or other is included and counted in.  
 
  
Baseline: Survey 
population mean 
Age -0.004 
pr. year 
Age (-0.004*5) + heart 
failure (-0.0106) + 
hypertension (-0.0123) 
+ comorb2 (-0.0080) 
Age (-0.004*10) + heart failure (-
0.0106) + hypertension (-0.0123) + 
COPD (-0.0100) + osteoporosis (-
0.0189) + comorb4 (-0.0130) 
Age (-0.004*3) + heart 
failure (-0.0106) + 
hypertension (-0.0123) + 
comorb2 (-0.0080) 
Age (-0.004*7) + heart 
failure (-0.0106) + 
hypertension (-0.0123) + 
diabetes type 2 (-0.0139) + 
stroke (-0.0100) + comorb4 
(-0.0050) 
Age (-0.004*12) + heart failure 
(-0.0106) + hypertension (-
0.0123) + diabetes type 2 (-
0.0139) + stroke (-0.0100) + 
COPD (-0.0100) + 
osteoporosis (-0.0189) + 
comorb6 (-0.0133) Age -0.004 
pr. year 
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Table 5-4. Extracts of the EQ-5D regression estimates of paper 3 - used in the 
example 
   Unadjusted EQ-5D scores 
ALDVMM model 2: 
Reg. adjusted EQ-5D scores 
   n Score SE disutility sig SE 
183 Depression c 
F32, F33, F34.1, 
F06.32 
4,619 0.686 0.0043 -0.0723 * 0.0027 
29 Diabetes type 2 c E11 3,253 0.752 0.0048 -0.0139 * 0.0029 
108 
Chronic obstructive lung 
disease (COPD) c 
J44, J96, J13–J18 2,435 0.733 0.0060 -0.0100 * 0.0033 
112 Ulcers c K25–K27 2,245 0.707 0.0061 -0.0289 * 0.0033 
79 Hypertensive diseases c I10–I15 14,504 0.776 0.0021 -0.0123 * 0.0019 
80 Heart failure c 
I11.0, I13.0, I13.2, 
I42.0, I42.6, I42.7, 
I42.9, I50.0, I50.1, 
I50.9 
369 0.678 0.0151 -0.0106  0.0087 
94 Stroke 
I60, I61,I63–I64, 
Z501 (rehabilitation) 
812 0.707 0.0093 -0.0166 * 0.0064 
165 Osteoporosis c M80–M81 1,817 0.710 0.0066 -0.0189 * 0.0038 
123 Rheumatoid arthritis c 
M05, M06, M07.1, 
M07.2, M07.3, M08, 
M09 
919 0.710 0.0088 -0.0297 * 0.0051 
 Age pr. year  N/a N/a N/a -0.0004  0.0003 
 Having 1 chronic condition  11,303 0.882 0.0016 - - - 
 Co-morbidity: 2 conditions  7,657 0.848 0.0023 -0.0080 * 0.0030 
 Co-morbidity: 3 conditions  5,698 0.820 0.0030 -0.0050 **** 0.0039 
 Co-morbidity: 4 conditions  3,959 0.789 0.0035 -0.0130 * 0.0050 
 Co-morbidity: 5 conditions  2,805 0.754 0.0047 -0.0113 *** 0.0066 
 Co-morbidity: 6 conditions  1,915 0.732 0.0061 -0.0133 *** 0.0079 
 
Co-morbidity: 7 or more 
conditions 
 4,143 0.641 0.0048 -0.0191 ** 0.0091 
 All - 55,616 0.852      
* p<0.01. ** p<0.05 *** p<0.1 ***** p<0.2. 
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